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   I	  
ABSTRACT  
Alternative	  splicing	  of	  the	  vascular	  endothelial	  growth	  factor	  A	  (VEGF-­‐A)	  terminal	  
exon	   generates	   two	   protein	   families	   with	   differing	   functions.	   Pro-­‐angiogenic	  
VEGFxxx	   isoforms	  are	  produced	  via	  selection	  of	  the	  proximal	  3’	  splice	  site	  of	  the	  
terminal	  exon.	  Use	  of	  an	  alternative	  distal	  splice	  site	  creates	  the	  anti-­‐angiogenic	  
VEGFxxxb	  proteins.	  	  
A	  bichromatic	  splicing-­‐sensitive	  reporter	  was	  designed	  to	  mimic	  VEGF	  alternative	  
splicing	   and	   used	   as	   a	   molecular	   tool	   to	   further	   investigate	   this	   alternative	  
splicing	   event.	   The	   terminal	   exon	   and	   preceding	   intron	   of	  VEGF	   were	   inserted	  
into	  a	  minigene	  construct	  followed	  by	  the	  coding	  sequences	  for	  two	  fluorescent	  
proteins.	   A	   different	   fluorescent	   protein	   is	   expressed	   depending	   on	   which	   3’	  
splice	  site	  of	  the	  exon	  is	  used	  during	  splicing.	  The	  fluorescent	  output	  can	  be	  used	  
to	  follow	  splicing	  decisions	  in	  vitro	  and	  in	  vivo.	  
Following	  successful	  reporter	  validation	  in	  different	  cell	  lines	  and	  altering	  splicing	  
using	   known	   modulators,	   small	   pilot	   screens	   were	   undertaken	   to	   search	   for	  
novel	   regulators	  of	   the	  splicing	  decision	   that	  creates	  pro-­‐/anti-­‐angiogenic	  VEGF	  
isoforms.	  A	  larger	  screen	  was	  performed	  using	  a	  library	  of	  1280	  small	  molecules	  
(LOPAC),	   all	   compounds	   of	   the	   library	  were	   pharmacologically	   active	   and	   have	  
known	  biological	  targets.	  Alterations	  to	  reporter	  splicing	  were	  measured	  using	  a	  
fluorescent	   plate	   reader	   to	   detect	   RFP	   and	   GFP	   expression.	   Compounds	   of	  
interest	  were	  further	  validated	  using	  flow	  cytometry	  and	  assessed	  for	  effect	  on	  
endogenous	  VEGF	  alternative	  splicing.	  In	  vitro	  angiogenesis	  assays	  were	  used	  to	  
demonstrate	   anti-­‐angiogenic	   effect.	   Anti-­‐angiogenic	   activity	   and	   the	   effect	   on	  
tumour	  growth	  were	  investigated	  in	  several	  in	  vivo	  models.	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Chapter	  1   
Introduction  
  
1.1  ANGIOGENESIS  
In	   species	   such	   as	   nematodes	   and	  Drosophila	  melanogaster,	   oxygen	   is	   able	   to	  
freely	   diffuse	   to	   all	   cells	   within	   the	   organism.	   Throughout	   evolution,	   in	   larger	  
organisms,	   the	   vasculature	   has	   developed	   as	   an	   efficient	   means	   to	   transport	  
oxygen	  to	  different	  tissues	  (Adams	  and	  Alitalo,	  2007;	  Carmeliet,	  2005).	  Vascular	  
development	   has	   also	   provided	   a	  way	   for	   circulating	   immune	   cells	   to	   traverse	  
tissues	  supplying	  immune	  protection.	  Nutrients	  and	  growth	  signals	  are	  delivered	  
via	   blood	   vessels	   allowing	   stimulation	   of	   organ	  morphogenesis	   (Carmeliet	   and	  
Jain,	   2011).	   The	   heart	   pumps	   blood	   into	   arteries	   which	   branch	   into	   smaller	  
arterioles	   which	   branch	   further	   to	   create	   capillary	   beds.	   Capillaries	   are	   the	  
smallest	  blood	  vessels	  and	  are	  arranged	   into	  an	  extensive	  meshwork.	   It	   is	  here	  
that	  metabolic	  and	  gaseous	  exchange	  occurs,	  with	  blood	  taken	  back	  to	  the	  heart	  
through	   the	  venous	   system.	  This	   forces	  almost	  all	   cells	   in	  a	   tissue	   to	  be	  within	  
close	  proximity,	  around	  100μm,	  of	  a	  capillary	  (Hanahan	  and	  Weinberg,	  2000).	  
During	   embryogenesis,	   early	   vascular	   networks	   are	   generated	   by	   the	  
differentiation	   of	   angioblasts	   from	   the	   mesoderm.	   Maturation	   of	   angioblasts	  
produces	  endothelial	  cells,	  which	  form	  a	  mesh	  of	  capillaries.	  This	   is	  the	  process	  
of	   vasculogenesis.	   To	   increase	   blood	   supply	   into	   developing	   tissues,	   the	  
vasculature	   is	   expanded	   further	   through	   angiogenesis:	   the	   formation	   of	   new	  
capillaries	   via	   sprouting	   from	   existing	   vessels	   (Risau,	   1997).	   Pericytes	   associate	  
with	   newly	   formed	   endothelial	   sprouts	   and	   act	   to	   stabilise	   the	   vessel	   and	  
regulate	   perfusion	   between	   the	   blood	   and	   tissues	   (Carmeliet	   and	   Jain,	   2011).	  
There	   are	   also	   several	   other	   forms	   of	   vessel	   development	   aside	   from	  
angiogenesis.	  In	  the	  process	  of	  arteriogenesis,	  smooth	  muscle	  cells	  also	  associate	  
with	   the	  vessels	  providing	   stabilisation.	  Occasionally,	   intussusception	  will	   occur	  
whereby	  capillaries	  will	  split	  to	  form	  two	  new	  daughter	  vessels.	  
	   2	  
Functional,	   regulated	   angiogenesis	   is	   vital	   for	   development,	   homeostasis	   and	  
wound	   healing.	   Abnormal	   or	   imbalanced	   angiogenesis	   is	   associated	   with	  
pathology	   in	  various	  diseases.	   Ischemia	  can	  be	  caused	  by	   lack	  or	  by	   insufficient	  
angiogenesis	   whereas	   cancer	   cells	   induce	   angiogenesis	   to	   sustain	   tumour	  
growth.	  
1.1.1 Mechanisms  of  angiogenesis  
Endothelial	  cells	  are	  arranged	  in	  a	  monolayer,	   linked	  to	  each	  other	  by	  adhesion	  
molecules	   such	   as	   claudins	   and	   cadherins.	   Without	   angiogenic	   stimuli,	  
endothelial	   cells	   are	   quiescent	   with	   a	   long	   half-­‐life.	   	   Their	   proliferation	   is	  
repressed	   by	   autocrine	   signals	   and	   survival	   factors	   secreted	   by	   associated	  
pericytes	  including	  VEGF,	  FGFs	  NOTCH	  ligands	  and	  angiopoietins	  (Carmeliet	  and	  
Jain,	   2011).	   Angiogenesis	   is	   a	   highly	   regulated	   process	   with	   many	   complex	  
signalling	   pathways	   required.	   Different	   combinations	   of	   angiogenic	   molecules	  
stimulate	  different	  cells	  and	  stages	  of	  vessel	  formation.	  
Hypoxia	   is	   a	   key	   angiogenic	   stimulus.	   Angiogenesis	   is	   induced	   in	   response	   to	  
hypoxia	  in	  order	  to	  increase	  oxygen	  supply	  to	  a	  tissue.	  Endothelial	  cells	  possess	  
oxygen-­‐sensing	  mechanisms.	   The	  prolyl	   hydroxylase	  domain	   (PHD)	  proteins	   act	  
as	  oxygen	  sensors.	  When	  oxygen	  levels	  are	  adequate,	  PHDs	  add	  hydroxyl	  groups	  
to	  hypoxia	   inducible	   factor	  proteins	   (HIF-­‐1α	  and	  HIF-­‐2α).	  Hydroxylation	   targets	  
the	   proteins	   for	   degradation	   via	   association	   with	   Von	   Hippel-­‐Lindau	   (VHL)	  
protein,	  which	  functions	  in	  a	  ubiquitin	  ligase	  complex.	  Under	  hypoxic	  conditions,	  
PHDs	   do	   not	   hydroxylate	   HIFs,	   preventing	   their	   degradation.	   HIFs	   are	  
transcription	  factors	  and	  upregulate	  the	  expression	  of	  many	  angiogenic	  proteins	  
including	  VEGF,	  nitric	  oxide	  synthase	  and	  PDGF	  (platelet	  derived	  growth	  factor).	  
When	  endothelial	  cells	  are	  exposed	  to	  an	  angiogenic	  signal,	  (such	  as	  VEGF,	  ANG-­‐
2,	   FGFb)	   junctions	   between	   the	   monolayer	   of	   endothelial	   cells	   become	   loose	  
making	   the	   vessel	  more	  permeable.	  Basement	  membrane	  proteins	   are	   cleaved	  
by	   matrix	   metalloproteinases	   to	   allow	   remodelling	   and	   associated	   pericytes	  
move	  away	   from	   the	   capillary	  wall.	  Due	   to	   the	   increase	   in	   vessel	   permeability,	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plasma	  proteins	  can	  travel	   from	  the	  blood	  and	  begin	   to	   form	  new	  extracellular	  
matrix	  as	  a	  scaffold	  for	  the	  nascent	  growing	  vessel.	  One	  endothelial	  cell,	  known	  
as	   the	   tip	   cell,	   is	   chosen	   to	   lead	   the	  newly	   forming	  vascular	   sprout.	   Stalk	   cells,	  
adjacent	   to	   the	   tip,	   proliferate	   to	  elongate	   the	   vessel	   and	   create	   lumen	  within	  
the	   sprout.	   Notch	   signalling	   is	   important	   in	   regulating	   tip	   and	   stalk	   cells	  
interaction.	  Delta-­‐like-­‐4	  ligand	  (DLL4)	  is	  highly	  expressed	  in	  the	  tip	  cell.	  Secreted	  
DLL4	   activates	   Notch	   receptors	   on	   neighbouring	   stalk	   cells,	   this	   is	   thought	   to	  
ensure	   only	   one	   cell	   is	   selected	   to	   lead	   the	   new	   sprout.	   Tip	   cells	   possess	   long	  
filopodia	   which	   detect	   angiogenic	   gradients.	   When	   a	   growing	   vessel	   meets	   a	  
capillary	   or	   another	   growing	   sprout,	   endothelial	   cell-­‐cell	   junctions	   are	   created.	  
The	  formation	  of	  the	  vascular	  lumen	  is	  facilitated	  by	  factors	  including	  cadherins,	  
VEGF	  and	  hedgehog	  ligands.	  
As	  endothelial	   cell	   proliferation	  and	  vessel	   elongation	   stops,	  pericytes	  begin	   to	  
re-­‐associate,	   stabilising	   the	   new	   vessel.	   Pericytes	   are	   recruited	   by	   release	   of	  
PDGF-­‐B,	  Notch	   ligands,	  ANG-­‐1	   and	   TGFβ.	   Inhibitors,	   including	   TIMPs,	   block	   the	  
action	  of	  MMPs	  allowing	  basement	  membrane	  proteins	   to	  accumulate	  and	   the	  
vessel	  to	  mature.	  
1.1.2 Angiogenesis  in  disease  
Given	   that	   angiogenesis	   is	   such	   a	   fundamentally	   important	   process,	   it	   is	  
unsurprising	  that	  pathology	  can	  arise	  when	  vessel	  growth	  is	  dysregulated.	  Many	  
disorders	   are	   associated	   with	   excessive	   or	   insufficient	   angiogenesis.	  
Neovascularization	   within	   the	   eye	   can	   lead	   to	   various	   eye	   diseases	   including	  
diabetic	  retinopathy	  and	  age-­‐related	  macular	  degeneration	  (AMD).	  Retinopathy	  
and	  wet	  AMD	  are	  caused	  by	  irregular	  growth	  of	  vessels	  in	  the	  retina	  and	  macula,	  
respectively.	  Both	  produce	   intraocular	   swelling	  and	  bleeding	  which	   can	   lead	   to	  
permanent	   blindness	   (Witmer	   et	   al.,	   2003).	   Abnormal	   angiogenesis	   is	   also	  
implicated	   in	   several	   disorders	   associated	   with	   the	   reproductive	   system	  
conditions.	   Hyper-­‐vascularisation	   and	   increased	   expression	   of	   pro-­‐angiogenic	  
factors	  is	  found	  in	  polycystic	  ovary	  syndrome	  and	  endometriosis	  (Reynolds	  et	  al.,	  
2002).	   In	   contrast,	   several	   other	   pathologies	   are	   related	   to	   insufficient	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vascularisation.	   Ischemia	   of	   the	   heart	   and	   limbs,	   stroke	   and	   hypertension	   are	  
both	   associated	   with	   inadequate	   vessel	   development.	   Malformed	   vessels	   are	  
also	  observed	  in	  pre-­‐eclampsia,	  psoriasis	  and	  various	  other	  conditions	  (Carmeliet	  
and	  Jain,	  2000).	  
1.1.3 Tumour  angiogenesis  
The	   relationship	   between	   sustained	   tumour	   growth	   and	   an	   increase	   in	  
vascularisation	   has	   been	   described	   since	   the	   beginning	   of	   the	   20th	   century.	   In	  
1927,	   Lewis	   described	   the	   vascular	   structures	   within	   rat	   tumours.	   It	   was	  
observed	  that	   the	  vascular	  architecture	  differs	  between	  tumours	  and	  proposed	  
that	  the	  tumour	  environment	  has	  a	  pronounced	  effect	  on	  vascular	  morphology	  
(Lewis,	   1927).	   The	   use	   of	   chamber	   assays	   enabled	   tumour	   angiogenesis	   to	   be	  
clearly	   observed	   in	   vivo	   and	   was	   also	   used	   to	   show	   the	   association	   between	  
tumours	  and	  vessel	  growth.	   It	  was	  observed	  that	  transplanted	  cancer	  cells,	  but	  
not	   normal	   cells,	   could	   induce	   neovascularization.	   It	   was	   hypothesised	   that	  
tumours	  acquire	  the	  capability	  to	  induce	  angiogenesis	  and	  that	  this	  is	  a	  key	  step	  
of	   tumourigenesis	   (Algire	   and	   Chalkley,	   1945;	   Ide	   et	   al.,	   1939).	   In	   1971,	   Judah	  
Folkman	   proposed	   that	   tumour	   growth	   was	   dependent	   on	   angiogenic	   vessel	  
growth	   and	   endothelial	   cell	   proliferation	   could	   be	   stimulated	   by	   a	   diffusible	  
factor	   produced	   by	   cancer	   cells.	   This	   factor	   enables	   endothelial	   cells	   to	   move	  
from	   their	   normal,	   quiescent	   phenotype	   to	   highly	   proliferative	   cells	   that	   form	  
new	   sprouting	  blood	   vessels.	   Tumour	   growth	   stalls	  without	  neovascularisation,	  
therefore,	   solid	   tumours	   larger	   than	   1-­‐2mm	   are	   always	   associated	   with	   blood	  
vessels	   predominantly	   via	   neovascularisation.	   Folkman	   coined	   the	   term	   “anti-­‐
angiogenesis”	   as	   a	   method	   of	   cancer	   therapy	   and	   hypothesised	   that	   tumours	  
may	   be	   most	   vulnerable	   to	   treatment	   in	   the	   short	   period	   before	   they	   induce	  
neovascularisation	  (Folkman,	  1971).	  Sustained	  angiogenesis	  was	  included	  as	  one	  
of	   the	  defining	   features	   common	   to	  all	   solid	   cancers	   in	   the	   seminal	  paper,	  The	  
Hallmarks	  of	  Cancer	  (Hanahan	  and	  Weinberg,	  2000).	  It	  is	  now	  clearly	  established	  
that	  angiogenesis	  is	  a	  rate-­‐limiting	  step	  during	  tumourigenesis	  and	  metastasis.	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The	   stimulation	  of	   vasculature	   expansion	  by	   the	   tumour	  has	   been	   traditionally	  
thought	   of	   as	   being	   controlled	   by	   the	   ‘angiogenic	   switch’.	   The	   switch	   is	  
controlled	  by	  the	  ratio	  between	  positive	  and	  negative	  regulators	  of	  angiogenesis.	  
Tumours	  secrete	  a	  variety	  of	  factors	  that	  simulate	  angiogenic	  growth.	  The	  VEGF	  
family	  of	  proteins,	  including	  VEGF-­‐A,	  VEGF-­‐C,	  VEGF-­‐D	  and	  PlGF,	  are	  all	  expressed	  
by	   cancer	   cells.	   FGF	   and	   ANGs	   are	   also	   implicated.	   VEGF-­‐A	   is	   a	   principle	   pro-­‐
angiogenic	  molecule	  during	  tumourigenesis.	  The	  hypoxic	  microenvironment	  of	  a	  
tumour	  can	  induce	  the	  release	  of	  many	  growth	  factors	  from	  the	  cancer	  cells.	  As	  
cancer	  cells	  divide	  to	  increase	  the	  tumour	  volume,	  oxygen	  availability	  is	  reduced.	  
Hypoxia	  stimulates	  transcriptional	  upregulation	  of	  pro-­‐angiogenic	  molecules.	  The	  
activity	  of	  certain	  oncogenes	  within	  cancer	  cells	  also	  contributes	  to	  the	  increased	  
expression	   of	   pro-­‐angiogenic	   factors.	   Acidity,	   hypoglycaemia	   and	   inflammation	  
also	  participate	  in	  the	  induction	  of	  the	  angiogenic	  switch	  (Bergers	  and	  Benjamin,	  
2003).	  
Before	   the	   induction	  of	  neovascularisation,	   small	   tumour	   lesions	  are	  avascular,	  
only	   tumours	   that	   induce	   angiogenesis	   can	   continue	   to	   expand	   (Figure	   1-­‐1).	  
Angiogenesis	   may	   be	   induced	   at	   varying	   stages	   during	   tumour	   development	  
depending	   on	   the	   cancer	   type	   and	   the	   surrounding	   microenvironment.	  
Furthermore,	   the	   vessel	   growth	   stimulated	   by	   tumours	   is	   different	   from	  
angiogenesis	   that	   occurs	   physiologically.	   	   Normal	   sprouted	   vessels	   mature	  
quickly	   and	  become	   stable	   structures.	   In	   tumour	   angiogenesis,	   the	  unbalanced	  
expression	  of	  pro	  vs.	  anti-­‐angiogenic	   regulators	   results	   in	  structurally	  abnormal	  
vessels.	  The	  shape	  of	   induced	  tumour	  vessels	   is	  disorganised	  and	  tortuous.	  The	  
capillaries	   within	   tumours	   are	   highly	   branched	   with	   variable	   diameter	   of	   the	  
vessel	   lumen.	   The	   vessels	   are	   also	   more	   permeable	   than	   normal,	   prone	   to	  
haemorrhage	   and	   have	   irregular	   interaction	  with	   pericytes.	  Due	   to	   the	   chaotic	  
organisation	   of	   tumour	   vasculature,	   the	   blood	   flow	   through	   the	   tumour	   is	  
irregular	   causing	   regions	  of	  hypoxia	  and	  acidity	  within	   the	   tumour.	   It	  has	  been	  
demonstrated	   that	   tumour	   cells	   can	   become	   incorporated	   into	   the	   vessel	  wall	  
forming	  a	  mosaic	  with	  endothelial	  cells	  (Carmeliet	  and	  Jain,	  2000).	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Figure	  1-­‐1	  Tumour	  angiogenesis	  
(A)	  During	  the	  early	  stages	  of	  tumour	  growth,	  cancer	  cells	  rely	  on	  pre-­‐existing	  
blood	  vessels	  for	  nourishment.	  (B)	  Hypoxia	  and	  factors	  secreted	  by	  the	  tumour	  
stimulate	  dilation	  of	  vessels	  and	  detachment	  from	  the	  basement	  membrane	  in	  
the	  angiogenic	  switch.	  (C)	  Nascent	  vessels	  begin	  to	  sprout	  through	  angiogenesis.	  
(D)	  Vessel	  growth	  continues	  with	  the	  vessels	  becoming	  more	  mature	  and	  
associated	  with	  pericytes.	  (E)	  Tumour	  can	  rapidly	  expand	  with	  its	  own	  
vasculature.	  Image	  from	  Bergers	  and	  Benjamin,	  2003.	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1.1.4 Anti-­‐angiogenesis  as  a  therapeutic  strategy  
Angiogenesis	   is	   infrequent	   in	   the	   healthy	   adult,	   but	   a	   major	   process	   in	   many	  
pathologies.	  This	  makes	  angiogenesis	  an	  attractive	  therapeutic	  target	  as	  it	  would	  
be	  expected	  for	  side	  effects	  to	  be	  limited.	  The	  growth	  factors	  and	  receptors	  that	  
mediate	   angiogenesis	   have	   been	   extensively	   investigated	   as	   drug	   targets	   with	  
several	  drugs	  approved	  for	  clinical	  use	  and	  many	  more	  in	  development.	  Most	  of	  
the	  approved	  therapies,	  for	  cancer	  and	  other	  angiogenic	  diseases,	  are	  anti-­‐VEGF	  
agents.	  
The	   humanized	  monoclonal	   antibody,	   bevacizumab,	   was	   the	   first	   angiogenesis	  
inhibitor	   to	   be	   used	   clinically	   in	   the	   United	   States	   (Ellis,	   2005).	   Bevacizumab	  
binds	   VEGF	   blocking	   its	   interaction	  with	   VEGFRs	   on	   the	   vascular	   endothelium.	  
Mouse	  models	  of	  angiogenesis	  were	  used	  to	  show	  the	  angiogenic	   inhibition	  via	  
VEGF	   blockade	   could	   impede	   tumour	   growth	   (Kim	   et	   al.,	   1993).	   The	   first	   trials	  
compared	   the	   effect	   of	   chemotherapeutic	   agents	   on	   colorectal	   cancer	   when	  
combined	  with	  bevacizumab	  or	  alone.	  Patient	  progression	  free	  survival	  (PFS)	  and	  
median	   overall	   survival	   (OS)	   were	   increased	   significantly	   by	   the	   use	   of	  
bevacizumab	  alongside	  chemotherapy	  (Hurwitz	  et	  al.,	  2004).	  The	  effectiveness	  of	  
bevacizumab	   has	   varied	   among	   different	   cancers.	   Neither	   PFS	   or	   OS	   were	  
changed	  when	  used	  in	  combination	  with	  capecitabine	  to	  treat	  metastatic	  breast	  
cancer	  (Miller	  et	  al.,	  2005).	  Bevacizumab	  is	  currently	  an	  approved	  therapy	  for	  the	  
treatment	   of	   metastatic	   colorectal	   cancer,	   non-­‐squamous	   non-­‐small	   cell	   lung	  
cancer	   (NSCLC),	   renal	   cell	   carcinoma	   (RCC)	   and	   glioblastoma	   (Cook	   and	   Figg,	  
2010).	  
As	  well	  as	  directly	  targeting	  VEGF,	  many	  attempts	  have	  been	  made	  to	  inhibit	  the	  
kinase	   activity	   of	   VEGF	   receptors.	   Sunitinib	   is	   a	   small	   molecule	   inhibitor	   of	  
VEGFR-­‐2	   and	   also	   has	   inhibitory	   action	   on	   PDFGR,	   Flt-­‐3	   and	   other	   receptor	  
tyrosine	   kinases.	   The	   inhibitor	   is	   used	   for	   treatment	   of	   gastrointestinal	   tract	  
tumours	  and	  renal	  cell	  carcinomas	  (Gan	  et	  al.,	  2009).	  The	  Raf	  inhibitor,	  sorafenib,	  
has	   been	   shown	   to	   have	   anti-­‐angiogenic	   activity	   via	   inhibition	   of	   VEGFR-­‐2,	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VEGFR-­‐3	  and	  PDGFRβ	  and	  provides	  survival	  benefit	  in	  hepatocellular	  cancers	  and	  
RCC	  (Wilhelm	  et	  al.,	  2008).	  
1.2  ALTERNATIVE  SPLICING  
1.2.1 Pre-­‐mRNA  splicing  
It	  was	   in	   1958	   that	   Crick	   first	   proposed	   ‘the	   sequence	  hypothesis’.	   This	   theory	  
suggested	   that	   the	   nucleotides	   of	   genetic	   material	   provide	   the	   code	   that	  
determines	  the	  amino	  acid	  sequence	  of	  proteins.	  This	  provides	  the	  basis	  for	  the	  
‘central	   dogma	  of	  molecular	   biology’-­‐	   double	   stranded	  DNA	   is	   transcribed	   to	   a	  
single	  stranded	  RNA	  molecule,	  which	  is	  then	  translated	  into	  protein	  (Crick,	  1958).	  
It	   was	   originally	   believed	   the	   mRNA	   molecules	   translated	   by	   ribosomes	   were	  
exact	  copies	  of	  DNA	  sequence.	  Through	   their	  work	  on	  viral	  genes,	  Roberts	  and	  
Sharp	   identified	  so-­‐called	   ’split	  genes’	   (Chow	  et	  al.,	  1977).	  They	  showed	  that	   in	  
viruses,	   some	  mRNAs	  were	   shorter	   than	   the	   DNA	   they	   were	   transcribed	   from	  
with	   large	   gaps,	   introns,	   cut	   out	   of	   the	   mRNA	   before	   it	   is	   translated.	   It	   was	  
quickly	   shown	   that	   most	   eukaryotic	   gene	   have	   this	   molecular	   structure,	   with	  
coding	   sequence	   (exons)	   interrupted	   by	   non-­‐coding	   sequence	   (introns).	   Pre-­‐
mRNA	   is	   transcribed	   from	  a	  gene,	   introns	   removed	  and	  exons	  are	   re-­‐joined	  by	  
the	  process	  of	  splicing	  to	  create	  mature	  mRNA	  transcripts.	  
For	  many	  years	   it	  was	  widely	  accepted	   that	  one	  gene	  holds	   the	   information	   to	  
create	   one	   polypeptide	   chain	   of	   amino	   acids	   (Beadle	   and	   Tatum,	   1941).	   This	  
proved	  to	  be	  an	  oversimplification.	  Sequencing	  of	  the	  human	  genome	  revealed	  
there	   to	   be	   far	   fewer	   genes	   than	   expected,	   especially	   in	   comparison	   to	   the	  
number	   of	   proteins	   that	   make	   up	   the	   proteome.	   The	   diversity	   of	   expressed	  
proteins	   is	   increase	   by	   various	   post-­‐translational	   and	   post-­‐transcriptional	  
modifications	   with	   one	   of	   the	  most	   important	   being	   alternative	   splicing.	   Early	  
estimates	   predicted	   around	   60%	   of	   human	   genes	   to	   be	   alternatively	   spliced	  
(Modrek	  and	  Lee,	  2002).	   	  More	  advanced	  transcriptomics	  has	  now	  revealed	  92-­‐
94%	  of	  genes	  may	  undergo	  alternative	  splicing	  (Pan	  et	  al.,	  2008).	  Comparison	  of	  
the	   transcriptomes	  between	   species	  has	  demonstrated	   that	  humans	  and	  other	  
primates	   have	   a	   higher	   frequency	   of	   alternative	   splicing	   events	   compared	   to	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other	   vertebrate	   species.	  Differences	   in	   alternative	   splicing	   patterns	   perform	  a	  
key	  role	   in	  creating	  species	  diversity.	  Around	  50%	  of	  alternative	  splicing	  events	  
are	   conserved	   between	   human	   and	   chimp.	   Conservation	   is	   further	   reduced	   in	  
mice,	  to	  less	  than	  30%	  commonality	  with	  humans	  (Barbosa-­‐Morais	  et	  al.,	  2012).	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1.2.2 The  spliceosome  
The	   molecular	   machinery	   that	   performs	   mRNA	   splicing	   is	   the	   spliceosome,	   a	  
large	   complex	   of	   protein	   and	   RNA	   molecules.	   The	   spliceosome	   components	  
assemble	  on	  an	  mRNA	   transcript	   and	   catalyse	   two	   transesterification	   reactions	  
to	   remove	   the	   intron	  and	   join	  exons.	  Splice	  sites,	  at	   the	  exon-­‐intron	  boundary,	  
are	  partially	  conserved	  sequences	  that	  are	  recognised	  by	  the	  splicing	  machinery.	  
5’	  splice	  sites	  have	  a	  conserved	  GU	  dinucleotide	  with	  the	  surrounding	  sequences	  
less	   conserved.	   At	   the	   end	   of	   the	   intron	   is	   a	   3’	   splice	   site,	   which	   has	   two	  
conserved	  bases,	   AG.	  Around	   15-­‐50	   bases	   upstream	  of	   the	   3’	   splice	   site	   is	   the	  
branch	  point,	   an	  adenosine	   that	   is	   critical	   for	   splicing	   catalysis	   is	   usually	   found	  
within	   this	   motif	   (Figure	   1-­‐2A).	   The	   branch	   point	   is	   followed	   by	   the	  
polypyrimidine	  tract,	  a	  sequence	  rich	  in	  uracil	  and	  cytosines.	  
The	  splicing	  reaction	  is	  guided	  by	  five	  small	  nuclear	  ribonucleoproteins	  (snRNPs),	  
U1,	  U2,	  U4,	  U5	  and	  U6,	  with	  many	  other	  associated	  proteins.	  SnRNPs	  associate	  
with	   transcripts	   via	   RNA-­‐RNA	   base	   pairing	   with	   short	   nucleotide	   motifs.	   The	  
mechanisms	   of	   spliceosome	   assembly	   and	   catalysis	   were	   predominantly	  
discovered	  using	  yeast	  as	  a	  model	  organism.	  During	  the	  first	  step	  of	  the	  splicing	  
reaction,	   the	  phosphate	  group	  of	   the	  guanine	  nucleotide	  at	   the	  5’	   splice	  site	   is	  
nucleophilically	  attacked	  by	  the	  2’	  hydroxyl	  group	  of	  the	  branch	  point	  adenosine	  
(Figure	  1-­‐2B).	  The	  upstream	  exon	  is	  released	  from	  the	  intron,	  which	  has	  formed	  a	  
lariat	   loop	   with	   the	   5’	   splice	   site	   joined	   to	   the	   branch	   point.	   In	   the	   second	  
transesterification	   step,	   the	   final	   phosphate	   of	   the	   intron	   is	   attacked	   by	   the	  
detached	   exon	   (Figure	   1-­‐2C).	   The	   intron	   lariat	   is	   released	   and	   the	   two	   exons	  
joined	  (Matera	  and	  Wang,	  2014).	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The	  spliceosome	  arranges	  into	  several	  different	  complexes	  through	  the	  different	  
stages	   of	   the	   splicing	   reaction	   (Figure	   1-­‐3).	   Exons	   are	   first	   recognised	   through	  
splice	   sites	   in	   the	   process	   of	   exon	   definition.	   Early	   spliceosome	   assembly	   is	  
centred	  around	  exons	  due	   to	   the	  much	   larger	   length	  of	   introns.	  This	   facilitates	  
splice	   site	   pairing	   to	   decide	   which	   sequence	   is	   removed	   from	   the	   transcript	  
(Berget,	   1995).	   The	   early	   components	   of	   the	   spliceosome	  make	   up	   complex	   E.	  
This	  stage	  is	  characterised	  by	  U1	  snRNP	  associating	  with	  the	  5’	  splice	  site	  via	  base	  
pairing.	  U2AF	  proteins	  35	  and	  65	  recognises	  the	  3’	  splice	  site	  and	  polypyrimidine	  
tract.	   Another	   spliceosomal	   protein	   component,	   SF1,	   binds	   the	   branch	   point	  
(Figure	   1-­‐3A)	   (Graveley	   et	   al.,	   2001).	   E	   complex	   formation	   is	   ATP-­‐dependent.	  

















Figure	  1-­‐2	  The	  splicing	  reaction	  
(A)	  The	  5’	  and	  3’	  splice	  sites	  form	  the	  boundaries	  between	  intron	  and	  exons.	  (B)	  
The	  first	  transesterification	  step	  joins	  the	  5’	  end	  of	  the	  intron	  to	  the	  branch	  point.	  
(C)	  In	  the	  second	  step,	  the	  5’	  exon	  attacks	  the	  3’	  splice	  site.	  (D)	  The	  two	  exons	  are	  
joined	  and	  the	  intronic	  lariat	  is	  released.	  Adapted	  from	  Black,	  2003.	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complex	  A,	   the	   pre-­‐spliceosome	   (Figure	   1-­‐3B).	   Interaction	   between	  U1	   and	  U2	  
from	   the	   5’	   and	   3’	   end	   of	   the	   intron	   makes	   the	   switch	   from	   exon	   to	   intron	  
definition.	   Complex	   A	   brings	   the	   splice	   sites	   and	   branch	   point	   within	   close	  
proximity.	  The	  pre-­‐assembled	  tri-­‐snRNP,	  formed	  by	  association	  of	  U4,	  U5	  and	  U6	  
snRNPs,	   joins	   the	   mRNA	   molecule	   creating	   complex	   B	   (Figure	   1-­‐3C).	   The	  
catalytically	  active	  complex	  B*	  is	  formed	  by	  further	  rearrangements	  releasing	  U1	  
and	  U4	  from	  the	  spliceosome	  and	  initiating	  the	  first	  transesterification	  reaction	  
(Figure	  1-­‐3D).	  The	  5’	  exon	  and	  intron	  lariat-­‐exon	  intermediate	  are	  bound	  by	  U2,	  
U5	  and	  U6	  snRNPs	  as	  the	  C	  complex	  (Figure	  1-­‐3E).	  The	  second	  transesterification,	  
to	   join	  the	  two	  exons,	   is	  carried	  out	  by	  complex	  C.	  U2,	  U5	  and	  U6	  are	  released	  
from	   the	   spliced	   mRNA	   bound	   to	   the	   intron	   lariat	   (Figure	   1-­‐3F)	   (Matera	   and	  
Wang,	  2014;	  Wahl	  et	  al.,	  2009).	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Figure	  1-­‐3	  Spliceosome	  assembly	  and	  splicing	  catalysis	  
(A)	  E	  complex	  is	  formed	  by	  U1	  snRNP	  binding	  the	  5’	  splice	  site	  and	  other	  factors	  
associating	  with	  the	  branch	  point	  and	  3’	  splice	  site.	  (B)	  U2	  snRNP	  replaces	  SF1	  at	  
the	  branch	  point	  forming	  A	  complex.	  (C)	  B	  complex	  is	  formed	  by	  tri-­‐snRNP	  joining	  
the	  spliceosome.	  (D)	  U1	  and	  U4	  dissociate	  from	  the	  pre-­‐mRNA.	  Rearrangements	  
make	  the	  B*	  complex	  which	  catalyses	  the	  first	  transesterification.	  (E)	  The	  C	  
complex	  catalyses	  the	  second	  reaction.	  (F)	  Two	  exons	  are	  joined	  and	  intron	  lariat	  





D	   E	  
F	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1.2.3 Alternative  splicing:  a  mechanism  to  increase  proteome  diversity  
Splicing	  is	  the	  process	  of	  removing	  intronic	  sequences	  and	  joining	  exons	  of	  mRNA	  
transcripts.	  The	  majority	  of	  human	  genes	  are	  multi-­‐exon	  with	  an	  average	  length	  
of	  an	  exon	  between	  50	  and	  250	  bases.	  Introns	  are	  far	  longer,	  usually	  thousands	  
of	   bases.	   Alternative	   splicing	   allows	   varying	   combinations	   of	   splice	   sites	   to	   be	  
used	  changing	  which	  exons	  or	  parts	  of	  exons	  are	  included	  in	  the	  final	  transcript.	  
Multiple	  mature	  mRNAs	  can	  be	  produced	  from	  a	  single	  gene	  leading	  to	  different	  
protein	   isoforms	  with	  altered	  amino	  acid	  sequences.	  This	  can	  cause	  changes	  to	  
the	  structure	  and	  function	  of	  the	  final	  protein	  (Black,	  2003).	  
Splicing	  mechanisms	   have	   been	   intensively	   studied	   in	   yeast.	   The	   splice	   sites	   in	  
Saccharomyces	   cerevisiae	   are	   highly	   conserved;	   this	   is	   not	   the	   case	   in	   higher	  
metazoans	   with	   far	   more	   variability	   in	   splice	   site	   sequences.	   This	   may	   be	   an	  
important	  feature	  in	  creating	  varied	  patterns	  of	  alternative	  splicing	  and	  produce	  
the	   need	   for	   many	   regulatory	   factors	   to	   promote	   or	   inhibit	   splice	   site	   use.	  
Genome	  sequencing	  has	  shown	  that	  humans	  do	  not	  possess	  many	  more	  genes	  
than	  many	  lower	  organisms	  despite	  being	  far	  more	  complex	  species.	  It	  is	  possible	  
that	   more	   opportunity	   for	   alternative	   splicing	   contributes	   to	   the	   increased	  
complexity	  of	  higher	  organisms	  (Kim	  et	  al.,	  2007).	  
The	   type	  of	   alternative	   splicing	   can	  be	   classified	   into	   several	   categories	   (Figure	  
1-­‐4).	  Constitutive	  exons	  are	  always	   included	   in	  the	  transcripts	  produced	  from	  a	  
particular	  gene.	  A	  cassette	  exon	  will	  be	   included	   in	   the	   final	   transcript	   in	  some	  
situations	  and	  excluded	  in	  others.	  Some	  genes	  have	  mutually	  exclusive	  cassette	  
exons,	   whereby	   one	   or	   the	   other,	   but	   never	   both	   exons,	   are	   included	   in	   the	  
mature	   mRNA.	   Some	   exons	   have	   multiple	   5’	   and	   3’	   splice	   sites,	   allowing	   the	  
length	   of	   the	   exon	   to	   be	   changed	   by	   alternative	   splicing.	   Intron	   retention	   is	   a	  
form	  of	  alternative	  splicing	  in	  which	  the	  intron	  remains	  as	  part	  of	  the	  final	  mRNA	  
transcript.	  	  Alternative	  promoters	  and	  polyadenylation	  sites	  can	  also	  be	  selected	  
changing	  the	  5’	  and	  3’	  exons	  of	  a	  transcript	  (Black,	  2003).	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C    Alternative 5’ splice site 
D    Alternative 3’ splice site 
E    Intron retention  
AAAA AAAA 
F     Alternative promoters 
G     Alternative polyadenylation sites 
A     Cassette exon 
B     Mutually exclusive exon 
Figure	  1-­‐4	  Forms	  of	  alternative	  splicing	  
(A)	  Skipping	  or	  inclusion	  of	  an	  alternatively	  spliced	  cassette	  exon.	  (B)	  Mutually	  exclusive	  
exons	  are	  never	  both	  included	  in	  the	  same	  mature	  mRNA.	  (C,	  D)	  Alternative	  5’	  and	  3’	  
splice	  sites	  shorten	  or	  lengthen	  an	  exon.	  (E)	  intron	  retention	  often	  produces	  a	  truncated	  
protein	  due	  to	  stop	  codons	  present	  in	  the	  intronic	  sequence.	  (F,	  G)	  Use	  of	  alternative	  
promoters	  and	  polyadenylation	  sites	  result	  in	  different	  proteins	  from	  the	  same	  
transcript	  but	  they	  are	  not	  purely	  an	  alternative	  splicing	  mechanism.	  Adapted	  from	  
Black,	  2003.	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1.2.4 Regulation  of  alternative  splicing  
Splicing	   removes	   introns	   and	   joins	   exons	   in	   pre-­‐mRNA	   transcripts	   from	  
multiexonic	  genes.	  Constitutively	  spliced	  exons	  are	  efficiently	  recognised	  by	  the	  
splicing	   machinery	   and	   follow	   the	   same	   pattern	   of	   splicing	   in	   all	   transcript	  
species	  from	  a	  particular	  gene.	  Alternative	  splicing	  allows	  different	  combinations	  
of	   exons	   to	   be	   joined	   resulting	   in	   a	   different	   protein	   product.	   95%	   of	   all	   split	  
genes	   are	   alternatively	   spliced	   in	   humans	   (Pan	  et	   al.,	   2008).	  During	   alternative	  
splicing,	   pairs	   of	   5’	   and	   3’	   splice	   sites	   are	   in	   competition	   with	   other	   potential	  
sites.	  The	  ‘strength’	  of	  a	  splice	  site	  will	  affect	  how	  often	  an	  exon	  is	  spliced,	  but	  
not	  all	   sequences	   that	  are	  predicted	  as	   strong	   splice	   sites	  are	  well	  used.	  There	  
are	   many	   ‘pseudo-­‐exons’	   within	   pre-­‐mRNA,	   which	   have	   exonic	   characteristics	  
but	  are	  not	  normally	  recognized	  by	  the	  spliceosome.	  
The	   decision	   of	   which	   splice	   sites	   are	   used	   -­‐determining	   which	   exons	   are	  
included	  in	  a	  mature	  transcript	  -­‐	  involves	  cis-­‐elements	  within	  the	  RNA	  sequence	  
and	   trans-­‐acting	   protein	   regulators.	   Cis-­‐splicing	   regulatory	   elements	   (SREs)	   are	  
divided	  into	  four	  categories	  depending	  on	  their	  function	  and	  location	  within	  pre-­‐
mRNA	   transcripts;	   exonic	   splicing	   enhancers	   (ESEs),	   exonic	   splicing	   silencers	  
(ESSs),	   intronic	   splicing	   enhancers	   (ISEs)	   and	   intronic	   splicing	   silencers	   (ISSs)	  
(Figure	   1-­‐5).	   Recognition	   of	   cis-­‐elements	   by	   splicing	   regulatory	   proteins	   is	  
involved	  in	  determining	  if	  a	  splice	  site	  is	  used.	  There	  are	  numerous	  RNA	  binding	  
proteins	   that	   recognise	   SREs	   and	   influence	   splicing	   decisions.	   Cis-­‐elements	   can	  
also	  influence	  splicing	  through	  the	  secondary/tertiary	  structure	  of	  the	  pre-­‐mRNA	  
molecule	  (Chen	  and	  Manley,	  2009).	  
Enhancer	   sequences	   are	   often	   bound	   by	  members	   of	   the	   serine/arginine	   (SR)-­‐
rich	  protein	  family,	  which	  can	  enable	  splice	  site	  recognition	  in	  both	  constitutive	  
and	   alternative	   splicing.	   Many	   SR	   proteins	   also	   have	   functional	   roles	   in	   other	  
mRNA	  related	  processes	  such	  as	  transcript	  nuclear	  export,	  translation	  and	  non-­‐
sense	  mediated	  decay	  of	  mRNAs.	  There	  are	  more	   than	   ten	  members	  of	   the	  SR	  
protein.	  At	  their	  N	  termini,	  SR	  proteins	  posses	  at	  least	  one	  RNA	  recognition	  motif	  
(RRM)	  domain	  allowing	  them	  to	  bind	  transcripts.	  SR	  proteins	  have	  many	  serine	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and	  arginine	  residues	  making	  up	  the	  RS	  domain,	  which	  can	  be	  phosphorylated	  to	  
regulate	   the	   protein	   activity	   (Long	   and	   Caceres,	   2009).	   SRs	   can	   facilitate	   the	  
recruitment	  of	  the	  U1	  snRNP	  and	  U2/U2AF	  complexes	  to	  particular	  splice	  sites	  by	  
association	  with	  an	  exonic	  enhancer	  sequence.	  SR	  proteins	  can	  form	  part	  of	  large	  
enhancing	   complexes	   with	   other	   splicing	   promoting	   factors	   including	  
transformer	  2	  (TRA2)	  and	  SRm	  proteins.	  Splice	  site	  recognition	  and	  recruitment	  
can	  also	  be	  facilitated	  by	  binding	  to	  intronic	  enhancers.	  SAM68	  promotes	  use	  of	  
a	   3’	   splice	   site	   in	  CD44	   transcripts	   through	   recruitment	  of	  U2AF	   (Tisserant	   and	  
Koenig,	   2008).	   In	   other	   cases,	   U1	   snRNP	   recruitment	   to	  weak	   5’	   splice	   sites	   is	  
enhanced	  by	  the	  protein	  T	  cell	  restricted	  intracellular	  antigen	  1	  (TIA1)	  binding	  to	  
a	  downstream	  intronic	  region	  (Forch	  et	  al.,	  2002).	  
Silencer	  sequences	  are	  highly	  variable.	  Some	  are	  known	  to	  be	  bound	  by	  hnRNPs	  
(heterogeneous	   ribonucleoprotein	  particle).	  hnRNPs	  also	   contain	  RRM	  domains	  
and	  also	  KH	  RNA	  binding	  domains.	  The	  hnRNP	  family	  have	  various	  roles	  in	  mRNA	  
processing.	  hnRNPA1	  and	  PTB	  (polypyrimidine	  tract	  binding	  protein)	  are	  known	  
splicing	  repressors.	  Splicing	  regulatory	  proteins	  frequently	  act	  by	  affecting	  early	  
spliceosome	  formation.	  Silencer	  sequences	  can	  inhibit	  splicing	  by	  interfering	  with	  
the	  binding	  of	  snRNPs	  to	  nearby	  splice	  sites.	  For	  example,	  PTB	  association	  with	  
the	   polypyrimidine	   tract	   can	   prevent	   U2AF	   binding	   required	   for	   spliceosome	  
assembly	  (Sauliere	  et	  al.,	  2006).	  FOX1	  and	  FOX2	  are	  important	  splicing	  factors	  in	  
muscle	  and	  neurons.	   FOXs	  prevent	   spliceosome	  assembly	  on	  CALCA	   transcripts	  
by	  binding	  an	  intronic	  sequence	  blocking	  SF1	  association	  with	  the	  branch	  point.	  
Inhibitory	  splicing	   factors	  also	  can	  reduce	  use	  of	  a	  splice	  site	  by	  preventing	  the	  
action	  of	  positive	  regulator	  proteins	  binding	  to	  enhancer	  sequences.	  FOX1	  and	  2	  
bind	  a	  sequence	  in	  a	  CALCA	  exon	  near	  an	  ESE	  binding	  site	  for	  TRA2,	  which	  is	  used	  
to	  recruit	  U2AF	  (Zhou	  and	  Lou,	  2008).	  But	  some	  silencer	  sequences	  are	   located	  
hundreds	   of	   bases	   away	   from	   enhancers	   and	   splice	   sites;	   therefore	   blocking	  
enhancer	  binding	  does	  not	  explain	  their	  silencing	  function.	  These	  sequences	  may	  
facilitate	   the	   formation	   of	   loops	   in	   the	   pre-­‐mRNA	  molecule	   structure,	   altering	  
spliceosome	  formation.	  Splice	  sites	  and	  ESEs/ISEs	  can	  be	  masked	  by	  changes	   in	  
the	   secondary	   structure	   of	   pre-­‐mRNA.	   Ultimately,	   splicing	   decisions	   are	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controlled	   by	   the	   combination	   of	   activators	   and	   repressors.	   Some	   splicing	  
regulatory	  proteins	  can	  even	   inhibit	  or	   induce	  splicing	  when	  bound	  at	  different	  
positions	  on	  the	  RNA	  (Ule	  et	  al.,	  2003).	  For	  example,	  some	  cassette	  exons	  can	  be	  
spliced	   or	   silenced	   by	   hnRNPL	   depending	   on	   which	   downstream	   sequence	   it	  
associates	  with.	  NOVA1	  binds	  an	  exonic	  silencer	  sequence	  in	  its	  own	  pre-­‐mRNA	  
but	  promotes	  inclusion	  of	  exons	  in	  other	  genes	  (Dredge	  et	  al.,	  2005).	  
	  
Figure	  1-­‐4	  Regulation	  of	  alternative	  splicing	  by	  SREs	  and	  trans-­‐acting	  factors	  
Splicing	  regulatory	  elements	  (SREs)	  are	  sequences	  within	  mRNA	  transcripts	  that	  
are	  bound	  by	  splicing	  regulatory	  proteins.	  SREs	  are	  classified	  according	  to	  their	  
location	  and	  activity:	  ISS	  (intronic	  splicing	  silencer),	  ESE	  (exonic	  splicing	  
enhancer),	  ESS	  (exonic	  splicing	  silencer),	  ISE	  (intronic	  splicing	  enhancer).	  SR	  
proteins	  commonly	  bind	  enhancers	  promoting	  selection	  of	  a	  certain	  splice	  site.	  
hnRNPs	  predominantly	  act	  as	  negative	  regulators.	  Adapted	  from	  Black,	  2003.	  
	  
Understanding	  splicing	  regulation	  becomes	  further	  complex	  by	  considering	  that	  
splicing	  occurs	   co-­‐transcriptionally.	  RNA	  binding	  proteins	  quickly	  associate	  with	  
the	  nascent	  pre-­‐mRNA	   transcript	   as	   it	   emerges	   from	  RNA	  polymerase	   II.	   Splice	  
factors	  may	   interact	  with	  RNA	  polymerase	   II	   to	  enhance	  or	   inhibit	   the	  use	  of	  a	  
particular	  splice	  site.	  There	  is	  also	  evidence	  indicating	  the	  speed	  of	  transcription	  
is	   associated	  with	   selection	   of	   alternative	   splice	   sites.	   Phosphorylation	   of	   RNA	  
polymerase	   II	   can	   alter	   the	   rate	   of	   pre-­‐mRNA	   synthesis	   potentially	   influencing	  
splicing	  (Naftelberg	  et	  al.,	  2015).	  
1.2.5 Cell  signalling  pathways  that  regulate  alternative  splicing  
Differential	   alternative	   splicing	  occurs	  between	   tissues,	  often	  via	   tissue	   specific	  
expression	  of	  many	  regulatory	  proteins.	  But	  various	  stimuli	  can	  the	  alter	  pattern	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of	  alternative	  splicing	  in	  a	  cell	  without	  changing	  the	  expression	  of	  splice	  factors.	  
Increasing	  evidence	  indicates	  that	  hormones	  and	  growth	  factors	  along	  with	  other	  
stimuli	   influence	   pre-­‐mRNA	   splicing.	   Like	   many	   other	   cellular	   processes,	  
signalling	  cascades	  can	  act	  to	  transduce	  signals	  to	  the	  nucleus	  in	  order	  to	  modify	  
alternative	  splicing	  events.	  
Post-­‐translational	   modifications	   of	   RNA	   binding	   proteins	   can	   be	   induced	   by	  
signals	   from	  within	   and	   outside	   the	   cell.	   Various	   signalling	  molecules,	   such	   as	  
JNK,	  MEK,	  PKC	  and	  ERK,	  have	  been	   shown	   to	  mediate	  pathways	   that	   influence	  
splicing	   decisions	   (Pelisch	   et	   al.,	   2005;	   van	   der	  Houven	   van	  Oordt	   et	   al.,	   2000;	  
Weg-­‐Remers	  et	  al.,	  2001;	  Xie	  and	  Black,	  2001).	  Phosphorylation	  of	  splice	  factors	  
by	   kinases	   can	   change	   their	   localisation	   within	   the	   cell	   and	   effect	   their	  
association	  with	  other	  proteins	  and	  RNA	  molecules.	  For	  example,	   stress	   signals	  
can	   induce	   changes	   to	   the	   MEK4/7-­‐MAPK	   p38	   pathway	   altering	   the	   cellular	  
localisation	  of	  hnRNP	  A1	  (van	  der	  Houven	  van	  Oordt	  et	  al.,	  2000).	  
SRSF	   protein	   kinases	   (SRPKs)	   	   are	   known	   to	   be	   important	   modulators	   of	  
alternative	  splicing	  via	  phosphorylation	  of	  SR	  proteins.	  Cell	  signalling	  by	  growth	  
factors	   can	   be	   linked	   to	   changes	   in	   splicing	   patterns	   via	   splice	   factor	  
phosphorylation.	  For	  example,	  epidermal	  growth	  factor	   (EGF)	  binding	  to	   its	  cell	  
surface	   receptor	   initiates	   a	   signalling	   cascade	   increasing	   the	   activity	   of	   SRPK1.	  
SRPK1	   is	   known	   to	  phosphorylate	   the	   SR	  protein	   SRSF1	   causing	   changes	   in	   the	  
alternative	  splicing	  of	  SRSF1	  target	  mRNAs.	  EGF	  signal	  transduction	  is	  thought	  to	  
be	  mediated	  by	  Akt,	  which	   is	   involved	   in	   regulating	  phosphorylation	  of	   various	  
splicing	  factors	  (Shultz	  et	  al.,	  2010;	  White	  et	  al.,	  2010).	  Interplay	  between	  growth	  
factors	  and	  SRPKs/SR	  proteins	  may	  provide	  key	  regulation	  of	  alternative	  splicing	  
decisions	  (Zhou	  et	  al.,	  2012).	  
1.2.6 Splicing  in  disease  and  therapy  
Given	  that	  splicing	  is	  a	  fundamental	  and	  widespread	  step	  in	  the	  process	  of	  gene	  
expression,	   it	   is	   unsurprising	   that	   disease	   can	   arise	   from	   abnormal	   splicing.	  
Mutations	  within	  the	  genome	  may	  affect	  the	  sequence	  of	  consensus	  splice	  sites	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or	  regulatory	  elements.	  New	  cryptic	  splice	  sites	  and	  enhancers/silencers	  may	  be	  
created	   by	   mutation	   or	   current	   sites	   and	   elements	   may	   be	   damaged	   (Garcia-­‐
Blanco	  et	  al.,	  2004).	  Many	  mutations	  that	  are	  predicted	  to	  be	  silent	  as	   they	  do	  
not	  alter	  the	  encoded	  amino	  acid	  may	  disrupt	  splicing	  or	  other	  RNA	  processing	  
mechanisms	  (Lee	  and	  Rio,	  2015).	  
Blood	  disorders,	   such	   as	  β-­‐	   thalassemia,	   can	   cause	   acute	  episodes	  of	   anaemia.	  
Some	  β-­‐thalassemia	  cases	  are	  caused	  by	  mutation	  of	  the	  β-­‐globin	  gene	  creating	  a	  
cryptic	   3’	   splice	   site	   (Busslinger	   et	   al.,	   1981).	   Another	   well-­‐described,	   splicing-­‐
related	   genetic	   disease	   is	   spinal	   muscular	   atrophy	   (SMA).	   The	   disease	   causes	  
muscle	  atrophy	  with	  anterior	  horn	  motor	  neurons	  becoming	  degenerated	  over	  
time.	  The	  phenotype	  ranges	  from	  mild	  to	  severe.	  Two	  paralogous	  genes,	  SMN1	  
and	  SMN2	  produce	   survival	   of	  motor	   neuron	  proteins.	   Loss	   of	   the	   SMN1	  gene	  
causes	  SMA	  but	  the	  severity	  of	  the	  disease	  is	  dependant	  on	  the	  protein	  produced	  
from	  the	  SMN2	  gene.	  SMN2	  has	  a	  mutation	  in	  exon	  7	  that	  increases	  skipping	  of	  
the	   exon	   during	   splicing	   creating	   non-­‐functional	   protein	   and	   a	   more	   severe	  
disease	  phenotype.	   It	   is	   thought	  that	  transition	  of	  a	  single	  nucleotide	   in	  exon	  7	  
may	  create	  a	  silencer	  sequence	  or	  disrupt	  an	  enhancer	  (Singh	  et	  al.,	  2004).	  
Alternative	   splicing	   can	   produce	   multiple	   proteins	   from	   a	   single	   gene.	   The	  
balance	   between	   expression	   of	   differentially	   spliced	   isoforms	   is	   important	   and	  
defects	   in	   isoform	  ratios	  can	  be	  disease	  causing.	  For	  example,	  the	  microtubule-­‐
associated	   protein,	   Tau,	   is	   encoded	   by	   the	   MAPT	   gene.	   Alternative	   splicing	  
produces	  six	  Tau	  protein	  isoforms,	  which	  either	  include	  or	  have	  exon	  10	  skipped.	  
Exon	  10	  encodes	  one	  of	   four	  microtubule	   repeats.	   The	   isoform	  balance	   is	   very	  
important	  for	  appropriate	  neuronal	  function.	  Normally	  in	  the	  brain,	  there	  is	  a	  1:1	  
ratio	  of	  protein	  isoforms	  with	  exon	  10	  included	  (four	  repeats)	  or	  skipped	  (three	  
repeats).	  Many	  mutations	   effecting	   Tau	   function	   are	   linked	   to	   development	   of	  
fronto-­‐temporal	  dementia	  with	  Parkinsonism	  (FTDP-­‐17).	  Several	  mutations	  have	  
been	  shown	  to	   induce	  or	  reduce	  exon	  10	   inclusion	   in	  MAPT	  transcripts	  altering	  
the	  isoform	  ratio	  leading	  to	  neurodegeneration	  (Spillantini	  et	  al.,	  1998;	  Spillantini	  
et	  al.,	  2000).	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Attempts	  have	  been	  made	  to	  change	  alternative	  splicing	  patterns	  as	  a	  method	  to	  
treat	   disease.	   Targeted	   oligonucleotides	   have	   been	   used	   to	   initiate	   or	   inhibit	  
certain	  splicing	  events	  by	  base	  pairing	  with	  an	  RNA	  sequence	  and	  either	  blocking	  
binding	   of	   regulators	   or	   recruiting	   other	   factors.	   One	   of	   the	   diseases	   that	   has	  
been	  intensively	  investigated	  in	  terms	  of	  using	  spicing	  modifiers	  as	  therapeutics	  
is	   Duchenne	  muscular	   dystrophy.	  Mutations	   in	   the	   dystrophin	   gene	   can	   cause	  
frame	   shifts	   in	   the	   sequence	   resulting	   in	   premature	   termination	   during	  
translation.	   Loss	  of	  dystrophin	   leads	   to	  muscle	  weakness	  and	  heart/respiratory	  
problems,	  and	  ultimately,	  premature	  mortality.	   In	  a	  mouse	  model	  of	  Duchenne	  
muscular	  dystrophy,	  mice	  have	  a	  mutation	  within	  exon	  23	  of	  the	  gene	  encoding	  
dystrophin	  in	  exon	  23.	  Dystrophin	  with	  exon	  23	  mutation	  is	  not	  functional	  due	  to	  
a	   frame	  shift.	  Antisense	  oligonucleotides	  were	  designed	  to	  base	  pair	  with	  exon	  
23	   pre-­‐mRNA	   and	   cause	   it	   to	   be	   skipped.	   The	   translated	   protein	   has	   partial	  
functionality.	  Mice	  treated	  with	  the	  oligomer	  had	  enhanced	  muscle	  function	  (Lu	  
et	  al.,	  2003).	  Similarly,	  oligo	  nucleotides	  have	  also	  reached	  human	  clinical	  trials.	  
Kinali	   et	   al.,	   delivered	   a	   dystrophin-­‐targeting	   oligo	   nucleotide	   to	   patients	   with	  
Duchenne	  muscular	   dystrophy	   as	   an	   intramuscular	   injection	   into	   the	   extensor	  
digitorum	   brevis	   muscle	   of	   the	   foot.	   The	   oligo	   induced	   skipping	   of	   dystrophin	  
exon	  51	  during	  splicing	  and	  increased	  to	  expression	  of	  dystrophin	  in	  the	  treated	  
muscle	   (Kinali	   et	   al.,	   2009).	   Additional	   investigations	   were	   performed	   using	  
intravenous	   infusions	   of	   the	   same	   oligo	   nucleotide	   as	   a	   novel	   treatment.	   No	  
adverse	   side	   effects	   were	   observed	   and	   dystrophin	   protiein	   expression	   was	  
increased	   (Cirak	   et	   al.,	   2011).	   Various	   clinical	   trails	   using	   different	  
oligonucleotides	  have	  also	  been	  conducted	   (Goemans	  et	  al.,	  2013;	  Goemans	  et	  
al.,	  2011).	  
Changes	   in	   the	   levels	   of	   splice	   factors	   and	   associated	   proteins	   can	   also	   cause	  
wide-­‐ranging	   defects.	   Small	   molecule	   inhibitors	   have	   been	   used	   to	   modify	  
splicing	  by	  interfering	  with	  upstream	  proteins	  involved	  in	  regulating	  splice	  factor	  
activity	   using	   post-­‐transcriptional	   modification.	   For	   example,	   inhibiting	   Clk1	  
kinase	  can	  alter	   splicing	  events	  dependent	  on	  one	  of	   its	   target	  proteins,	   SRSF1	  
(Muraki	  et	  al.,	  2004).	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1.2.7 Cancer  and  alternative  splicing  
Cancer	   cells	   exhibit	   radical	   changes	   across	   all	   regulatory	   stages	   of	   gene	  
expression	   including	   chromatin	   arrangement,	   transcription,	   mRNA	  
polyadenylation,	   alternative	   splicing,	   translation	   or	   post-­‐translational	  
modifications.	   Faulty	   alternative	   splicing	   in	   cancer	   has	  wide-­‐ranging	   effects	   on	  
cellular	  processes	  such	  as	  control	  of	  the	  cell	  cycle,	  angiogenesis	  and	  invasion	  and	  
metastasis.	  Cancer	  cells	  can	  alter	  the	  splicing	  regulatory	  mechanisms	  to	  produce	  
protein	   isoforms	   that	   are	   beneficial	   for	   their	   survival	   and	   growth.	   Aberrant	  
splicing	  occurs	  on	  a	  large	  scale	  in	  tumours	  often	  caused	  by	  distorted	  expression	  
and/or	   regulation	   of	   RNA	   binding	   proteins.	   hnRNP	   A1	   expression	   is	   linked	   to	  
increased	   cell	   proliferation	   and	   is	   upregulated	   in	   breast,	   colorectal,	   lung	   and	  
other	   cancers.	   hnRNP	   A2	   is	   also	   frequently	   overexpressed	   in	   various	   cancers	  
(David	  and	  Manley,	  2010).	  Increased	  hnRNPs	  can	  reduce	  apoptosis	  and	  increase	  
proliferation.	  Another	   important	   splicing	   regulatory	  protein,	  PTB,	  has	   increased	  
expression	   in	   ovarian	   cancers	   and	   glioma.	   The	   SR	   protein,	   SRSF1,	   has	   been	  
investigated	   regarding	   its	   role	   in	   promoting	   cancer	   growth.	   SRSF1	   has	   been	  
classed	  as	  proto-­‐oncogene	  and	  is	  associated	  with	  alternative	  splicing	  events	  that	  
can	  alter	  cell	  motility	  and	  can	  transform	  immortalised	  cells	   in	  vitro	  (Karni	  et	  al.,	  
2007).	  
Some	  of	  the	  changes	  to	  alternative	  splicing	  have	  functional	  activity	  in	  helping	  to	  
promote	  cancer	  growth.	  Frequently,	  alternative	  splicing	  can	  create	  two	  proteins	  
from	  the	  same	  gene	  with	  opposing	  activity.	  Cancer	  cells	  can	  use	  this	   feature	  to	  
increase	  expression	  of	  a	  splice	  isoform	  that	  is	  beneficial	  for	  the	  tumour.	  A	  well-­‐
studied	   example	   of	   this	   is	   the	   proteins	   of	   apoptotic	   pathways.	   One	   of	   the	  
important	   features	   of	   cancer	   cells	   is	   their	   ability	   to	   evade	   cell	   death	   through	  
apoptotic	  pathways.	  Several	  genes	  that	  encode	  apoptotic	  regulatory	  proteins	  can	  
produce	   isoforms	  with	   pro-­‐	   or	   anti-­‐apoptotic	   activity	   depending	   on	   alternative	  
splicing	  of	  the	  pre-­‐mRNA.	  For	  example,	  the	  protein	  Bcl-­‐x(s)	   is	  pro-­‐apoptotic	  but	  
use	  of	  a	  alternative	  5’	  splice	  site	  in	  exon	  2	  of	  the	  pre-­‐mRNA	  creates	  the	  protein	  
Bcl-­‐x(L),	  which	  inhibits	  cell	  death	  through	  apoptosis.	  Various	  cancers	  display	  high	  
Bcl-­‐x(L)	   to	   –x(s)	   ratio	   with	   increased	   Bcl-­‐x(L)	   associated	   with	   higher	   risk	   of	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metastasis	   and	   a	   reduced	   response	   to	   chemotherapy.	   The	   significance	   of	   Bcl-­‐x	  
splicing	  regulation	  was	  demonstrated	  by	  targeting	  oligonucleotide	  probes	  to	  Bcl-­‐
x	  RNA,	   increasing	  use	  of	   the	   splice	   site	   for	   the	  pro-­‐apoptotic	  Bcl-­‐x(s).	  Changing	  
the	  ratio	  of	  Bcl-­‐x(L)	  to	  –x(s)	  was	  able	  stimulate	  apoptosis	  in	  a	  prostate	  cancer	  cell	  
line	  (Mercatante	  et	  al.,	  2002).	  
Alternative	   splicing	   is	   an	   important	   regulatory	   step	   in	   another	   of	   the	   cancer	  
hallmarks,	   invasion	   and	  metastasis.	   As	   tumours	   grow	   they	   can	   acquire	   a	  more	  
invasive	   phenotype	   by	   undergoing	   epithelial-­‐mesenchymal	   transition	   (EMT).	  
Transition	  of	  epithelial	  cells	  towards	  a	  mesenchymal	  phenotype	  involves	  changes	  
in	   transcription,	   post-­‐transcriptional	  modifications	   and	   alternative	   splicing.	   It	   is	  
well	  established	  that	  the	  alternative	  splicing	  of	  fibroblast	  growth	  factor	  receptor	  
II	   (FGFRII)	   transcripts	   is	   linked	   to	   EMT.	   FGFRII	   has	   two	   mutually	   exclusive	  
alternative	  exons-­‐	  exon	  IIIb	  and	  IIIc.	  Epithelial	  cells	  select	  exon	  IIIb	  to	  be	  included	  
in	  FGFRII.	  During	  EMT	  there	  is	  a	  switch,	  with	  exon	  IIIc	  inclusion	  characteristic	  of	  
mesenchymal	   phenotype.	   Many	   other	   changes	   in	   cellular	   function	   occur	  
alongside	   the	   switch	   in	   IIIb/IIIc.	   The	   RNA	   binding	   proteins	   hnRNPA1	   and	   PTB,	  
which	  are	  known	  to	  be	  overexpressed	  in	  cancers,	  are	  involved	  in	  silencing	  exon	  
IIIc	  (Yasumoto	  et	  al.,	  2004).	  Two	  key	  regulators	  of	  alternative	  splicing,	  ESRP1	  and	  
ESRP2,	  were	  identified	  by	  searching	  for	  genes	  involved	  in	  promoting	  IIIb	  splicing.	  
ESRPs	   (epithelial	   splicing	   regulatory	   proteins)	   are	   expressed	   only	   in	   epithelial	  
cells	  with	  expression	  lost	  during	  EMT.	  Overexpression	  of	  ESRPs	  in	  mesenchymal	  
cells	   can	   reverse	   the	   splicing	   of	   FGFRII,	   silencing	   IIIc.	   ESRPs	   are	   thought	   to	   be	  
tumour	  suppressors	  by	  acting	  as	  master	  regulators	  of	  the	  splicing	  decisions	  that	  
define	  epithelial	  phenotype	  (Warzecha	  et	  al.,	  2009).	  
1.2.8 Using  small  molecules  to  modulate  alternative  splicing  
With	   the	   implication	   of	   aberrant	   alternative	   splicing	   during	   various	   diseases	  
established	   and	   the	  mechanisms	   of	   regulation	   becoming	   clearer,	   attempts	   are	  
being	  made	  to	  find	  small	  molecules	  that	  can	  change	  alternative	  splicing	  patterns	  
during	  disease	  to	  provide	  therapeutic	  benefit.	  Small	  molecule	  modifiers	  are	  also	  
important	   during	   basic	   research	   as	   tools	   to	   further	   our	   understanding	   of	   the	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biological	  processes	  that	  control	  splicing.	  Some	  chemotherapeutic	  drugs,	  such	  as	  
cisplatin,	   also	   have	   an	   effect	   on	   alternative	   splicing.	   The	   splicing	   of	   several	  
apoptotic	   genes	  are	  modified	  by	   chemotherapy,	  which	  may	   contribute	   to	   their	  
anti-­‐tumour	  activity	  (Shkreta	  et	  al.,	  2008).	  	  
Many	   small	  molecules	   shown	   to	  modify	   splicing	   directly	   target	   components	   of	  
the	   spliceosome,	   inhibiting	   splicing	   in	   general	   but	   others	   have	   been	   found	   to	  
indirectly	   modify	   alternative	   splicing	   patterns	   by	   interfering	   with	   upstream	  
regulatory	  pathways.	  For	  example,	  amiloride	  is	  an	  inhibitor	  of	  sodium/hydrogen	  
exchanger	   isoform	   1	   (NHE1).	   NHE1	   is	   a	   membrane	   spanning	   ion	   transporter	  
involved	   in	   regulating	   the	   volume	   and	   pH	   of	   the	   cell.	   Amiloride	   acts	   as	   a	  
potassium	  sparing	  diuretic	  and	  as	  been	  used	  to	  treat	  hypokalaemia,	  oedema	  and	  
as	  an	  anti-­‐hypertensive.	  More	  recently,	  amiloride	  has	  also	  been	  found	  to	  effect	  
alternative	   splicing	   in	   leukaemic	   cells.	   	   The	   Bcl-­‐x	   and	   HIPK3	   gene	   are	   both	  
apoptotic	   regulators,	   their	   transcripts	   can	   be	   alternatively	   spliced	   to	   create	  
isoforms	   with	   either	   pro-­‐	   or	   anti-­‐apoptotic	   activity.	   Amiloride	   treatment	   of	  
leukaemic	   cells	   increased	   the	   presence	   of	   pro-­‐apoptotic	   transcripts.	   A	   genome	  
wide	   exon	   array	   showed	   amiloride	   to	   also	   affect	   the	   alternative	   splicing	   of	  
several	  other	  gene	  transcripts	  associated	  with	  apoptosis,	  including	  SURVIVIN	  and	  
APAF-­‐1.	   The	   effect	   of	   amiloride	   on	   alternative	   splicing	   may	   be	   mediated	   via	  
changes	  in	  activity	  and/or	  expression	  of	  certain	  splice	  factors.	  SRSF1	  expression	  
and	   phosphorylation	   were	   reduced	   upon	   amiloride	   treatment,	   whereas	  
hnRNP	  A1	  expression	   increased.	   SR	  proteins	  are	   targets	   for	  phosphorylation	  by	  
certain	   kinases	   and	   dephosphorylation	   by	   phosphatases.	   Amiloride	   treatment	  
increased	   activation	   of	   the	   phosphatase,	   PP1.	   Reduction	   in	   SR	   protein	  
phosphorylation	  by	  amiloride	  may	  be	  mediated	  by	  activated	  PP1	   (Chang	  et	  al.,	  
2011).	  
In	  another	  example,	  several	  small	  molecules	  have	  been	  identified	  with	  the	  ability	  
to	   influence	   SMN2	   alternative	   splicing	   (Naryshkin	   et	   al.,	   2014).	   As	   described	  
above,	   the	  SMN2	  protein	   is	  non-­‐functional	  due	   to	  a	  mutation	   in	  exon	  7	  of	   the	  
gene,	  which	  promotes	  skipping	  of	  the	  exon	  leading	  to	  the	  protein	  product	  being	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degraded.	   The	  neuromuscular	   disorder,	   SMA,	  occurs	  when	   the	  paralogue	   gene	  
SMN1	   is	   deleted	   (Lewelt	   et	   al.,	   2012).	   There	   is	   currently	   no	   treatment	   that	  
targets	   the	   cause	   of	   the	   disease.	   Disease	   severity	   depends	   on	   the	   levels	   of	  
functional	  SMN	  protein	  produced	  with	  a	  70%	  reduction	  in	  protein	  during	  severe	  
type	   I	   SMA	   and	   30%	   with	   mild	   type	   III	   SMA.	   Changing	   alternative	   splicing	   to	  
increase	  the	  level	  of	  full	  length	  SMA	  may	  provide	  therapeutic	  benefit.	  	  A	  screen	  
was	   performed	   using	   a	   large	   library	   of	   compounds	   and	   three	   small	   molecules	  
identified	  as	  able	   to	   induce	   inclusion	  of	  exon	  7	   in	  SMN2	   transcripts,	   increasing	  
levels	  of	  full-­‐length	  protein	  in	  cells	  from	  SMA	  patients.	  Whole-­‐transcriptome	  RNA	  
sequencing	   demonstrated	   that	   these	   molecules	   are	   relatively	   specific,	   only	  
changing	   splicing	   of	   a	   few	   pre-­‐mRNAs.	   In	   a	  mouse	  model	   of	   severe	   SMA,	   the	  
levels	   of	   full-­‐length	   SMN	   were	   increased	   by	   treatment	   with	   the	   compounds.	  
Motor	   functions	   of	   the	   mice	   were	   improved	   and	   the	   life	   span	   extended	  
(Naryshkin	   et	   al.,	   2014).	   In	   a	   separate	   investigation,	   several	   analogues	   of	  
cantharidin,	   a	   phosphatase	   inhibitor,	   were	   found	   to	   increase	   the	   inclusion	   of	  
exon	  7	   in	  SMN2	   transcripts.	   Cantharidin	   and	   the	  analogues	  block	   the	  action	  of	  
the	   phosphatase	   PP1	   causing	   reduced	   phosphorylation	   of	   the	   splicing	   factor	  
TRA2β	  and	  increased	  exon	  7	  inclusion	  (Zhang	  et	  al.,	  2011).	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1.3  VASCULAR  ENDOTHELIAL  GROWTH  FACTOR  
1.3.1 VEGF  
The	   regulation	   and	   co-­‐ordination	   of	   angiogenesis	   is	   an	   intricate	   process	   with	  
numerous	  growth	  factors,	  cytokines,	  signalling	  molecules	  and	  receptors	  involved.	  
Vascular	   endothelial	   growth	   factor	   is	   an	   essential	   and	   the	   most	   intensively	  
investigated	  regulator	  of	  angiogenesis.	  VEGF,	  also	  known	  as	  VEGF-­‐A,	  is	  part	  of	  a	  
family	   of	   growth	   factors,	   which	   include	   VEGF-­‐B,	   -­‐C,	   -­‐D,	   and	   placental	   growth	  
factor	   (PlGF).	   VEGF-­‐C	   and	   VEGF-­‐D	   have	   important	   roles	   in	   the	   regulation	   of	  
lymphangiogensis	   whereas	   PlGF	   seems	   to	   only	   be	   important	   during	   pathology	  
(Ferrara	  et	  al.,	  2003).	  
When	  Folkman	  proposed	  inhibiting	  angiogenesis	  as	  a	  method	  to	  treat	  cancer,	  he	  
hypothesised	   that	   a	   diffusible	   factor	   produced	   by	   tumours	   promotes	   vessel	  
growth	   (Folkman,	   1971).	   This	   had	   previously	   been	   demonstrated	   in	   vivo	   as	  
implanted	  melanoma	  cells	  were	  able	  to	  induce	  vessel	  growth	  even	  when	  a	  filter	  
was	  applied	  between	  the	  tumour	  and	  the	  host	  (Ehrmann	  and	  Knoth,	  1968).	  This	  
diffusible	   molecule	   was	   partially	   isolated	   from	   tumour	   and	   able	   to	   induce	  
neovascularisation	  in	  the	  dorsal	  air	  sac	  model	  (Folkman	  et	  al.,	  1971)	  and	  released	  
by	   cultured	   tumour	   cells	   (Klagsbrun	   et	   al.,	   1976).	   In	   1983,	   a	   protein	   that	  
promoted	  microvascular	   leakage	  was	   shown	   to	   be	   released	   by	   several	   tumour	  
cell	   lines.	   The	   protein	   was	   given	   the	   name	   vascular	   permeability	   factor	   (VPF)	  
(Senger	   et	   al.,	   1983).	   Separately,	   Ferrara	   and	   colleagues	   isolated	   a	   mitogenic	  
factor	   that	   could	   promote	   endothelial	   proliferation.	   Sequencing	   of	   the	   protein	  
did	  not	  match	  any	  of	   the	  currently	  known	  angiogenic	   factors	  such	  as	  bFGF	  and	  
was	   termed	   vascular	   endothelial	   growth	   factor.	   Sequencing	   of	   the	   cDNA	  
encoding	  VEGF	   and	  VPF	   revealed	   them	   to	  be	   the	   same	  protein	   (Ferrara,	   2002;	  
Keck	  et	  al.,	  1989;	  Leung	  et	  al.,	  1989).	  
1.3.2 VEGF-­‐A  gene  
Vascular	   endothelial	   growth	   factor	   A	   is	   encoded	   by	   the	   VEGF-­‐A	   gene	   (Figure	  
1-­‐5A).	   Alternative	   splicing	   of	   the	   gene’s	   8	   exons	   creates	   several	   isoforms	   of	  
varying	  lengths	  (Tischer	  et	  al.,	  1991).	  Exons	  1-­‐5	  are	  constitutive,	  with	  alternative	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splicing	   of	   exons	   6-­‐8	   creating	   the	   different	   isoforms.	   The	   most	   commonly	  
described	  are	  VEGF121,	  VEGF165	  and	  VEGF189,	  the	  number	  indicates	  the	  amino	  acid	  
length	  of	  the	  translated	  protein	  (Figure	  1-­‐5B,	  upper	  panel).	  
The	  longer	  isoforms,	  VEGF189	  and	  VEGF206,	  contain	  amino	  acids	  encoded	  by	  exon	  
6	   and	   bind	   to	   the	   cell	   surface	   and	   the	   extracellular	  matrix.	   VEGF165	   is	   partially	  
secreted	   with	   a	   proportion	   sequestered	   by	   ECM	   binding.	   The	   ECM	   associated	  
VEGF	   isoforms	   can	   be	   released	   to	   be	   active,	   diffusible	   fragments	   via	   plasmin	  
cleavage	   at	   the	   protein’s	   carboxy	   terminus.	   Isoforms	   that	   contain	   exon	   7	  
sequence	  bind	   the	  glycosaminoglycan,	  heparin,	  with	  high	  affinity.	  VEGF121	  lacks	  
all	   of	   exons	   6	   and	  7	  making	   it	   a	   freely	   diffusible	   protein	   isoform	  and	  does	  not	  
have	   any	   association	   with	   heparin	   (Figure	   1-­‐5C).	   But	   association	   with	   heparin	  
enhances	  the	  activity	  of	  VEGF	  as	  a	  mitogen	  (Ferrara	  et	  al.,	  2003).	  The	  loss	  of	  the	  
C	   terminal	   or	   heparin	   binding	   ability	   of	   the	   protein	   significantly	   reduces	   the	  
potency	  of	  VEGF	  as	  a	  mitogen	  (Keyt	  et	  al.,	  1996).	  
As	  described	  above,	  VEGF	  gene	  expression	  is	  regulated	  by	  hypoxia.	  Low	  oxygen	  
reduces	   hydroxylation	   of	   the	   HIF	   transcription	   factors	   allowing	   them	   to	   evade	  
degradation.	  Therefore,	  under	  hypoxic	  conditions	  HIFs	  promote	  transcription	  of	  
various	   genes	   including	  VEGF.	  Additionally,	  many	   growth	   factors	   and	   cytokines	  
have	   been	   shown	   to	   regulate	  VEGF	   expression	   alongside	   hypoxia.	   Paracrine	   or	  
autocrine	   secretion	   of	   EGF,	   TGFα,	   TGFβ,	   IGF1,	   FGF,	   IL6	   and	   more	   can	   induce	  
VEGF	  expression	  in	  various	  cell	  types	  (Ferrara	  et	  al.,	  2003).	  
	   	  





Figure	  1-­‐5	  Structure	  of	  VEGF	  gene,	  mRNA	  and	  protein	  
(A)	  The	  human	  VEGF-­‐A	  gene	  is	  located	  on	  chromosome	  17.	  (B)	  Exons	  1-­‐5	  are	  
constitutively	  spliced.	  Alternative	  splicing	  of	  exons	  6-­‐8	  creates	  many	  VEGF	  protein	  
isoforms.	  Exon	  8	  has	  two	  alternative	  3’	  splice	  sites,	  alternate	  use	  creates	  VEGF	  
isoforms	  with	  pro-­‐	  or	  anti-­‐angiogenic	  activity.	  (C)	  Domains	  and	  features	  of	  VEGF	  
protein.	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1.3.3 VEGF  receptors  
The	  effects	  of	  VEGF	  are	  mediated	  via	  two	  cell	  surface	  receptor	  tyrosine	  kinases	  
(RTKs),	  VEGFR-­‐1	  and	  VEGFR-­‐2.	  The	  extracellular	  portion	  of	  the	  receptors	  is	  made	  
of	   seven	   Ig-­‐like	   domains.	   A	   single	   transmembrane	   domain	   links	   to	   the	  
intracellular	   domain,	   which	   has	   tyrosine	   kinase	   activity.	   VEGFRs	   commonly	  
associate	  with	  neuropillins,	  a	  group	  of	  co-­‐receptors.	  
The	  first	  VEGF	  receptor	  to	  be	  identified	  was	  VEGFR-­‐1,	  which	  is	  also	  referred	  to	  as	  
Flt-­‐1.	  VEGF,	  PlGF	  and	  VEGF-­‐B	  can	  all	  interact	  with	  VEGFR-­‐1	  but	  its	  exact	  role	  still	  
requires	  investigation.	  A	  VEGFR-­‐1	  soluble	  isoform,	  created	  by	  alternative	  splicing,	  
acts	   as	   an	   endogenous	   inhibitor	   of	   VEGF.	   Only	   weak	   tyrosine	  
autophosphorylation	   is	   induced	   by	   ligand	   binding	   to	   VEGFR-­‐1,	   leading	   to	   the	  
hypothesis	  that	  VEGFR-­‐1	  doesn’t	  primarily	  function	  as	  a	  signal	  transducer	  but	  as	  
a	  decoy	   receptor	   to	   reduce	   the	  effect	  of	  VEGF	  on	  endothelial	   cells	   (Park	  et	  al.,	  
1994).	   The	   importance	   of	   VEGFR-­‐1	   during	   embryogenesis	   has	   been	   shown	   by	  
Flt1-­‐/-­‐	  knockout	   in	  mice,	  which	   causes	   embryonic	   lethality	   between	  8.5	   and	  9.5	  
days.	   In	  VEGFR-­‐1	  deficient	  mice,	  endothelial	  tubes	  cannot	  form	  and	  mortality	   is	  
caused	   by	   uncontrolled	   angioblast	   proliferation	   (Fong	   et	   al.,	   1999).	   This	  
hypothesis	  is	  also	  supported	  by	  the	  finding	  that	  tyrosine	  kinase	  deficient	  VEGFR-­‐
1	  is	  not	  lethal	  and	  does	  not	  cause	  vascular	  abnormalities	  in	  mice	  (Hiratsuka	  et	  al.,	  
1998).	  
The	  majority	  of	  VEGF’s	  effects	  are	  mediated	  via	  binding	  to	  and	  the	  subsequent	  
signalling	  through	  VEGFR-­‐2,	  which	  is	  also	  referred	  to	  as	  KDR	  or	  Flk-­‐1.	  VEGFR-­‐2	  is	  
crucial	   for	   functional	   angiogenesis	   during	   development.	   This	   is	   clearly	  
demonstrated	  by	  the	  defects	  of	  mice	  lacking	  VEGFR2.	  Vasculogenesis	  and	  vessel	  
organisation	  is	  impaired	  leading	  to	  death	  between	  days	  8-­‐9	  in	  utero	  (Shalaby	  et	  
al.,	   1995).	   VEGFR-­‐2	   proteins	   dimerize	   and	   ligand	   binding	   induces	   auto-­‐
phosphorylation	   of	   tyrosine	   residues.	   Various	   signalling	   molecules	   within	  
endothelial	   cells	   are	   activated	   by	  VEGFR-­‐2	   stimulation,	   including	   Ras,	   PI3K	   and	  
PLCγ.	  
	   30	  
Neuropillins	   (NRP1	   and	   NRP2)	   are	   co-­‐receptors	   involved	   in	   VEGF	   and	   VEGFR	  
binding.	   NRP1	   expression	   enhances	   the	   association	   between	   VEGFR-­‐2	   and	  
VEGF165.	  VEGF121	  does	  not	  interact	  with	  NRP1	  which	  can	  rationalise	  why	  VEGF121,	  
even	  though	  freely	  diffusible,	  is	  not	  as	  potent	  a	  mitogen	  as	  VEGF165	  (Soker	  et	  al.,	  
1998).	  
1.3.4 The  role  of  VEGF  in  development  and  physiology  
The	  in	  vitro	  and	  in	  vivo	  action	  of	  VEGF	  on	  endothelial	  cells	  and	  angiogenesis	  has	  
been	  well	  studied.	  A	  strong	  angiogenic	  response	  is	  stimulated	  by	  VEGF	  in	  various	  
in	   vivo	   models	   of	   angiogenesis	   (Leung	   et	   al.,	   1989).	   VEGF	   promotes	   the	  
proliferation	  and	  survival	  of	  endothelial	  cells	   in	  vitro	  and	   in	  vivo	   (Carmeliet	  and	  
Jain,	  2011;	  Gerber	  et	  al.,	  1999)	  
The	   expression	   of	   VEGF	   is	   essential	   during	   embryogenesis.	   Embryonic	   lethality	  
occurs	  at	  day	  11-­‐12	  with	  a	  knock	  out	  of	  just	  a	  single	  Vegf-­‐a	  allele.	  The	  other	  VEGF	  
family	  members	  cannot	  compensate	  for	  the	  knockout	  with	  major	  developmental	  
abnormalities	   observed	   in	   the	   embryos	   (Carmeliet	   et	   al.,	   1996;	   Ferrara	   et	   al.,	  
1996).	   Whereas,	   homozygous	   knockout	   of	   Vegf-­‐b	   or	   pgf	   does	   not	   cause	   any	  
discernable	  developmental	  malformations.	  
VEGF	  was	   also	   shown	   to	   be	   crucial	   for	   early	   development	   and	   growth.	   Partial	  
Vegf	   knockout	  was	   induced	   in	  newborn	  mice	  using	  Cre-­‐loxP	  gene	  ablation.	  The	  
knockout	   produced	   an	   increased	   death	   rate,	   reduced	   growth	   and	   diminished	  
development	   of	   the	   organs,	   particularly	   the	   liver	   and	   kidneys.	   In	   further	  
experimentation,	  administration	  of	  a	  soluble	  VEGFR-­‐1	  chimeric	  protein	  was	  used	  
to	   inhibit	   VEGF	   in	   young	   mice.	   The	   inhibition	   of	   VEGF	   was	   lethal,	   causing	  
endothelial	   deformities	   alongside	   renal	   and	   liver	   failure	   (Gerber	   et	   al.,	   1999).	  
Likewise,	   anti-­‐VEGF	   antibodies	   and	   deletion	   of	   VEGF	   in	   renal	   podocytes	   can	  
cause	  glomerular	  dysfunction.	  Homozygous	  glomerular	  specific	  knockout	  of	  Vegf	  
results	   in	   perinatal	   death	   whereas	   heterozygous	   knockout	   leads	   to	   profound	  
renal	  disease	  within	  three	  weeks	  of	  birth	  (Eremina	  et	  al.,	  2003).	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In	  the	  developed	  adult,	  angiogenesis	  only	  occurs	  in	  particular	  situations	  such	  as	  
wound	  healing	  or	  in	  the	  female	  reproductive	  system.	  VEGF	  is	  highly	  expressed	  in	  
the	   ovarian	   corpus	   luteum	   and	   needed	   of	   follicle	   development.	   Inhibitors	   of	  
VEGF	   block	   the	   proliferation	   of	   vessels	   in	   the	   corpus	   luteum	   and	   disrupts	  
follicular	  growth	  (Phillips	  et	  al.,	  1990).	  
1.3.5 The  role  of  VEGF  in  disease  
Expression	   of	   VEGF	   is	   high,	   but	   not	   uniform,	   in	   tumours.	   Ischaemic	   parts	   of	  
tumours	   have	   the	   greatest	   VEGF	   expression,	   this	   observation	   lead	   to	   the	  
discovery	   of	   hypoxia	   as	   a	   regulator	   of	   VEGF	   allowing	   vascular	   expansion	   into	  
ischaemic	  areas	   (Plate	  et	  al.,	  1992).	  Anti-­‐VEGF	  agents,	   such	  as	  VEGF	  antibodies	  
and	  small	  molecule	  inhibitors	  of	  VEGF	  receptors,	  can	  inhibit	  the	  growth	  of	  cancer	  
cells	   in	   many	   in	   vivo	   tumour	   models.	   Tumour	   and	   surrounding	   stromal	   cells	  
secrete	   high	   levels	   of	   VEGF.	   VEGF	   activity	   is	   also	   enhanced	   by	   upregulation	   of	  
matrix	  metalloproteinases,	  which	  release	  VEGF	  isoforms	  sequestered	  in	  the	  ECM	  
via	  proteolyic	  cleavage.	  
Intraocular	   neovascularization	   and	   vessel	   leakage	   are	   characteristic	   of	   eye	  
diseases	   such	   as	   diabetic	   retinopathy	   and	   age-­‐related	   macular	   degeneration.	  
Aqueous	   and	   vitreous	   humour	   of	   retinopathic	   eyes	   have	   increased	   levels	   for	  
VEGF,	  with	  neovascularisation	  of	  the	  retina	  reduced	  by	  administration	  of	  soluble	  
VEGFR-­‐1	  or	  VEGFR-­‐2	  protein	  in	  animal	  models	  (Aiello	  et	  al.,	  1995).	  
Many	   inflammatory	   conditions	   have	   links	   with	   VEGF.	   Epidermal	   keratinocytes	  
produce	   high	   levels	   of	   VEGF	   during	   the	   process	   of	   wound	   healing	   and	   in	  
psoriasis.	   Chronic	   inflammation	   in	   the	   skin	   can	   be	   caused	   by	   VEGF	   shown	   by	  
targeted	  overexpression	  in	  the	  skin	  of	  transgenic	  mice.	  High	  density	  of	  cutaneous	  
microvessels	   was	   observed	   with	   increased	   adhesion	   and	   rolling	   of	   leukocytes	  
(Auerbach	  et	  al.,	  2003).	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1.3.6 Anti-­‐angiogenic  VEGF  isoforms  
As	  described,	   there	  are	  various	  alternatively	   spliced	  VEGF	   isoforms	  of	  different	  
length.	  Alternative	  splicing	  of	  exons	  6	  and	  7	  creates	  isoforms	  with	  high	  or	  weak	  
affinity	   for	   the	   glycosaminoglycan	   heparin.	   In	   2002,	   a	   previously	   unreported	  
alternative	  splicing	  event	  in	  the	  terminal	  exon	  of	  VEGF	  pre-­‐mRNA	  was	  described.	  
An	   alternative	   distal	   3’	   splice	   site	   (DSS)	   in	   exon	   8	   was	   found	   66	   base	   pairs	  
downstream	   from	   the	   canonical	   proximal	   exon	   8	   3’	   splice	   site	   (PSS),	   splitting	  
exon	  8	  into	  two	  sub-­‐exons	  8a	  and	  8b.	  Selection	  of	  the	  exon	  8	  DSS	  creates	  a	  new	  
open	  reading	  frame	  containing	  an	  equal	  number	  of	  nucleotides	  as	  with	  PSS	  use	  
(Figure	  1-­‐5B,	  lower	  panel).	  Selection	  of	  this	  splice	  site	  results	  in	  a	  change	  of	  the	  
six	  amino	  acids	  at	  the	  C	  terminus	  of	  the	  protein.	  This	  creates	  an	  alternative	  sister	  
family	   of	   VEGF	   protein	   isoforms,	  which	   are	   given	   the	   names	   VEGFxxxb,	  with	   xxx	  
indicating	   the	   number	   of	   amino	   acids	   in	   the	   protein.	   The	   canonical	   VEGFxxx	  
proteins	   contain	   sequence	   encoded	   by	   exon	   8a	   resulting	   in	   the	   amino	   acids	  
CDKPRR	   in	   the	   translated	   protein.	   Distal	   splice	   site	   selection	   causes	   VEGFxxxb	  
isoforms	  to	  possess	  the	  unique	  sequence	  of	  SLTRKD	  encoded	  by	  exon	  8b	  (Figure	  
1-­‐7).	   The	   canonical	   VEGFxxx	   proteins	   and	   their	   sister	   isoforms	   have	   different	  
biological	   properties	   caused	   by	   the	   change	   in	   amino	   acids	   at	   the	   C	   terminus	  
(Figure	  1-­‐5C,	  Figure	  1-­‐7)	  (Bates	  et	  al.,	  2002;	  Woolard	  et	  al.,	  2009).	  Expression	  of	  
xxxb	  versions	  of	  many	  VEGF	  isoforms	  has	  been	  detected	  in	  various	  tissues	  and	  cell	  
lines,	   including	  VEGF121b,	  VEGF145b,	  VEGF165b	  and	  VEGF189b	  (Perrin	  et	  al.,	  2005).	  
The	  sister	   isoform	  family	  have	  been	  shown	  to	  be	  anti-­‐angiogenic,	   in	  contrast	  to	  
the	  potent	  pro-­‐angiogenic	  activity	  of	  VEGFxxx.	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1.3.7 The  properties  and  function  of  VEGFxxxb  
The	  change	  in	  exon	  8	  3’	  splice	  site	  selection	  has	  consequences	  on	  the	  structure,	  
interaction	  with	  receptors	  and	  functional	  properties	  of	  the	  resulting	  protein.	  The	  
tertiary	   structure	   of	   VEGFxxxb	   proteins	   is	   altered,	   as	   they	   do	   not	   contain	   a	   key	  
cysteine	   residue,	   Cys160,	   which	   is	   required	   to	   create	   a	   disulphide	   bond	   with	  
Cys146	  encoded	  by	  exon	  7.	  Changes	  in	  the	  charge	  of	  the	  amino	  acids	  encoded	  by	  
exons	  8a/8b	  also	  affect	  the	  protein	  structure.	  The	  C	  terminus	  of	  VEGFxxx	  has	  two	  
charged	   arginine	   residues,	   which	   are	   replaced	   by	   lysine	   and	   aspartic	   acid	   in	  
VEGFxxxb	  isoforms	  (Bates	  et	  al.,	  2002;	  Woolard	  et	  al.,	  2009).	  
VEGFxxxb	  isoforms	  retain	  exons	  3	  and	  4	  present	  in	  the	  canonical	  isoforms.	  These	  
are	   the	   sequences	   responsible	   for	   protein	   dimerization	   and	   binding	   to	   VEGF	  
receptors.	   VEGFxxxb	   molecules	   can	   for	   homodimers	   and	   bind	   VEGFR-­‐1	   and	  
VEGFR-­‐2.	   Binding	   assays	   proved	   that	   VEGF165b	   binds	   to	   VEGFRs	  with	   the	   same	  
affinity	   as	   VEGF165	   but	   the	   phosphorylation	   and	   activation	   of	   the	   receptor	  was	  
reduced	   (Kawamura	  et	  al.,	  2008).	  Therefore,	  VEGF165b	  can	  act	  as	  a	  competitive	  
inhibitor.	   The	   phosphorylation	   pattern	   induced	   by	   VEGFxxxb	   is	   different	  
compared	   to	   the	   pro-­‐angiogenic	   isoforms.	   VEGF165b	   binding	   does	   not	   cause	  








Figure	  1-­‐7	  Alternative	  splicing	  of	  VEGF	  exon	  8	  
VEGF	  exon	  8	  has	  two	  alternative	  3’	  splice	  sites.	  Use	  of	  either	  splice	  site	  determines	  
the	  final	  six	  amino	  acids	  of	  the	  translated	  VEGF	  protein.	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region	   of	   the	   receptor.	   VEGR-­‐2	   downstream	   signalling	   induces	   the	  
phosphorylation	   of	   Erk,	   JNK	   and	   Akt.	   In	   comparison,	   the	   activation	   of	   these	  
molecules	  is	  more	  transient	  and	  weaker	  when	  VEGF165b	  activates	  VEGFR-­‐2.	  
The	   presence	   of	   VEGF165b	   and	   the	   other	   xxxb	   proteins	   has	   been	   detected	   in	  
various	   tissues	  and	   cell	   lines.	  mRNA	  of	  VEGF165b	   transcripts	  was	   first	   identified	  
via	   RT-­‐PCR	   of	   renal	   cortex	   RNA.	   VEGFxxxb	   protein	   and/or	   RNA	  have	   since	   been	  
found	   in	   primary	   cell	   lines	   such	   as	   retinal-­‐pigmented	   epithelial	   cells	   and	  
podocytes.	   In	  many	  human	   tissues	  VEGFxxxb	   isoforms	  comprises	  almost	  50%	  or	  
more	   of	   the	   total	   levels	   of	   VEGF,	   but	   this	   does	   vary	   significantly	   between	  
different	  tissues.	  VEGF165b	  has	  been	  found	  in	  bladder,	  lung,	  urine,	  colon,	  kidney,	  
vitreous	  fluid,	  prostate	  and	  many	  other	  human	  tissues	  (Bates	  et	  al.,	  2002;	  Bevan	  
et	  al.,	  2008;	  Perrin	  et	  al.,	  2005).	  
VEGF165b	  protein	  has	  been	  shown	  to	  be	  anti-­‐angiogenic	   in	  vitro	  and	   in	  vivo	  and	  
does	  not	  increase	  the	  permeability	  of	  microvessels.	  VEGF165b	  does	  not	  stimulate	  
the	   proliferation	   or	   migration	   of	   endothelial	   cells	   in	   vitro,	   and	   furthermore,	  
inhibits	   the	   increased	   proliferation	   and	   migration	   induced	   by	   pro-­‐angiogenic	  
VEGF	  isoforms.	  VEGF165b	  can	  abolish	  vasodilatation	  promoted	  by	  VEGF165	  in	  vitro	  
(Bates	  et	  al.,	  2002).	  
The	   anti-­‐angiogenic	   role	   of	   VEGF165b	   in	   physiology	   has	   been	   investigated	   in	  
several	  models.	  VEGF165b	  is	  highly	  expressed	  in	  human	  and	  mouse	  breast	  tissue	  
with	  reduced	  expression	  when	  lactation	  occurs.	  A	  transgenic	  model	  was	  created	  
whereby	  VEGF165b	  was	  overexpressed	  during	  mammary	  development.	  The	  mice	  
have	   reduced	   vessel	   growth	   and	   less	   blood	   in	   the	   mammary	   tissue.	   Pups	  
produced	   by	   the	   mice	   die	   as	   the	   mother	   cannot	   generate	   enough	   milk.	   This	  
demonstrates	   that	   the	   down-­‐regulation	   of	   VEGF165b	   is	   necessary	   for	   sufficient	  
lactation	  and	  the	  VEGFxxxb	  proteins	  have	  an	  important	  role	  in	  normal	  physiology	  
(Qiu	  et	  al.,	  2008).	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As	   part	   of	   the	   rabbit	   corneal	   pocket	   assay,	   tumour	   cells	   are	   implanted	   in	   the	  
cornea	  eliciting	  an	  angiogenic	  response.	  An	  increase	  in	  corneal	  angiogenesis	  was	  
induced	   by	   breast	   cancer	   cells	   expressing	   VEGF165	   compared	   to	   control	   cells,	  
whereas	   cells	   expressing	  VEGF165b	   did	   not	   increase	   angiogenesis.	   Furthermore,	  
tumour	   cells	   overexpressing	   both	   isoforms,	   pro-­‐	   and	   anti-­‐angiogenic,	   reduced	  
the	   angiogenic	   response	   compared	   to	   VEGF165	   alone.	   This	   demonstrates	   that	  
VEGF165b	  can	  inhibit	  angiogenesis	  stimulated	  by	  pro-­‐angiogenic	  VEGF	  isoforms.	  A	  
similar	  effect	  was	  observed	   in	  other	   in	   vivo	  models	  of	  angiogenesis	   including	  a	  
rat	  mesenteric	  angiogenesis	  assay	  (Woolard	  et	  al.,	  2004).	  
1.3.8 Anti-­‐angiogenic  VEGF  isoforms  and  disease  
Many	   diseases	   characterised	   by	   neovascularisation	   have	   been	   shown	   to	   be	  
associated	  with	  altered	  levels	  of	  the	  anti-­‐angiogenic	  VEGF	  isoforms.	  The	  level	  of	  
VEGFxxxb	   was	   decreased	   in	   vitreous	   fluid	   taken	   from	   patients	   suffering	   from	  
diabetic	   retinopathy	   and	   in	   the	   placenta	   of	   preeclamptic	   women.	   VEGFxxxb	  
protein	   expression	   is	   decreased	   in	   many	   cancers	   compared	   to	   normal	   tissue	  
including,	  renal	  cell	  carcinoma,	  colorectal	  cancer,	  melanoma	  and	  prostate	  cancer	  
(Bates	  et	  al.,	  2002;	  Pritchard-­‐Jones	  et	  al.,	  2007;	  Rennel	  et	  al.,	  2008;	  Varey	  et	  al.,	  
2008b;	  Woolard	  et	  al.,	  2004).	  
The	   effect	   of	   anti-­‐angiogenic	   isoforms	   on	   cancer	   cells	   and	   their	   influence	   on	  
tumour	   growth	   has	   been	   investigated.	   The	   subcutaneous	   injection	   of	   LS174t	  
colon	   carcinoma	   cells	   over-­‐expressing	   VEGF165	   into	   nude	   mice	   caused	   the	  
formation	  of	  large	  vascular	  tumours	  that	  were	  significantly	  bigger	  than	  tumours	  
of	   control	   cells.	   Tumours	   formed	   by	   cells	   overexpressing	   VEGF165b	   were	  
significantly	  smaller	  than	  control	  tumours.	  Also,	  tumour	  size	  was	  reduced	  when	  
expressing	   both	   VEGF165	   and	   VEGF165b	   compared	   to	   only	   pro-­‐angiogenic	   VEGF	  
expression.	  A	  similar	  effect	  was	  seen	  in	  tumour	  models	  of	  renal	  cell	  carcinoma,	  
prostate	  cancer	  and	  Ewing’s	  sarcoma	  (Rennel	  et	  al.,	  2008;	  Varey	  et	  al.,	  2008b).	  
VEGF165b	   is	   anti-­‐angiogenic	   and	   reduces	   cancer	   growth	   by	   inhibiting	  
neovascularisation	  of	   tumours.	   The	  microvessel	  density	  observed	   in	   tumours	   is	  
	   36	  
decreases	   when	   overexpressing	   anti-­‐angiogenic	   VEGF.	   VEGF165b	   expression	  
decreases	   tumour	  growth	   in	   vivo	  but	  does	  not	  alter	   the	  proliferation	  of	   cancer	  
cells	   in	   vitro,	   indicating	   the	   anti-­‐tumour	   activity	   is	   caused	   by	   anti-­‐angiogenic	  
mechanisms.	   Media	   taken	   from	   cultured	   sarcoma	   cells	   secreting	   VEGF165b	  
reduced	  the	  migration	  and	  proliferation	  of	  human	  microvascular	  endothelial	  cells	  
(HMVECs)	  stimulated	  by	  VEGF165	  (Rennel	  et	  al.,	  2008).	  
1.3.9 Regulation  of  VEGF  alternative  splicing  
VEGF	  exon	  8	  splice	  site	  selection	  is	  thought	  to	  be	  under	  the	  control	  of	  several	  SR	  
proteins.	   Sequence	   analysis	   of	   the	   pre-­‐mRNA	   revealed	   exon	   8a	   to	   have	   a	  
predicted	   binding	   site	   for	   SRSF1	   upstream	   of	   the	   distal	   3’	   splice	   site.	   Located	  
downstream	   of	   the	   distal	   splice	   site	   was	   an	   SRSF6,	   also	   known	   as	   Srp55,	  
predicted	  binding	  site.	  Overexpression	  of	  SRSF1	  in	  cells	  promotes	  proximal	  splice	  
site	   selection	   creating	   VEGF165.	   Whereas	   SRSF6	   overexpression	   increased	  
VEGF165b	  transcripts	  (Nowak	  et	  al.,	  2008).	  
The	   action	   of	   these	   splice	   factors	   on	   VEGF	   pre-­‐mRNA	   is	   subject	   to	   control	   by	  
other	  regulators	  upstream.	  SRSF1	  is	  a	  known	  target	  of	  the	  protein	  kinases	  SRPK1	  
and	   SRPK2.	   Inhibiting	   SRPK1	   blocks	   phosphorylation	   of	   SRSF1	   and	   reduces	  
shuttling	  of	  SRSF1	  to	  the	  nucleus	  upon	  stimulation.	  Blocking	  SRPK1	  activity	  with	  
small	   molecule	   inhibitors	   or	   knock-­‐down	   of	   expression	   via	   RNAi	   switches	   the	  
ratio	   of	   VEGF	   splicing,	   increasing	   anti-­‐angiogenic	   isoforms.	   Interference	   with	  
SRPK1	  induces	  an	  anti-­‐angiogenic	  effect	  in	  vitro	  and	  in	  vivo	  with	  reduced	  growth	  
and	  microvessel	  density	  of	  tumours	  (Amin	  et	  al.,	  2011;	  Mavrou	  et	  al.,	  2014).	  
It	   is	   understood	   that	   like	   other	   gene	   expression	   regulatory	   mechanisms,	  
alternative	   splicing	   can	   be	   modified	   by	   extracellular	   factors	   via	   signalling	  
cascades.	   Various	   growth	   factors	   have	   been	   shown	   to	   affect	   the	   balance	  
between	   VEGF	   pro-­‐	   and	   anti-­‐angiogenic	   isoforms	   through	   alternative	   splicing.	  
IGF1	  and	  TNFα	   favoured	  use	  of	  exon	  8	  proximal	   splice	   site,	  whereas	  TGFβ	  had	  
the	  opposite	  effect	  and	  increased	  distal	  splice	  site	  use.	  Inhibiting	  SRPK1/2	  or	  PKC	  
reversed	   the	   effect	   of	   IGF1	   on	   VEGF	   splicing.	   TGFβ	   induced	   distal	   splice	   site	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selection	   was	   blocked	   by	   inhibiting	   p38	   MAPK.	   This	   effect	   is	   thought	   to	   be	  
mediated	   via	   CLK	   (CDC-­‐like	   kinase)	   activation	   by	   p38	   MAPK,	   which	   then	  
phosphorylates	  SRSF6	  promoting	  use	  of	  the	  distal	  splice	  site	  (Figure	  1-­‐8)	  (Nowak	  
et	  al.,	  2008).	  
	  
	  









Figure	  1-­‐8	  Regulation	  of	  VEGF	  exon	  8	  proximal	  and	  distal	  3'	  splice	  site	  selection	  
Growth	  factors	  and	  other	  stimuli	  activate	  signalling	  pathways,	  which	  control	  the	  
activity	  of	  regulatory	  kinases.	  Phosphorylation	  of	  splice	  factors	  can	  modulate	  their	  
activity	  to	  promote	  use	  of	  different	  alternative	  splice	  sites.	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1.4  HIGH-­‐THROUGHPUT  SCREENING  AND  DRUG  DISCOVERY  
High-­‐throughput	   screening	   is	   a	   method	   that	   was	   first	   employed	   by	  
pharmaceutical	   industry	   to	   aid	   drug	   discovery,	  with	   the	   aim	   to	   rapidly	   identify	  
candidate	   chemicals	   that	   can	   be	   entered	   into	   the	   therapeutic	   research	   and	  
development	   process.	   Screening	   has	   gained	   popularity	   due	   to	   its	   speed	   and	  
relatively	  low	  cost.	  Miniaturisation,	  automation	  and	  robotics	  have	  all	  enabled	  the	  
rapid	  expansion	  of	  screening	  methods	  (Pereira	  and	  Williams,	  2007).	  
Drug	   discovery	   and	   validation	   is	   an	   exhaustive,	   lengthy	   procedure	   with	   many	  
necessary	   stages.	   Screening	   is	   one	   of	   the	   initial	   stages	   following	   target	  
identification,	  whereby	  thousands,	  even	  millions,	  of	  chemicals	  can	  be	  tested	  for	  
inhibition	  of	  a	   specific	  protein	  or	  modulation	  of	  a	   cellular	   function	  as	  part	  of	  a	  
quantitative	  bioassay.	  A	   large,	  diverse	  chemical	   library	  will	  be	  reduced	  to	  a	  few	  
hit	   compounds,	   which	   can	   then	   be	   investigated	   further	   in	   lower	   throughput	  
assays	  to	  confirm	  effect	  on	  the	  target.	  Once	  hit	  chemicals	  have	  been	  established,	  
medicinal	   chemists	   can	  work	   to	  optimise	   the	  potency	  and	  pharmacokinetics	  of	  
the	   chemical	   to	   provide	   better	   therapeutic	   potential.	   High-­‐throughput	   screens	  
have	   routinely	   been	   performed	   in	   a	   96-­‐well	   plate	   format.	   More	   recently,	  
miniaturisation	  has	  enabled	  assays	  to	  be	  scaled	  up	  to	  a	  384-­‐well	  and	  sometimes	  
1536-­‐well	   plate	   format,	   vastly	   increasing	   the	   number	   of	   chemicals	   that	   can	   be	  
screened	  at	  once	  (Macarron	  et	  al.,	  2011).	  
Several	   different	   types	   of	   library	   can	   now	   be	   screened	   in	   bioassays	   including	  
chemicals,	  cDNAs,	  siRNAs,	  proteins	  and	  peptides.	  Genome-­‐wide	  cDNA	  and	  siRNA	  
libraries	   are	   commonly	   used	   to	   elucidate	   which	   genes	   are	   important	   during	   a	  
particular	  cellular	  process.	  
1.4.1 Bioassays  for  use  in  high-­‐throughput  screens  
Assays	   used	   as	   part	   of	   a	   screen	   are	   normally	   either	   biochemical	   or	   use	   live	  
cultured	   cells.	   Biochemical	   screens	   often	   look	   for	   inhibitors	   of	   a	   particular	  
enzyme	  (e.g.	  kinases,	  proteases),	  agonists/antagonists	  of	  a	  receptor	  (e.g.	  GPCR)	  
or	  a	  molecule	  that	  can	  interfere	  with	  a	  specific	  protein-­‐protein	  association.	  This	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is	   normally	   performed	   in	   vitro	   using	   purified	   proteins.	   However,	   chemicals	  
identified	   during	   in	   vitro	   biochemical	   assays	   will	   not	   always	   demonstrate	   the	  
same	   activity	   in	   a	   physiological	   setting;	   this	   could	   be	   caused	   by	   the	   chemical	  
being	   unable	   to	   permeate	   the	   cell	   membrane,	   non-­‐specific	   effects	   on	   other	  
proteins	  or	  toxicity.	  
Assays	  that	  use	  cultured	  cells	  more	  closely	  reflect	  how	  potential	  lead	  compounds	  
would	   act	   physiologically.	   A	   specific	   molecular	   target	   does	   not	   need	   to	   be	  
defined	   for	   cell-­‐based	   screens,	   with	   many	   assays	   looking	   for	   ways	   to	   alter	   a	  
whole	   pathway	   or	   regulatory	   mechanism	   within	   the	   cell	   rather	   than	   inhibit	   a	  
specific	   target.	  Also,	   such	  screens	  can	  be	  adapted	   for	  use	  with	  siRNAs	  or	  cDNA	  
overexpression	  vectors	   to	  elucidate	  proteins	   important	   for	   the	  cellular	   function	  
being	  investigated.	  
Various	  methods	   are	   employed	   to	   assay	   for	   the	   activity	   of	   small	   molecules	   in	  
cells.	  But	   the	  chosen	  assay	  must	  be	  adaptable	   for	  a	  high	   throughput	   format.	  A	  
functional	   bioassay	   commonly	   used	   to	   find	   inhibitors	   or	   activators	   of	   the	   G-­‐
protein	   coupled	   receptor	   superfamily	   (GPCRs)	   involves	   measuring	   levels	   of	  
cAMP,	  which	   is	   produced	   as	   a	   second	  messenger	   upon	  GPCR	   activation.	   GPCR	  
activation	   can	   be	   detected	   by	   measuring	   competition	   for	   binding	   to	   an	   anti-­‐
cAMP	  antibody	  between	  radiolabelled	  cAMP	  and	  cAMP	  endogenously	  produced	  
by	  the	  cell.	  Only	  radiolabelled	  cAMP	  bound	  to	  the	  antibody	  is	  detected	  allowing	  
quantification	   of	   cAMP	   production	   and	   therefore	  GPCR	   activation	   (Kariv	   et	   al.,	  
1999).	  
Other	  bioassays	  aim	  to	  look	  for	  a	  change	  in	  cell	  phenotype	  or	  the	  disruption	  of	  a	  
cellular	  process	  such	  as	  migration	  or	  proliferation.	  An	  example	  of	  such	  a	  screen	  is	  
the	   high-­‐throughput	   wound-­‐healing	   assay	   developed	   by	   Yarrow	   et	   al.	   In	   this	  
study,	  a	  wound	  was	  made	  in	  the	  monolayer	  of	  cells	  cultured	  in	  384-­‐well	  plates.	  
16,000	   small	   molecules	   were	   tested	   for	   their	   effect	   on	   migration	   with	   an	  
automated	  microscope	   used	   to	   image	   fixed	   cells	   and	  measure	  wound	   closure.	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This	  screen	   identified	  a	  Rho-­‐kinase	   inhibitor,	  which	  reduced	  formation	  of	  stress	  
fibres	  required	  for	  migration	  (Yarrow	  et	  al.,	  2005).	  
Reporter	  gene	  assays	  have	  also	  been	  widely	  used	  in	  high-­‐throughput	  screening.	  
Commonly,	  expression	  plasmids	  are	  cloned	  with	  the	  whole	  or	  part	  of	  a	  gene	  of	  
interest	   fused	   with	   the	   coding	   sequence	   of	   a	   reporter	   molecule	   such	   as	   lacZ,	  
luciferase	  or	  a	  fluorescent	  protein.	  Detection	  of	  the	  reporter	  molecule	  provides	  
information	  on	  gene	  expression	  or	  signalling	  to	  a	  specific	  promoter.	  The	  effect	  of	  
a	   gene,	   siRNA	   or	   chemical	   from	   a	   screening	   library	   can	   be	   measured	   using	  
various	   detection	   methods	   e.g.	   luciferase	   oxidation	   of	   luciferin,	   with	   emitted	  
light	  measured	  using	  a	  luminometer.	  	  
1.4.2 Examples  of  high-­‐throughput  screening  derived  therapeutics  
Drugs	   found	  by	  high-­‐throughput	   screening	  have	   gone	  on	   to	   be	  used	   in	   human	  
clinical	  trials	  with	  some	  eventually	  finding	  use	  as	  therapeutics.	  An	  early	  example	  
a	   high	   throughput	   screening	   success	   is	   nevirapine,	   the	   anti-­‐HIV	   agent.	   A	  
compound	  library	  was	  tested	  for	  inhibitory	  action	  on	  HIV-­‐1	  reverse	  transcriptase	  
with	  dipyridodiazepinones	  identified	  in	  as	  potent	  inhibitors.	  The	  pharmacokinetic	  
properties	   were	   optimized	   and	   nevirapine	   shown	   to	   block	   HIV-­‐1	   reverse	  
transcriptase	  activity	  and	  inhibit	  virus	  replication	  in	  culture.	  Nevirapine	  has	  been	  
approved	   and	   used	   for	   the	   treatment	   of	   HIV-­‐1	   and	   AIDS	   for	   almost	   20	   years	  
(Coster	  and	  Kumar,	  2012;	  Merluzzi	  et	  al.,	  1990).	  
Another	   anti-­‐retroviral	   used	   in	   HIV	   treatment,	   maraviroc,	   was	   developed	   as	   a	  
result	   of	   a	   500,000	   compound	   library	   screen	   for	   inhibitors	   of	   CC-­‐chemokine	  
receptor	  5.	  A	   ligand-­‐binding	  assay	  was	  used	  to	  screen	  the	   library	   identifying	  an	  
imidazopyridine as	   an	   agonist	   of	   the	   receptor.	  Work	   by	  medicinal	   chemists	   to	  
alter	   the	   compound	  produced	  maraviroc,	  which	  antagonises	   the	  CC-­‐chemokine	  
receptor	  5	  causing	  inhibition	  of	  the	  membrane	  fusion	  process	  required	  for	  virus	  
particles	  to	  enter	  a	  host	  cell	  (Dorr	  et	  al.,	  2005)	  .	  Similarly,	  chemical	  optimisation	  
of	  a	  screen	  hit	  was	  used	  to	  create	  a	  drug	  for	  the	  treatment	  of	  thrombocytopenia	  
(low	  platelet	  count).	  The	  thrombopoietin	  receptor	  is	  important	  for	  the	  activation	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of	   JAK-­‐STAT	   signalling	   required	   for	   megakaryocyte	   proliferation	   and	   platelet	  
production.	  A	  screen	  for	  thrombopoietin	  receptor	  agonists	  was	  performed	  using	  
a	  luciferase	  reporter	  under	  the	  control	  of	  a	  promoter	  activated	  by	  STAT.	  The	  final	  
optimised	  compound,	  eltrombopag,	  was	   shown	   to	   increase	  platelet	  production	  
and	  approved	  for	  use	  by	  the	  FDA	  to	  treat	  thrombocytopenia	  purpura	  (Erickson-­‐
Miller	  et	  al.,	  2005;	  Merli	  et	  al.,	  2015).	  
Cell	   based	   screens	   allow	   chemical	   modulators	   of	   a	   cellular	   process	   to	   be	  
identified	  without	   a	   specific	   protein	   target	   in	  mind.	   For	   example,	   a	   compound	  
screen	   identified	   a	   molecule	   that	   blocked	   the	   replication	   of	   hepatitis	   C	   virus.	  
FRET	  was	  used	  to	  measure	  the	  activity	  of	  a	  viral	  protease	  giving	  an	  indication	  of	  
viral	   replication.	   Analysis	   of	   virus	   strains	   that	  were	   resistant	   to	   the	   compound	  
revealed	   that	   the	   molecule	   was	   an	   inhibitor	   of	   the	   protein	   NS5A	   protein,	  
involved	  in	  hepatitis	  C	  RNA	  replication	  (Lemm	  et	  al.,	  2010;	  O'Boyle	  et	  al.,	  2005).	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1.5  HYPOTHESIS  AND  AIMS  
Angiogenesis	   and	   alternative	   splicing	   are	   the	   two	   processes	   focused	   on	   in	   this	  
thesis.	  Vascular	  endothelial	  growth	  factor	  (VEGF)	  is	  a	  one	  of	  the	  most	  important	  
signalling	  molecules	  associated	  with	  angiogenesis,	   and	   is	   an	   interesting	  protein	  
with	  regards	  to	  its	  alternative	  splicing	  creating	  isoforms	  with	  opposing	  functions.	  
Many	  studies	  have	  shown	  that	  VEGFxxxb	  proteins	  are	  anti-­‐angiogenic	  compared	  
with	  the	  strongly	  angiogenic	  VEGFxxx	  isoforms.	  Some	  of	  the	  pathways	  involved	  in	  
regulating	  this	  splicing	  event	  have	  been	  elucidated.	  
Anti-­‐angiogenic	  therapy	  has	  been	  intensively	  trialled	  as	  a	  treatment	  method	  for	  a	  
variety	   of	   cancers	   with	   limited	   success.	   The	   vast	  majority	   of	   anti-­‐angiogenesis	  
drugs	  target	  VEGF	  or	  VEGF	  receptors.	   Inhibiting	  the	  action	  of	  all	  VEGF	   isoforms	  
also	   blocks	   the	   anti-­‐angiogenic	   effect	   of	   the	  VEGFxxxb	   family.	   As	  VEGF	   is	   highly	  
expressed	  by	  cancer	  cells,	  switching	  alternative	  splicing	  of	  VEGF	  transcripts	  could	  
increase	   expression	   of	   anti-­‐angiogenic	   VEGF	   having	   an	   inhibitory	   effect	   on	  
tumour	  angiogenesis	  and	  cancer	  progression.	  Some	  small	  molecule	  inhibitors	  of	  
splicing	   pathways	   have	   already	   been	   shown	   to	   be	   potentially	   useful	   as	   anti-­‐
angiogenic/anti-­‐cancer	   agents	   via	   altering	   VEGF	   terminal	   exon	   splicing	  
(Gammons	  et	  al.,	  2013a;	  Gammons	  et	  al.,	  2014;	  Gammons	  et	  al.,	  2013b;	  Mavrou	  
et	  al.,	  2014)	  
This	  project	  aimed	   to	   find	  molecules	  able	   to	   reduce	  angiogenesis	  by	  modifying	  
VEGF	   alternative	   splicing.	   VEGF	   terminal	   exon	   alternative	   splicing	   was	  
investigated	   using	   a	   novel	   approach,	   splicing-­‐sensitive	   fluorescent	   reporters.	  
Splicing	   reporters	   provide	   a	  way	   to	   investigate	   an	   alternative	   splicing	   event	   by	  
following	   the	   expression	   of	   fluorescent	   proteins.	   A	   bichromatic	   VEGF	   splicing	  
reporter	  (pRG8ab)	  was	  designed	  using	  the	  plasmid	  backbone	  of	  another	  splicing	  
reporter	  and	  sequences	  from	  the	  VEGF-­‐A	  gene.	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The	  following	  aims	  were	  considered:	  
I.	   Validation	   of	   a	   splicing-­‐sensitive	   fluorescent	   reporter	   designed	   to	   mimic	  
alternative	  splicing	  of	  VEGFxxx/VEGFxxxb	  in	  culture.	  
	  
II.	   Use	   of	   VEGF-­‐based	   splicing-­‐sensitive	   fluorescent	   reporters	   as	   a	   molecular	  
screening	  tool:	  screening	  for	  small	  molecules	  that	  can	  alter	  VEGF	  terminal	  exon	  
splicing	  promoting	  anti-­‐angiogenic	  VEGF	  isoform	  production.	  
	  
III.	  Test	  molecules	  which	  change	  VEGF	  splicing	  for	  anti-­‐angiogenic	  activity	  in	  vitro	  
and	  in	  vivo.	  
	  
IV.	   Further	   investigate	   the	   activity	   of	   the	   small	   molecules	   to	   understand	   their	  
mechanism	  of	  action	  in	  terms	  of	  VEGF	  splicing	  and	  anti-­‐angiogenic	  activity.	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Chapter	  2   
Materials  and  Methods    
  
2.1  CELL  CULTURE  
2.1.1 Cell  lines  
Several	  different	   cell	   lines	  were	  used.	  HEK293	  cells	  are	  a	   cell	   line	  derived	   from	  
human	   embryonic	   kidney.	   PC3	   cells	   are	   prostate	   cancer	   cell	   live	   derived	   from	  
metastatic	  bone.	  Normal	  human	  dermal	  fibroblasts	  are	  derived	  from	  either	  adult	  
skin	   dermis	   or	   neonatal	   foreskin	   dermis.	   HEK293,	   PC3	   and	   NHDF	   cells	   sub-­‐
cultured	   from	   existing	   cultures	   within	   the	   lab.	   All	   were	   cultured	   in	   DMEM	  
(D6429,	  Sigma)	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (10270,	  GIBCO)	  and	  
1%	   penicillin	   streptomycin	   (GIBCO).	   Human	   umbilical	   vein	   endothelial	   cells	  
(HUVECs)	   were	   cultured	   in	   EBM-­‐2	   media	   (Lonza)	   supplemented	   with	   EGM-­‐2	  
Bulletkit	  (Lonza).	  All	  cell	  lines	  were	  cultured	  at	  37°C	  and	  in	  a	  humidified	  incubator	  
with	  5%	  CO2.	  	  
2.1.2 Sub-­‐culture  
Cell	   lines	   were	   maintained	   in	   T75	   cell	   culture	   flasks	   with	   growth	   medium	  
refreshed	   every	   2-­‐3	   days.	   Once	   cells	   reached	   ~80%	   confluency	   they	   were	  
passaged	  at	  a	  ratio	  of	  1:5-­‐	  1:10.	  To	  passage	  cells,	  the	  growth	  media	  was	  removed	  
with	   an	   aspirator	   and	   the	   monolayer	   washed	   with	   10ml	   1xPBS.	   Cells	   were	  
detached	   from	   the	   culture	   flask	   by	   adding	   2ml	   of	   0.5%	   trypsin-­‐EDTA	   (Sigma-­‐
Aldrich)	   and	   incubation	   at	   37°C	   for	   4	   minutes.	   Detachment	   was	   confirmed	   by	  
examining	  cells	  under	  a	  light	  microscope.	  Trypsin	  was	  neutralised	  by	  addition	  of	  
8ml	   culture	   medium.	   The	   cell	   suspension	   was	   centrifuged	   for	   3	   minutes	   at	  
1,200rpm.	   The	   supernatant	   was	   aspirated	   from	   the	   cell	   pellet	   and	   cells	   were	  
resuspended	   in	   10ml	   culture	   medium.	   An	   appropriate	   number	   of	   cells	   were	  
seeded	  into	  a	  T75	  culture	  flask.	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2.1.3 Thawing  cells  
Cryo-­‐preserved	  cells	  were	  thawed	  in	  a	  37°C	  water	  bath.	  Cells	  were	  transferred	  to	  
a	  sterile	  tube	  and	  10ml	  of	  serum	  rich	  media	  was	  slowly	  added	  to	  the	  cells.	  Cells	  
were	  centrifuged	  for	  3	  minutes	  at	  1200rpm.	  The	  supernatant	  was	  removed	  with	  
an	  aspirator.	  The	  cell	  pellet	  was	  resuspended	  in	  5ml	  normal	  growth	  medium	  with	  
serum	  and	  transferred	  to	  a	  T25	  culture	  flask.	  
2.1.4 Freezing  cells  
Cells	  were	  cultured	  in	  T75	  culture	  flasks	  until	  ~80%	  confluent.	  Cells	  were	  washed,	  
trypsinised	   and	   centrifuged	   as	   previously	   described.	   Each	   cell	   type	   was	  
resuspended	  in	  4ml	  of	  the	  appropriate	  culture	  medium	  containing	  10%	  FBS	  and	  
10%	   DMSO	   (Fisher	   Scientific).	   1.2ml	   of	   cell	   suspension	   was	   transferred	   to	  
cryovials	  and	  stored	  at	   -­‐80°C	   in	  an	   isopropanol	  chamber	   (Thermo	  Scientific)	   for	  
24	  hours.	  For	   long-­‐term	  storage,	  frozen	  cryovials	  were	  placed	   in	   liquid	  nitrogen	  
tanks.	  
2.2  TRANSFECTION  OF  CELL  LINES  
2.2.1 Transient  plasmid  transfection  
Cells	  were	  seeded	  into	  6	  well	  plates.	  When	  they	  reached	  ∼80%	  confluency	  cells	  
were	   transfected	  with	   plasmid.	   2µg	   of	   plasmid	  was	   diluted	   in	   100µl	   OptiMEM	  
(GIBCO).	  6µl	  of	  Fugene	  transfection	  reagent	  (Promega)	  was	  added	  to	  the	  solution	  
to	  create	  a	  1:3	  ratio	  of	  plasmid:transfection	  reagent.	  The	  solution	  was	  mixed	  by	  
shaking	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature	  before	  being	  directly	  
added	  to	  cells	  growing	  in	  6	  well	  plates.	  After	  24	  hours,	  successful	  transfection	  of	  
fluorescent	  reporter	  plasmids	  was	  confirmed	  by	  fluorescence	  microscopy.	  
2.2.2 Creating  stably  transfected  cell  lines  
After	  48	  hours,	  transiently	  transfected	  cells	  were	  washed	  with	  2ml	  of	  1xPBS	  and	  
detached	   from	   6-­‐well	   plate	   using	   0.5ml	   trypsin-­‐EDTA	   and	   incubation	   at	   37°C.	  
9.5ml	  of	  DMEM	  was	   added	   to	   tryspinised	   cells	   and	   they	  were	   transferred	   to	   a	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T75	   flask.	   G418	   selection	   antibiotic	   was	   added	   to	   the	   culture	   media	   to	   allow	  
selection	   for	   cells	   expressing	   the	   plasmid.	   Cells	   were	   cultured	   in	   selection	  
antibiotic	  for	  14	  days	  to	  obtain	  stable	  plasmid	  transfection.	  500µg/ml	  G418	  was	  
used	  to	  select	  in	  HEK293	  cells.	  750µg/ml	  was	  used	  to	  select	  PC3s.	  
2.3  FLOW  CYTOMETRY    
2.3.1 Analytical  flow  cytometry  
The	  percentage	  of	  cells	  stably	  transfected	  with	  pRG8ab	  was	  quantified	  using	  flow	  
cytometry.	  Trypsinised	  cells	  were	  counted	  using	  a	  haemocytometer	  and	  diluted	  
with	  DMEM	  to	  give	  concentration	  of	  ∼200,000	  cells/ml.	  Cells	  were	  transferred	  to	  
round-­‐bottom	   FACS	   tubes.	   4%	  PFA	  was	   added	   to	   the	   cell	   suspension	   to	   give	   a	  
final	   concentration	  of	   1%	  PFA.	   Fluorescence	  of	   the	   sample	   cells	  was	  measured	  
and	  recorded	  using	  a	  BD	  FACS	  CantoII	  flow	  cytometer.	  Untransfected	  cells	  were	  
first	   measured	   by	   the	   flow	   cytometer	   to	   gauge	   the	   background	   fluorescence	  
produced	   by	   the	   cell	   type.	   The	   cytometer	   software	  was	   used	   to	   create	   a	   gate	  
threshold	   around	   the	   background	   measurement.	   Fluorescent	   readings	   outside	  
the	  gate	  were	  deemed	  to	  be	  true	  fluorescent	  signal	  produced	  by	  dsRED	  and/or	  
within	  reporter-­‐expressing	  cells.	  
2.3.2 Fluorescent  activated  cell  sorting  
FACS	  was	  used	   to	  sort	   fluorescent	  cells	   from	  the	  non-­‐fluorescent	  population	   in	  
cell	   lines	   stably	   transfected	   with	   fluorescent	   reporter	   plasmids.	   More	   than	   20	  
million	  cells	  were	  used	  per	  sort.	  Cells	  were	  washed	  with	  1xPBS,	  trypsinised	  and	  
counted.	  Cells	  were	  centrifuged	  for	  three	  minutes	  at	  1200	  rpm.	  The	  media	  was	  
removed	  from	  pelleted	  cells	  and	  they	  were	  resuspended	  in	  1xPBS	  25mM	  HEPES,	  
2.5mM	   EDTA,	   0.5%	   BSA	   to	   give	   5-­‐8	   million	   cells/ml.	   Cells	   in	   the	   buffer	   were	  
transferred	   to	   round	   bottom	   FACS	   tubes	   (BD	   Falcon)	   that	   had	   been	   coated	   in	  
fetal	  bovine	  serum.	  The	  cytometer	   (BD	   influx	  cell	   sorter)	   fluidics	   system	  moves	  
cells	   through	   laser	   light	   sources	   in	   a	   single	   file	  manner.	  As	  each	   cell	   breaks	  off	  
from	   the	   fluid	   stream,	   the	   droplet	   is	   given	   a	   charge.	   In	   this	   case,	   fluorescent	  
reporter	  expressing	  cells	  were	  given	  the	  opposite	  charge	  to	  untransfected	  cells.	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The	   opposing	   charges	   were	   used	   to	   separate	   the	   two	   populations.	   Charged	  
deflection	   plates	   cause	   the	   charged	   droplets	   to	   be	   moved	   into	   separate	  
collection	  tubes	  coated	  in	  fetal	  bovine	  serum.	  Sorted	  cells	  were	  centrifuged	  for	  3	  
minutes	  at	  1200	  rpm	  and	  resuspended	  in	  DMEM	  supplemented	  with	  G418.	  Cells	  
were	  cultured	  until	  confluent	  and	  fluorescent	  reporter	  expression	  was	  confirmed	  
by	   analytical	   flow	   cytometry.	   Two	   sorts	   were	   performed	   on	   both	   PC3	   and	  
HEK293	   reporter	  expressing	   cells	   to	   gain	  a	  high	  percentage	  of	   fluorescent	   cells	  
within	  the	  population.	  
2.4  RNA  WORK  
2.4.1 RNA  extraction    
Cells	  were	  cultured	  in	  6	  well	  plates	  until	  confluency	  was	  reached.	  The	  cells	  were	  
washed	  with	  1xPBS.	  1ml	  of	  Trizol	  Reagent	  (Life	  Technologies)	  was	  added	  to	  each	  
well	  and	  the	  plate	  incubated	  at	  room	  temperature	  to	  allow	  lysis	  to	  occur.	  Lysates	  
were	  transferred	  to	  sterile	  eppendorf	  tubes.	  200µl	  of	  chloroform	  was	  added	  to	  
each	   lysate	   and	   tubes	   shaken	   vigorously	   for	   15	   seconds	   before	   15	   minutes	  
incubation	  at	   room	  temperature.	  The	  samples	  were	  then	  centrifuged	  at	  12,000	  
rpm	  for	  15	  minutes	  at	  4°C.	  The	  aqueous	  phase	  was	  separated	  from	  the	  organic	  
phase	   and	   transferred	   to	   a	   new,	   sterile	   eppendorf.	   500µl	   of	   isopropanol	   was	  
added	   to	   each	   sample	   and	   mixed	   by	   shaking	   for	   15	   seconds	   followed	  
centrifugation	   at	   12,000rpm	   for	   20	   minutes	   at	   4°C.	   The	   supernatant	   was	  
separated	  from	  the	  pellet	  and	  discarded.	  1ml	  of	  75%	  ethanol	  used	  to	  wash	  the	  
pellet	   and	   centrifuged	   for	   5	  minutes.	   The	  ethanol	  was	   removed	  and	   the	  pellet	  
left	   to	   dry	   for	   a	   few	   minutes	   and	   subsequently	   resuspended	   in	   20µl	   of	   DEPC	  
water.	   The	   concentration	   of	   RNA	   in	   each	   sample	   was	   quantified	   using	   a	  
Nanodrop	  spectrophotometer.	  	  
2.4.2 Treatment  with  DNase  and  cDNA  synthesis  
2µg	  of	  RNA	  was	  diluted	  with	  DEPC	  water	  to	  give	  a	  final	  volume	  of	  8µl.	  RNA	  was	  
treated	  with	   DNase	   to	   degrade	   any	   genomic	   DNA	   contaminants.	   1	   unit	   (U)	   of	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RQ1	  RNase-­‐FreeDNase	   enzyme	   (M6101,	   Promega)	  was	   added	   to	   each	   reaction	  
along	   with	   1µl	   of	   10x	   reaction	   buffer	   and	   incubated	   at	   37°C	   for	   1	   hour.	   The	  
addition	  of	  1µl	  of	  RQ1	  DNase	  Stop	  Solution	  and	  10	  minutes	   incubation	  at	  65°C	  
was	  used	  to	  stop	  the	  DNase	  reaction.	  The	  next	  step	  was	  to	  anneal	  DNA	  primers	  
to	   the	  RNA	   template.	   500ng	  of	  both	  oligo(dT)15	   (C1101,	  Promega)	   and	   random	  
hexamer	   primers	   (C1181,	   Promega)	   were	   used.	   Primers	   were	   incubated	   with	  
template	   at	   95°C	   for	   10	   minutes	   and	   samples	   were	   then	   cooled	   on	   ice	   for	   5	  
minutes.	   After	   primer	   annealing,	   the	   cDNA	   second	   filament	   was	   synthesised.	  
0.4mM	   dNTP	   mixture,	   5µl	   M-­‐MLV	   5X	   reaction	   buffer	   and	   200	   units	   M-­‐MLV	  
reverse	   transcriptase	   (M1701,	   Promega)	  were	   added	   to	   each	   reaction	   and	   the	  
total	   volume	   was	   made	   up	   to	   25ul	   with	   DEPC	   water.	   cDNA	   production	   was	  
completed	  via	  90	  minutes	  incubation	  at	  37°C.	  
2.4.3 Reverse  transcriptase  PCR  second  strand  synthesis  
Polymerase	  chain	   reaction	  was	  used	   to	  amplify	  and	  demonstrate	  expression	  of	  
pRG8ab	  plasmid	  (Figure	  2-­‐1)	  within	  transfected	  cell	   lines.	  Specific	  primers	  were	  
designed	   to	   bind	   to	   the	   reporter	   plasmid	   artificial	   exon	   and	   dsRED	   sequences	  
therefore	   amplifying	   transcripts	   splice	   at	   either	   the	   reporter	   proximal	   or	   distal	  
splice	   site	   (reporter	   design	   detailed	   in	   Chapter	   3).	   The	   expected	   size	   of	   PCR	  
products	   was	   193	   and	   127	   base	   pairs	   for	   proximally	   and	   distally	   spliced	  
transcripts	   respectively.	   25µl	   of	   reaction	   mixture	   was	   made	   using	   12.5µl	   of	  
2xPCR	   MasterMix	   (M7502,	   Promega),	   0.8µM	   of	   forward	   and	   reverse	   primer	  
mixture	  and	  DEPC	  water	  to	  bring	  the	  reaction	  to	  a	  volume	  of	  23µl.	  2µl	  of	  cDNA	  
was	  added	  to	  each	  reaction	  and	  amplified	  using	  a	   thermal	  cycler.	  Primers	  used	  
and	   cycling	   conditions	   are	   described	   in	   Table	   1	   Primer	   sequences	   and	   cycle	  
conditions	   used	   for	   polymerase	   chain	   reactions.	   All	   PCR	   reactions	   included	   an	  
initial	  step	  of	  95°C	  for	  5	  minutes	  and	  final	  elongation	  step	  of	  10	  minutes	  at	  72°C.	  
Alternatively	   spliced	   VEGF165/VEGF165b	   transcripts	   were	   also	   amplified	   from	  
cDNA	   using	   PCR.	   For	   each	   reaction,	   5µl	   of	   5x	   Green	   GoTaq	   reaction	   buffer,	  
0,8µM	   forward	   and	   reverse	   primer	   mix,	   0.2mM	   dNTP	   mix,	   2µl	   cDNA	   and	   1U	  
	   49	  
GoTaq	  DNA	  polymerase	  were	  made	  up	  to	  a	  final	  volume	  of	  25µl	  with	  dH2O.	  Table	  
1	  lists	  the	  primer	  sequences	  and	  cycling	  conditions	  used.	  




pRG8ab	   F:	  5’-­‐catatgccaagtacgccccctattgacg-­‐3’	  
R:	  5’-­‐ctacaggaacaggtggtggc-­‐3’	  
40	  cycles:	  
95°C	  for	  30s	  
55°C	  for	  30s	  






R:	  5’-­‐atggatccgtatcagtctttcctgg	  -­‐3’	  
40	  cycles:	  
95°C	  for	  60s	  
55°C	  for	  60s	  
72°C	  for	  60s	  
153	  &	  
57bp	  
Table	  1	  Primer	  sequences	  and	  cycle	  conditions	  used	  for	  polymerase	  chain	  
reactions.	  All	  PCR	  reactions	  included	  an	  initial	  step	  of	  95°C	  for	  5	  minutes	  and	  final	  
elongation	  step	  of	  10	  minutes	  at	  72°C	  
	  
2.4.4 Quantitative  RT-­‐PCR  
Quantitative	  RT-­‐PCR	  was	  used	  to	  detect	  expression	  of	  mouse	  Vegfr-­‐2	  as	  a	  marker	  
of	  blood	  vessel	  presence	  in	  Matrigel	  plug	  in	  an	  in	  vivo	  angiogenesis	  assay.	  cDNA	  
was	   made	   from	   extracted	   RNA	   as	   described.	   cDNA	   was	   diluted	   1:3	   with	  
RNase/DNase	   free	   water.	   Primers	   specific	   for	   mouse	   Vegfr-­‐2	   were	   used	   at	   a	  
concentration	  of	  425nM	  were	  used	  with	  12.5μl	  of	  2xSYBR	  Green	  Master	  Mix	  (Life	  
Technologies)	   RNase/DNase	   and	   water	   to	   make	   21μl	   reaction	   mixture.	   4μl	   of	  
cDNA	   was	   added	   to	   each	   reaction.	   PCR	   reactions	   were	   amplified	   using	   the	  
Applied	   Biosystems	   StepOne	   Plus	   Real	   Time	   PCR	   System	   using	   the	   standard	  
cycling	  mode:	  95°C	  for	  10	  minutes	  followed	  by	  40	  cycles	  of	  95°C	  15	  seconds	  and	  
60°C	   for	   1	   minute.	   Relative	   expression	   of	   mouse	   Vegfr-­‐2	   was	   quantified	   by	  
normalising	   to	   the	   expression	   of	   a	   reference	   gene,	   human	   GAPDH,	   using	   the	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comparative	  Ct	  method.	  Reactions	  were	  set-­‐up	  as	  described	  with	  GAPDH	  primers	  
used	  at	  1μM	  concentration.	  
ΔCt=Ct(target	  gene)-­‐Ct(reference	  gene)	  
ΔΔCt=ΔCt(treatment	  group)-­‐ΔCt(control	  group)	  
Fold	  change=2(-­‐ΔΔCt)	  
2.5  PROTEIN  WORK  
2.5.1 Protein  extraction  
Culture	  plates	  were	  placed	  on	  ice	  and	  washed	  with	  ice	  cold	  1xPBS.	  A	  lysis	  buffer	  
comprising	   of	   1%	   NP-­‐40,	   150mM	   NaCl,	   50mM	   Tris	   and	   1x	   Halt	   protease	   and	  
phosphatase	   inhibitor	  cocktail	   (Thermo	  Scientific)	  was	  directly	  added	  to	  cells	   in	  
culture	  plates.	  50μl	  was	  used	  for	  each	  well	  of	  a	  six	  well	  plate.	  Cells	  in	  lysis	  buffer	  
were	   scraped	   from	   culture	   plates	   and	   transferred	   to	   cold	   eppendorf	   tubes.	  
Samples	   were	   kept	   on	   ice	   for	   30	   minutes	   with	   30	   seconds	   vortexing	   seconds	  
every	  5	  minutes.	   Lysates	  were	  centrifuged	  at	  4°C	   for	  20	  minutes	  at	  12000rpm.	  
Supernatant	  was	  collected	  and	  transferred	  to	  fresh,	  cold	  eppendorfs	  and	  stored	  
at	  -­‐20°C.	  
2.5.2 Western  blotting    
Protein	   samples	   were	   mixed	   with	   5X	   protein	   loading	   buffer	   (National	  
Diagnostics)	  and	  boiled	  at	  100°C	  for	  5	  minutes.	  Samples	  were	  loaded	  into	  4-­‐15%	  
Mini-­‐PROTEAN	   TGX	   Stain-­‐Free	   precast	   gels.	   A	   gel	   tank	   was	   filled	   with	   running	  
buffer	   compromising	   of	   25mM	  Tris-­‐HCl,	   192mM	  glycine	   and	   0.1%	   SDS.	   Protein	  
samples	  were	  separated	  by	  electrophoresis	  for	  around	  1	  hour	  at	  150V.	  Exposure	  
to	  UV	   in	  Gel	  Doc	  EZ	  (BioRad)	  was	  used	  to	  react	  trihalo	  compounds	   in	  the	  mini-­‐
PROTEAN	   TGX	   Stain-­‐Free	   gels	   with	   Trp	   residues	   in	   separated	   protein	   samples	  
producing	  fluorescence.	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Separated	   proteins	   were	   transferred	   from	   the	   polyacrylamide	   gel	   to	   a	  
polyvinylidene	   difluoride	   (PVDF)	   membrane	   using	   the	   electroblotting	   wet	  
transfer	  method.	  PVDF	  was	  activated	  by	  incubation	  in	  methanol	  for	  10	  minutes	  
before	   gel	   and	   membrane	   were	   placed	   in	   a	   transfer	   tank	   and	   covered	   with	  
25mM	  Tris-­‐HCl,	  192mM	  glycine,	  20%	  methanol,	  0.1%	  SDS	   transfer	  buffer.	   Tank	  
was	  placed	  on	  ice	  and	  transfer	  performed	  at	  90V	  for	  two	  hours.	  Total	  protein	  on	  
the	  transferred	  membrane	  was	  visualised	  and	  imaged	  using	  Gel	  Doc	  EZ.	  
Membranes	  were	   blocked	   in	   either	   5%	  BSA	   or	   5%	   dried	   skimmed	  milk	   in	   TBS-­‐
Tween20	   0.3%	   (TBS-­‐T	   0.3%).	   Blocking	   was	   performed	   for	   1	   hour	   at	   room	  
temperature	   on	   a	   shaker.	   Membranes	   were	   probed	   with	   primary	   antibody	  
diluted	   in	   TBS-­‐T	   0.3%	   overnight	   at	   4°C.	   The	   next	   day,	   primary	   antibody	   was	  
removed	   and	   membranes	   were	   washed	   with	   TBS-­‐T	   0.3%	   three	   times	   for	   five	  
minutes.	  Membranes	  were	   incubated	  with	   secondary	   antibodies	   conjugated	   to	  
horseradish	  peroxidase	  (either	  anti-­‐mouse	  IgG	  or	  anti-­‐rabbit	  IgG)	  diluted	  1:10000	  
in	   2.5%	   dried	   skimmed	   milk	   TBS-­‐T	   0.3%.	   Membranes	   were	   incubated	   with	  
secondary	   antibody	   for	   1	   hour	   at	   room	   temperature	   before	   washing	   in	   TBS-­‐T	  
0.3%	   three	   times	   for	   five	   minutes.	   Clarity	   ECL	   Western	   Blotting	   Substrate	   kit	  
(BioRad)	  was	  used	  to	  visualise	  detected	  proteins	  on	  the	  membrane.	  Membranes	  
were	  imaged	  in	  Amersham	  Imager	  600	  (GE	  Healthcare).	  	  
Primary	   antibodies	   used	   and	   dilutions	   were:	   phosho-­‐SR	   mab104	   1:4,	   SR	   1H4	  
1:1000	   (sc-­‐13509,	   Santa	  Cruz	  Biotechnology),	  VEGFxxxb	  56/1	  1:1000	   (MAB3045-­‐
100,	  R&D	  Systems),	  VEGF	  A20	  1:2000	  (sc-­‐152,	  Santa	  Cruz	  Biotechnology).	  	  
	  
2.6  BACTERIAL  TRANSFORMATION  
Agar	   plates	   were	   made	   using	   LB	   broth	   with	   agar	   (L7533,	   Sigma-­‐Aldrich).	   One	  
sachet	   was	   dissolved	   in	   500ml	   of	   dH2O	   and	   was	   autoclaved	   to	   121°C	   for	   15	  
minutes	   to	   sterilize.	   After	   cooling	   to	   around	  50°C,	   the	   agar	  was	   supplemented	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with	  ampicillin	  at	  100µg/ml.	  Agar	  was	  poured	  into	  Petri	  dishes	  and	  solidified	  at	  
room	  temperature.	  	  
1µl	  of	  plasmid	  DNA	  was	  mixed	  with	  30µl	  of	  DH5α	  competent	  cells	   (18258-­‐012,	  
Invitrogen)	  and	  placed	  on	  ice	  for	  30	  minutes.	  Bacteria	  were	  heat	  shocked	  at	  42°C	  
for	   30	   seconds	   and	   placed	   back	   on	   ice	   for	   2	  minutes.	   300µl	   of	   S.O.C.	  Medium	  
(15544-­‐034,	  Invitrogen)	  was	  added	  to	  competent	  cells	  and	  incubated	  in	  a	  shaker	  
for	  45	  minutes	  at	  37°C.	  	  50-­‐200µl	  of	  bacteria	  in	  S.O.C.	  medium	  was	  pipetted	  onto	  
an	  agar	  plate	  and	  spread	  across	  at	  agar	  surface.	  Plates	  were	  incubated	  overnight	  
at	  37°C.	  	  
20g	  of	  LB	  broth	  growth	  medium	  (L3022,	  Sigma-­‐Aldrich)	  was	  suspended	   in	  1L	  of	  
dH2O	   and	   autoclaved	   for	   sterilization.	   5ml	   of	   LB	   broth	   containing	   100µg/ml	  
ampicillin	  was	  place	   in	   a	   sterile	   tube.	  A	   sterile	  pipette	   tip	  was	  used	   to	   touch	  a	  
single	   transformed	   colony	   grown	   on	   the	   agar	   and	   placed	   in	   the	   LB	   broth.	   Lid	  
were	   placed	   loosely	   on	   the	   tubes,	   which	   were	   incubated	   overnight	   in	   a	   37°C	  
shaker.	   Plasmid	   clones	   were	   extracted	   from	   transformed	   bacteria	   using	   the	  
QIAprep	  Spin	  Miniprep	  Kit	  (27104,	  Qiagen).	  
2.7  CLONING  OF  CONTROL  REPORTER  PLASMIDS  
2.7.1 PCR  product  generation  
Polymerase	   chain	   reaction	   was	   used	   was	   used	   to	   amplify	   the	   DNA	   sequences	  
from	  the	  pRG8ab	  plasmid.	  The	  primers	  used	  allowed	  amplification	  of	  fragments	  
beginning	  at	  an	  NdeI	  restriction	  site	  at	  the	  3’	  and	  ending	  at	  the	  exon	  7-­‐intron	  7	  
junction.	  Two	  different	  reverse	  primers	  were	  used	  to	  create	  the	  fragments-­‐	  one	  
hand	  an	  overhanging	  region	  complementary	  to	  the	  proximal	  splice	  site	  and	  the	  
other	  the	  distal	  splice	  site.	  These	  were	  termed	  Fragment	  A-­‐PSS	  and	  Fragment	  A-­‐
DSS.	   Two	  more	   fragments	   were	   produced	   beginning	   at	   either	   the	   proximal	   or	  
distal	  splice	  site	  and	  ending	  at	  a	  SacII	  restriction	  site.	  In	  this	  instance	  the	  forward	  
primers	  had	  overhang	  complementary	  to	  exon	  7.	  These	  fragments	  were	  termed	  
Fragment	  B-­‐PSS	  and	  Fragment	  B-­‐DSS	   (Figure	  2-­‐1).	  Amplification	   reactions	  were	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performed	   using	   Pfu	   polymerase	   (Thermo	   Scientific).	   Primers	   and	   cycling	  
temperatures	   used	   are	   described	   in	   Table	   2.	   One	   50µl	   reaction	   was	   made	   as	  
follows;	   5µl	   Pfu	   10x	   buffer,	   1.25mM	   dNTP	   mix,	   0.5µM	   forward	   and	   reverse	  
primers,	   1µg	   of	   pRG8ab	   plasmid	   and	   2U	   Pfu	   polymerase.	   Resulting	   products	  
were	   run	   on	   2%	   agarose	   gels	   and	   extracted	   from	   agarose	   using	   QIAquick	   gel	  
extraction	   kit	   (28704,	   Qiagen).	   Extracted	   fragments	   were	   cleaned	   up	   using	  
QIAquick	   PCR	   purification	   kit	   (28104,	   Qiagen)	   and	   5µl	   of	   each	   run	   on	   a	   2%	  
agarose	  gel	  to	  confirm	  efficient	  gel	  extraction.	  
	  
	  
Figure	  2-­‐1	  Fragments	  for	  control	  reporter	  constructs	  were	  amplified	  from	  pRG8ab	  
plasmid.	  	  
Primers	  used	  to	  amplify	  the	  fragments	  possessed	  complementary	  overhanging	  
regions	  to	  allow	  joining	  of	  the	  fragments	  by	  PCR	  overlap	  extension	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R:	  5’-­‐	  cgccgcggtctacaggaacaggaacaggtggtggc-­‐3’	  
40	  cycles:	  
95°C	  for	  30s	  
70°C	  for	  30s	  
72°C	   for	   2	  
minutes	  
723bp	  
Table	  2	  Primer	  and	  PCR	  conditions	  used	  to	  create	  control	  reporter	  fragments.	  
Each	  reaction	  was	  initiated	  with	  5	  minutes	  and	  95°C	  and	  final	  10	  minute	  
elongation	  step	  at	  72°C.	  
	  
2.7.2 Overlap  extension  PCR  
Overlap	  extension	  PCR	  was	  used	  to	  create	  longer	  fragments	  from	  the	  two	  shorter	  
templates	   that	   had	   been	   amplified	   as	   described	   above.	   This	  was	   performed	   in	  
two	  stages-­‐	  during	  the	  first	  15	  PCR	  cycles,	  no	  primers	  were	  used	  as	  the	  templates	  
were	   originally	   generated	   using	   primers	   that	   have	   overhanging	   regions	  
complementary	   to	   the	  other	   fragment	   that	   it	   is	   to	   join	   (Figure	  2-­‐1).	  This	  allows	  
the	   two	   fragments	   to	   anneal	   at	   these	   overlapping	   regions	   and	   act	   as	   primers.	  
After	   15	   cycles,	   in	   the	   second	   stage,	   1µM	  mix	   of	   forward	   and	   reverse	   primers	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that	   anneal	   to	   each	   end	   of	   the	   template	   (restriction	   sites)	   were	   added	   to	   the	  
reaction	  and	  PCR	  continued	  for	  another	  20	  cycles.	  One	  reaction	  was	  made	  up	  as	  
follows;	  100µg	  of	  each	  template,	  2.5U	  Pfu	  polymerase,	  2.5µl	  10x	  Pfu	  buffer	  plus	  
DEPC	  water	  to	  a	  final	  volume	  of	  25µl.	  15	  cycles	  were	  performed	  with	  denaturing	  
for	   30	   seconds	   at	   95°C,	   annealing	   for	   30	   seconds	   at	   60°C	   and	  elongation	   for	   2	  
minutes	  at	  72°C.	  	  
2.7.3 Ligation  into  plasmid  vector  
PSS/DSS	  fragments	  and	  plasmid	  were	  cut	  using	  the	  restriction	  enzymes	  SacII	  and	  
NdeI	   (New	   England	   Biolabs).	   Each	   60µl	   reaction	   contained	   6µl	   10x	   cut	   smart	  
buffer,	  60	  units	  SacII,	  60	  units	  NdeII	  and	  either	  2µg	  plasmid	  or	  50µg	  of	  fragment	  
(PSS	  or	  DSS).	  Reactions	  were	  incubated	  for	  3	  hours	  at	  37°C.	  The	  digested	  plasmid	  
was	   run	   on	   a	   1%	   agarose	   gel	   to	   separate	   the	   vector	   from	   the	   insert	   and	   the	  
vector	  cut	  and	  isolated	  from	  the	  gel	  using	  QIAquick	  gel	  extraction	  kit.	  	  
The	  PSS	  and	  DSS	  inserts	  were	  ligated	  into	  to	  pRG	  vector	  using	  T4	  DNA	  ligase.	  10µl	  
reactions	  were	  made	  with	  400	  units	  T4	  ligase,	  1µl	  10x	  T4	  ligase	  buffer,	  3µl	  insert,	  
1µl	  vector	  and	  4µl	  DEPC	  H2O	  and	  incubated	  at	  room	  temperature	  for	  1	  hour.	  A	  
control	  reaction	  performed	  with	  no	  DNA	  ligase.	  1µl	  of	  each	  reaction	  was	  used	  to	  
transform	  competent	  cells	  as	  described	  above.	  
In	   cases	   that	   direct	   ligation	  pRG	  plasmid	   vector	   and	   insert	  was	   unsuccessful,	   a	  
Zero	   Blunt	   TOPO	   PCR	   cloning	   kit	   (450245,	   Invitrogen)	  was	   used.	   PCR	   products	  
were	   inserted	   into	   the	   TOPO	   cloning	   vector	   as	   described	   in	   manufacturers	  
instructions.	  	  
2.7.4 Site-­‐directed  mutagenesis  
Errors	  in	  plasmid	  sequences	  were	  fixed	  using	  site-­‐directed	  mutagenesis.	  Plasmid	  
DNA	   was	   amplified	   using	   two	   complementary	   primers	   containing	   the	   desired	  
mutation	   in	   the	  middle	  and	  Pfu	  Turbo	  DNA	  polymerase.	   For	  each	   reaction,	  5µl	  
10x	  Pfu	   reaction	  buffer,	   50ng	  plasmid	   template,	   125ng	  of	   each	  primer,	   0.5mM	  
	   56	  
dNTP	  mix,	  2.5U	  Pfu	  Turbo	  were	  made	  up	   to	  a	   final	   volume	  of	  50µl	  with	  dH2O.	  
Plasmid	  was	  denatured	  for	  30	  seconds	  at	  95°C,	  primers	  annealed	  for	  1	  minute	  at	  
55°C	  and	  an	  extension	  step	  of	  10	  minutes	  at	  68°C.	  This	   reaction	  was	  cycled	  18	  
times.	   After	   cycling,	   10U	   of	   Dpn1	   restriction	   enzyme	   (R0176S,	   New	   England	  
Biolabs)	  was	  added	  to	  each	  reaction	  and	  incubated	  at	  37°C	  for	  1	  hour	  to	  digest	  
the	  original	  methylated	  template	  DNA.	  1µl	  of	  Dpn1	  treated	  reactions	  were	  used	  
to	   transform	   competent	   cells	   and	   mutated	   plasmid	   was	   isolated	   as	   described	  
above.	  
	  
2.8  CHEMICAL  SCREEN  
2.8.1 LOPAC  primary  screen    
A	   library	   containing	   1280	   FDA-­‐approved	   chemicals,	   LOPAC,	   Library	   of	  
Pharmaceutically	   Active	   Compounds	   (LO4200,	   Sigma-­‐Aldrich)	   was	   used.	  
Chemicals	  in	  the	  library	  were	  dissolved	  DMSO	  at	  a	  stock	  concentration	  of	  10mM.	  
PC3	   pRG8ab	   cells	   were	   trypsinised	   and	   diluted	   to	   8x104	   cell/ml	   using	   DMEM.	  
100µl	  of	  the	  cell	  solution	  was	  seeded	  into	  each	  well	  of	  a	  black	  96-­‐well	  plate.	  	  
All	  compounds	  of	  the	  LOPAC	  were	  dissolved	  in	  DMSO.	  Each	  was	  diluted	  from	  the	  
stock	  concentration	  of	  10mM	  to	  300µM	  using	  DMSO.	  The	  cells	   in	  each	  96-­‐well	  
plate	  were	  treated	  with	  DMSO	  only	  and	  16	  different	  compounds	  from	  the	  LOPAC	  
in	  triplicate	  at	  10µM.	  Wells	  of	  the	  outside	  edges	  of	  96-­‐well	  plates	  were	  not	  used	  
for	  treatments	  or	  measured	  for	  fluorescence.	  Plates	  were	  incubated	  at	  48	  hours	  
at	  37°C.	  Changes	  in	  reporter	  alternative	  splicing	  caused	  by	  treatment	  with	  LOPAC	  
compounds	   were	  measured	   using	   a	   VICTOR	   X	   multi-­‐label	   plate	   reader	   (Perkin	  
Elmer).	  Different	  sets	  of	  narrow	  band	  excitation	  and	  emission	  filters	  were	  used	  in	  
the	   plate	   reader	   to	   detect	   dsRED	   and	   EGFP	   expression.	   dsRED	   was	   measured	  
using	   550nm	   excitation	   and	   632nm	   emission	   filter.	   Excitation	   485nm	   and	  
emission	  535nm	  filters	  were	  used	  for	  EGFP	  detection.	  Each	  plate	  was	  measured	  
using	  VICTOR	  plate	  reader	  three	  times.	  DMSO	  treated	  wells	  were	  used	  as	  control	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measurements	  and	  statistically	  compared	  to	  treated	  wells	  from	  within	  the	  same	  
96-­‐well	  plate	  using	  a	  one-­‐way	  ANOVA.	  
2.8.2 Elimination  of  false  positives  in  the  control  screen  
Potential	  hit	  compounds	  identified	  in	  the	  primary	  chemical	  screen	  were	  used	  to	  
treat	   two	   PC3	   cell	   lines	   stably	   transfected	   with	   control	   reporters	   for	   pRG8ab	  
proximal	   (dsRED)	   and	   distal	   (EGFP)	   splice	   site	   selection	   (PSS	   control	   and	   DSS	  
control).	   8,000	  PSS	   control	  or	  DSS	   control	   cells	  were	   seeded	   into	  black	  96-­‐well	  
plates.	   Cells	   were	   treated	   with	   10µM	   of	   each	   compound	   for	   48	   hours	   before	  
fluorescence	  was	  measured	  using	  VICTOR.	   The	   same	  parameters	  were	  used	   to	  
measure	   dsRED	   and	   EGFP	   as	   in	   the	   primary	   screen.	   Differences	   between	   each	  
treatment	   and	   control	   wells	   within	   the	   same	   plate	  were	   analysed	   by	   one-­‐way	  
ANOVA	  and	  Dunnett’s	   post-­‐test.	   Treatments	   that	   increased	  EGFP	  or	   decreased	  
dsRED	  were	  considered	  false	  positives	  and	  eliminated	  from	  the	  screen.	  
2.9  IN  VITRO  CELL  ASSAYS  
2.9.1 Endothelial  cell  tube  formation  assay  
HUVECs	  at	  passage	  6	  or	  lower	  were	  grown	  in	  6	  well	  plates	  until	  ~70%	  confluent.	  
HUVECs	  were	   cultured	   in	   EBM-­‐2	   cell	   culture	  medium	   including	   the	   serum	   and	  
growth	   factors	   of	   the	   EGM-­‐2	   bullet	   kit	  with	   the	   exception	   of	   VEGF.	   Cells	  were	  
treated	  with	  ESSO	  compounds	  or	  controls	  for	  48	  hours	  before	  assay.	  	  
50µl	  of	  Matrigel	  basement	  membrane	  matrix	  (734-­‐1100,	  VWR)	  was	  seeded	  into	  
the	  appropriate	  number	  of	  wells	  of	  a	  chilled	  96-­‐well	  plate.	  The	  plate	  was	  placed	  
at	   37°C	   for	   >30	  minutes	   to	   solidify	   the	  Matrigel.	   Pre-­‐treated	  HUVECs	   in	   6-­‐well	  
plates	  were	  detached	  from	  culture	  plates	  using	  trypsin-­‐EDTA	  and	  counted	  using	  a	  
haemocytometer.	   The	   cells	   were	   diluted	   using	   EBM-­‐2	   to	   a	   concentration	   of	  
200,000	  cells/ml.	  50ul	  of	  treated	  cells	  were	  seeded	  into	  wells	  of	  the	  96-­‐well	  plate	  
onto	   the	   solidified	  Matrigel.	   The	   HUVECs	  were	   incubated	   at	   37°C	   for	   8	   hours.	  
Treatment	  with	  ESSO	  compounds	  and	  controls	  was	  continued	  during	  this	  period.	  
Cells	  were	   imaged	  using	   phase	   contrast	   at	   a	  magnification	   of	   10x.	   Five	   images	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were	   captured	   per	   well.	   Tubule	   length	   and	   number	   of	   branch	   points	   were	  
quantified	  for	  each	  image	  using	  ImageJ	  software.	  
In	  a	  similar	  experiment,	  PC3	  cells	  were	  cultured	  in	  EBM-­‐2	  media	  and	  treated	  with	  
chemicals	  at	  10μM	  concentration.	  Following	  48	  hour	  treatment,	  the	  conditioned	  
media	  was	  removed	  and	  stored	  at	  -­‐20°C.	  Matrigel	  was	  used	  to	  coat	  the	  bottom	  
of	  a	  96-­‐well	  plate	  as	  described	  above.	  10,000s	  HUVEC	  were	  diluted	  in	  each	  of	  the	  
conditioned	   media	   taken	   from	   compound-­‐treated	   PC3	   cells	   and	   seeded	   into	  
Matrigel-­‐coated	  wells.	  Cells	  were	  incubated	  and	  37°C	  for	  8	  hours	  and	  imaged.	  
2.9.2 Angiogenesis  co-­‐culture  assay  
PC3	  cells	  were	  cultured	  in	  T75	  culture	  flasks.	  When	  70-­‐80%	  confluent,	  the	  media	  
was	   removed	  and	   replaced	  with	  EBM-­‐2	  endothelial	   cell	  media	   containing	  ESSO	  
compounds,	  DMSO	  control	  or	  1nM	  VEGF165	  recombinant	  protein.	  After	  48	  hours,	  
the	  conditioned	  media	  was	  removed	  from	  the	  PC3s	  and	  stored	  at	  -­‐20°C.	  
An	   11-­‐day	   protocol	   was	   performed	   with	   endothelial	   cells	   co-­‐cultured	   with	  
confluent	   fibroblasts.	   Day	   1-­‐normal	   human	   dermal	   fibroblasts	   (NHDF)	   were	  
cultured	   in	   DMEM	   supplemented	   with	   10%	   FBS.	   Confluent	   NHDF	   cells	   were	  
harvested	  with	  trypsin	  and	  counted	  using	  a	  haemocytometer.	  Cells	  were	  diluted	  
in	  EBM-­‐2	  endothelial	  media	  to	  produce	  a	  concentration	  of	  3x104	  cells/ml.	  1ml	  of	  
the	   cell	   suspension	   was	   seeded	   onto	   sterile	   coverslips	   in	   12	   well	   plates	   and	  
incubated	   at	   37°C.	  Day	   4-­‐	  media	  was	   removed	   from	  NHDFs	   and	   replaced	  with	  
fresh	   EBM-­‐2.	   Day	   5-­‐	   human	   umbilical	   vein	   endothelial	   cells	   (HUVECs)	   were	  
diluted	  to	  3x104	  cells/ml	  in	  EBM-­‐2.	  The	  media	  on	  the	  fibroblasts	  in	  12	  well	  plates	  
was	   removed	   and	   replaced	   with	   1ml	   of	   the	   cell	   solution.	   Day	   7-­‐	   EBM-­‐2	   was	  
removed	  and	  refreshed.	  Day	  9-­‐	  EBM-­‐2	  was	  removed	  from	  cells	  and	  replaced	  with	  
the	  conditioned	  media	  taken	  from	  PC3s	  treated	  with	  ESSOs.	  Day	  11-­‐	  cells	  were	  
fixed	  and	  stained	  for	  endothelial	  markers	  via	  immunofluorescence.	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2.9.3 Trypan  Blue  cell  viability  assay  
Cells	  were	  washed	   and	   trypsinised	   and	   described	   previously	   and	   diluted	   to	   an	  
approximate	   concentration	   of	   2x105	   cells	   per	  ml.	   0.5ml	   of	   cell	   suspension	  was	  
transferred	  to	  a	  screw	  cap	  tube	  and	  mixed	  thoroughly	  with	  100µl	  of	  0.4%	  Trypan	  
Blue	   stain.	   Cells	   and	   the	   stain	   were	   incubated	   for	   5	   minutes	   at	   room	  
temperature.	   A	   haemocytometer	   was	   filled	   and	   used	   to	   count	   cells	   under	   a	  
microscope.	  Stained	  cells	  were	  non-­‐viable	  and	  unstained	  that	  had	  excluded	  the	  
stain	  were	  viable.	  
2.10  CD31  IMMUNOFLUORESCENCE    
The	  media	  was	  removed	  from	  the	  cells	  and	  the	  coverslips	  were	  washed	  with	  1ml	  
1xPBS	   and	   fixed	   for	   15	   minutes	   in	   1ml	   4%	   paraformaldehyde.	   After	   fixation,	  
coverslips	  were	  washed	  twice	  with	  1xPBS.	  Non-­‐specific	  binding	  of	  antibodies	  was	  
blocked	  by	   incubating	  with	  3%	  bovine	  serum	  albumin	   (BSA)	  1xPBS	  overnight	  at	  
4°C.	   The	   co-­‐culture	   was	   stained	   for	   endothelial	   cell	   marker	   CD31	   (PECAM).	  
Monoclonal	   CD31	   primary	   antibody	   (3528,	   Cell	   Signalling	   Technology)	   was	  
diluted	   1:500	   in	   1%	  BSA	   and	   the	   coverslips	   stained	   for	   1	   hour.	   Two	  washes	   in	  
1xPBS	  were	   performed	  before	   staining	  with	  Alexa	   Fluor	   488	   rabbit	   anti-­‐mouse	  
antibody.	   The	   fluorescent	   secondary	   antibody	   was	   diluted	   1:1500	   in	   1%	   BSA	  
1xPBS	  and	  coverslips	  were	  stained	  for	  1	  hour.	  The	  co-­‐cultures	  were	  washed	  two	  
final	   times	   with	   1xPBS	   and	   mounted	   onto	   microscope	   slides	   with	   Vectashield	  
mounting	  medium	  with	  DAPI	  (H-­‐1200,	  Vector	  Labs)	  to	  visualise	  the	  nuclei.	  
2.11  IN  VIVO   MODELS  
2.11.1 Matrigel  plug  angiogenesis  assay  
PC3	   cells	   were	   cultured	   in	  media	   containing	   10μM	   a	   potential	   anti-­‐angiogenic	  
compound	  or	  DMSO	  for	  48	  hours.	  Cells	  were	  detached	  from	  culture	  plates	  and	  
diluted	   in	   DMEM	   to	   a	   concentration	   of	   2x107/ml	   and	   placed	   on	   ice.	   Matrigel	  
basement	  membrane	  protein	  (734-­‐1100,	  VWR)	  was	  thawed	  on	  ice.	  100μl	  of	  cell	  
suspension	  was	  mixed	  with	  400μl	  of	  Matrigel	  and	  10μM	  of	  the	  test	  compound.	  
The	  mix	  of	  cells	  and	  matrix	  was	  subcutaneously	  injected	  into	  each	  upper	  flank	  of	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Crl:CD1-­‐Foxn1nu	   nude	  mice	   (Charles	  River).	   Four	  days	  post-­‐injection,	  mice	  were	  
culled	  by	  cervical	  dislocation	  (Schedule	  1)	  and	  the	  Matrigel	  plugs	  were	  extracted.	  
Images	  of	  each	  plug	  were	  taken	  and	  their	  colour	  quantified	  using	  Photoshop	  as	  
an	  indication	  of	  blood	  vessel	  infiltration	  into	  the	  matrix.	  Plugs	  were	  flash	  frozen	  
in	   liquid	   nitrogen.	   1ml	   of	   Trizol	   was	   added	   to	   each	   plug	   and	   samples	   were	  
homogenised	  for	  RNA	  extraction	  as	  described.	  
2.11.2   Subcutaneous  xenograft  models  
The	   same	   procedure	   was	   followed	   as	   described	   above	   during	   the	   Matrigel	  
angiogenesis	   assays.	   Two	   weeks	   following	   subcutaneous	   injection,	   mice	   were	  
culled	  by	  cervical	  dislocation	  (Schedule	  1)	  and	  tumours	  were	  extracted.	  Tumours	  
were	  weighed	  and	  frozen.	  	  
2.12  STATISTICAL  ANALYSIS  
Comparisons	  of	  two	  datasets	  were	  performed	  using	  Students’	  t-­‐test	  or	  a	  Mann	  
Whitney	  U-­‐test.	  A	  comparison	  of	  three	  or	  more	  groups	  was	  performed	  using	  
one-­‐way	  analysis	  of	  variance	  (ANOVA)	  with	  Dunnett’s	  post-­‐test.	  P<0.05	  was	  
considered	  to	  indicate	  a	  statistically	  significant	  difference.	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Chapter	  3   
Construction   and   validation   of   the   VEGF  
splicing-­‐sensitive  fluorescent  reporter  
  
3.1  INTRODUCTION  
Several	  studies	  have	  utilised	  fluorescent	  splicing	  reporters	  to	  screen	  for	  splicing	  
modulators.	   Initially	  monochromatic	   splicing	   reporters	  were	  commonly	  used	   to	  
investigate	   interesting	   splicing	   events	   (Kemp	   et	   al.,	   2005;	   Moore	   et	   al.,	   2010;	  
Oltean	  et	  al.,	  2006).	  In	  such	  reporters,	  expression	  of	  a	  fluorescent	  protein	  would	  
be	  caused	  by	   inclusion	  or	  exclusion	  of	  an	  alternatively	   spliced	   region	  within	  an	  
mRNA	  transcript.	  For	  example,	  Oltean	  et	  al	  developed	  a	  fluorescent	  minigene	  to	  
investigate	  epithelial	  to	  mesenchymal	  transitions	  (EMT).	  The	  reporter	  was	  based	  
on	  the	  alternative	  splicing	  of	  fibroblast	  growth	  factor	  receptor	  2	  (FGFR2)	  mRNA.	  
FGFR2	  transcripts	  contain	  two	  mutually	  exclusive	  exons-­‐	  exon	  IIIb	   is	   included	  in	  
epithelial	   cells	   whereas	   in	   mesenchymal	   cells,	   IIIb	   is	   silenced	   and	   exon	   IIIc	   is	  
included.	   The	   pRIIIcI2	   reporter	   was	   used	   to	   follow	   the	   inclusion	   of	   the	  
mesenchymal	  IIIc	  exon-­‐	  the	  design	  of	  the	  reporter	  was	  such	  that	  inclusion	  of	  IIIc	  
disrupts	   the	   open	   reading	   frame	   of	   RFP,	   therefore	   epithelial	   cells	   express	   RFP	  
and	  the	  fluorescence	  is	  lost	  in	  mesenchymal	  cells.	  
Moore	  et	  al	  made	  use	  of	  two	  different	  monochromatic	  reporters	  to	  explore	  the	  
alternative	   splicing	   of	   Bcl-­‐2	   family	   of	   apoptotic	   regulatory	   proteins.	   The	  mRNA	  
transcripts	  of	  Bcl-­‐2	  like	  proteins	  can	  be	  alternatively	  spliced	  to	  give	  long	  or	  short	  
isoforms,	   which	   are	   anti-­‐	   and	   pro-­‐apoptotic	   respectively.	   Two	   reporters	   were	  
designed	   based	   on	   the	   Bcl-­‐x	   and	   Mcl-­‐1	   genes	   with	   open	   reading	   frame	   and	  
intronic	  regions	  fused	  to	  Venus	  or	  mCherry	  sequences.	  A	  premature	  stop	  codon	  
was	   inserted	   into	   the	   alternatively	   spliced	   region,	   such	   that	   only	   short	  
transcripts,	  which	  mimic	  pro-­‐apoptotic	  variants,	  allow	  translation	  of	  fluorescent	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proteins.	   These	   reporters	  were	   used	   to	   uncover	   novel	  modulators	   of	   pro-­‐	   and	  
anti-­‐apoptotic	  splice	  variants	  via	  a	  genome-­‐wide	  siRNA	  screen.	  
In	   addition	   to	   fluorescent	   proteins,	   luciferase	   reporters	   have	   been	   utilised	   in	  
small	   molecule	   screens	   like	   for	   instance	   in	   SMN	   splicing.	   Due	   to	   alternative	  
splicing	   only	   a	   small	   quantity	   of	   functional	   SMN	   protein	   is	   produced	   from	   the	  
SMN2	  gene.	  Loss	  of	  SMN	  expression	  via	  mutation	  of	  the	  paralogous	  gene	  SMN1	  
causes	  spinal	  muscular	  atrophy.	  A	  splicing	  reporter	  screen	  was	  used	  to	  elucidate	  
small	   molecules	   that	   could	   alter	   alternative	   splicing	   of	   SMN2	   transcripts	   to	  
increase	   expression	   of	   functional	   SMN	   protein.	   The	   reporter	   was	   designed	   in	  
such	   a	   way	   that	   the	   luciferase	   coding	   sequence	   was	   in	   frame	   only	   when	   an	  
alternative	   exon	   was	   included	   in	   the	   reporter	   transcripts.	   Monochromatic	  
reporters	   have	   been	   useful	   investigating	   alternative	   splicing	   especially	   in	   the	  
context	   of	   screening	   and	   following	   splicing	   decisions	   in	   vivo	   but	   they	   do	   have	  
limitations.	  A	  drawback	  to	  using	  monochromatic	  reporters	  is	  that	  they	  only	  allow	  
quantification	   of	   one	   alternatively	   spliced	   transcript-­‐	   changes	   cannot	   be	  
compared	   to	   the	   other	   possible	   alternative	   splicing	   patterns	   (Naryshkin	   et	   al.,	  
2014).	  
A	   bichromatic	   splicing-­‐sensitive	   fluorescent	   reporter	   (SSFR),	   RG6,	   was	  
constructed	   by	   (Orengo	   et	   al.,	   2006).	   This	   system	   allows	   two	   patterns	   of	  
alternative	   splicing	   to	   be	   followed	   from	   the	   same	   reporter	   (Figure	   3-­‐1).	   The	  
design,	  crucially,	   relies	  on	  the	   fact	   that	   the	   fluorescent	  protein	  dsRED	  does	  not	  
have	   any	   translational	   stop	   codons	   in	   its	   +1	   reading	   frame.	   The	   alternative	  
splicing	  event	  exploited	  in	  the	  original	  reporter	  was	  skipping	  of	  exon	  5	  of	  chicken	  
cardiac	   troponin	   T	   (cTNT).	   dsRED	   and	   EGFP	   coding	   sequences	  were	   positioned	  
downstream	   of	   cTNT	   exon	   5	   and	   its	   surrounding	   introns.	   Skipping	   of	   the	  
alternative	   exon	   completes	   the	   open	   reading	   frame	   for	   dsRED.	   The	   alternative	  
exon	  inclusion	  causes	  a	  frame	  shift;	  it	  has	  28	  nucleotides,	  not	  a	  multiple	  of	  three.	  
dsRED+1	  is	  translated	  and	  a	  fusion	  protein	  with	  EGFP	  is	  formed.	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Figure	  3-­‐1	  RG6	  bichromatic	  fluorescent	  reporter	  designed	  by	  Orengo	  et	  al	  
The	  reporter	  minigene	  begins	  with	  an	  artificial	  exon	  and	  can	  be	  adapted	  to	  
include	  a	  cassette	  or	  alternative	  3’	  splice	  sites	  of	  interest	  allowing	  productions	  of	  
two	  different	  fluorescent	  proteins	  upon	  selection	  of	  different	  alternative	  splice	  
sites	  (Figure	  from	  Orengo	  et	  al.)	  
	  
A	   similar	   bichromatic	   reporter	   construct	   was	   used	   to	   investigate	   inclusion	   or	  
exclusion	  of	   exon	  10	   in	  MAPT	   (microtubule	   associated	  protein	   tau)	   transcripts.	  
Frontotemporal	  dementia	  is	  linked	  with	  changes	  in	  MAPT	  splicing.	  Exon	  inclusion	  
in	   the	   construct	   creates	   the	   correct	   reading	   frame	   for	  RFP	   translation	  whereas	  
GFP	   is	   translated	   when	   exon	   10	   is	   spliced	   out	   of	   the	   construct	   (Stoilov	   et	   al.,	  
2008).	  
Dual	   colour	   reporters	   such	   as	   these	   can	   be	   utilized	   to	   evaluate	   the	   ratio	   of	  
transcripts	   produced	   as	   a	   result	   of	   an	   alternative	   splicing	   event.	   An	   important	  
feature	  of	  bichromatic	  reporters	   is	  that	  they	  allow	  measurement	  of	  an	  increase	  
in	   one	   fluorescent	   protein	   and	   decrease	   in	   the	   other.	   This	   conveys	   greater	  
sensitivity	   and	   dynamic	   range	   of	   the	   assay	   compared	   to	   a	   monochromatic	  
reporter	  construct.	  
A	  bichromatic	  SSFR	  was	  designed	  to	  mimic	  the	  alternative	  splicing	  event	  of	  VEGF	  
exon	  8,	  which	  results	  in	  expression	  of	  either	  pro-­‐	  or	  anti-­‐angiogenic	  VEGF	  protein	  
isoforms.	   It	   was	   aimed	   to	   validate	   the	   reporter	   for	   use	   in	   culture	   and	   to	  
determine	   it’s	  usefulness	  as	  a	  molecular	  screening	   tool	   for	   the	   identification	  of	  
VEGF	  alternative	  splicing	  regulators.	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3.2  RESULTS  
3.2.1 Cloning  and  design  of  VEGF  reporter  
The	  VEGF	  SSFR	  design	  was	  based	  on	  the	  bichromatic	  splicing	  reporter,	  pRG6.	  The	  
RG6	  plasmid	  contains	  conveniently	  placed	  restriction	  sites	  that	  allow	  insertion	  of	  
different	  alternatively	  spliced	  sequences.	  The	   function	  of	   the	  reporter	   relies	  on	  
the	   inclusion	  or	  skipping	  of	  a	  variable	  region.	   In	   the	  case	  of	   the	  VEGF	  reporter,	  
the	  variable	  region	  came	  from	  selection	  of	  either	  the	  proximal	  or	  distal	  3’	  splice	  
site	   for	  exon	  8.	  The	   relevant	   sequences	  of	   the	  VEGF	   gene	  were	  amplified	   from	  
genomic	  DNA.	  PCR	  amplification	  produced	  a	  2,699bp	  DNA	   fragment	  containing	  
the	   last	   11	   bases	   of	   VEGF	   exon	   7,	   all	   of	   intron	   7,	   exon	   8a	   and	   8b.	   The	   VEGF	  
fragment	  was	   cloned	   into	   the	  RG6	  backbone	  between	  XbaI	   and	  AgeI	   sites,	   the	  
resulting	  reporter	  plasmid	  was	  assigned	  the	  name	  pRG8ab	  (Figure	  3-­‐2).	  
The	   expression	   of	   the	   construct	   is	   under	   control	   of	   a	   CMV	   promoter	   and	   the	  
coding	   region	   begins	   with	   an	   artificial	   exon	   sequence	   from	   RG6.	   The	   artificial	  
exon	  contains	  the	  XbaI	  restriction	  site-­‐	  this	  is	  where	  the	  fragment	  amplified	  from	  
VEGF	   begins.	   The	   endogenous	   VEGF	   region	   of	   the	   reporter	   ends	   at	   the	   AgeI	  
restriction	  site.	  dsRED	  and	  EGFP	  coding	  sequences	  immediately	  follow.	  Crucially,	  
the	  stop	  codons	  of	  exons	  8a	  and	  8b	  have	  been	  mutated	  to	  allow	  translation	  of	  
the	   fluorescent	   proteins	   downstream.	   As	   previously	   described,	   the	   reporter	  
function	  relies	  on	  dsRED	  and	  EGFP	  being	  in	  mutually	  exclusive	  reading	  frames.	  
Pro-­‐angiogenic	   VEGF	   protein	   isoforms	   are	   produced	   when	   exon	   8’s	   proximal	  
3’splice	   site	   is	   used.	   Distal	   splice	   site	   selection	   leads	   to	   expression	   of	   anti-­‐
angiogenic	  VEGF.	   pRG8ab	  was	   designed	   to	   cause	   expression	  of	   dsRED	  or	   EGFP	  
depending	  on	  splice	  site	  selection.	  During	  reporter	  pre-­‐mRNA	  splicing,	  if	  the	  PSS	  
is	   chosen,	   both	   the	   8a	   and	   8b	   regions	   of	   exon	   8	   are	   included	   in	   the	   mature	  
transcript.	  Under	  these	  circumstances,	  dsRED	  is	  in-­‐frame	  during	  translation.	  The	  
out	  of	  frame	  GFP	  sequence	   is	  not	  translated	  due	  to	  a	  stop	  codon	  at	  the	  end	  of	  
the	  dsRED	  open	  reading	  frame.	  A	  different	  reading	  frame	  is	  used	  when	  the	  DSS	  is	  
chosen.	  In	  this	  case,	  the	  8a	  region	  is	  not	  included	  in	  the	  mRNA	  transcript	  which	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causes	   a	   frame	   shift.	   Exon	   8b	   is	   translated	   but	   the	   dsRED	   sequence	   is	   out	   of	  
frame	   leading	   to	   dsRED+1	   being	   translated.	   	   A	   fusion	   protein	   is	   formed	   with	  
EGFP,	  which	   is	   in-­‐frame.	   Essentially,	   the	   pro-­‐angiogenic	   splicing	   pattern	   causes	  




Figure	  3-­‐2	  pRG8ab	  splicing-­‐sensitive	  fluorescent	  reporter	  design	  
A	  VEGF	  splicing	  reporter	  was	  designed	  based	  on	  the	  RG6	  construct.	  VEGF	  exon	  7	  
3’end,,	  intron	  7	  and	  exon	  8	  were	  ligated	  into	  RG6	  plasmid	  backbone.	  Depending	  
on	  reporter	  3’	  splice	  site	  selection,	  either	  dsRED	  or	  GFP	  is	  translated.	  
	  
3.2.2 Reporter  expression  in  culture  
It	  was	  first	  determined	  as	  to	  whether	  the	  pRG8ab	  construct	  was	  well	  expressed	  
with	  functional	  fluorescent	  protein	  production	  when	  tranfected	  into	  cultured	  cell	  
lines.	  Human	  embryonic	  kidney	  cells	  (HEK293)	  were	  transiently	  transfected	  with	  
reporter	   plasmid	   via	   lipofection.	   Reporter	   expression	   was	   confirmed	   by	  
fluorescence	   microscopy	   48	   hours	   after	   transfection.	   Cells	   were	   fixed	   in	   4%	  
paraformaldeyde	  and	  the	  nuclei	  stained	  with	  Hoechst.	  The	  cell	  population	  had	  a	  
transfection	   efficiency	   of	   ∼50%.	   Expression	   of	   both	   dsRED	   and	   EGFP	   was	  
8a# 8b# dsRED# EGFP#intron7 CMV 
TAA PSS 
DSS 
8a# 8b# dsRED# EGFP# 8b# dsRED+!# EGFP#
TAA 
Proximal splicing Distal splicing 
pRG8ab reporter 
RG8ab mRNA 
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observed;	  this	  indicated	  that	  it	  is	  possible	  for	  the	  reporter	  RNA	  to	  be	  spliced	  from	  
both	   the	   proximal	   (dsRED)	   and	   distal	   (EGFP)	   splice	   sites.	  Many	   cells	   expressed	  
both	   dsRED	   and	   EGFP	   whereas	   other	   expressed	   only	   one	   of	   the	   fluorescent	  
proteins	  (Figure	  3-­‐3).	  EGFP	  was	  localised	  mainly	  in	  the	  nucleus	  due	  to	  a	  nuclear	  
localisation	  sequence	  within	  the	  in-­‐frame	  EGFP	  sequence.	  	  
	  
	  
Figure	  3-­‐3	  HEK293	  cells	  transiently	  transfected	  with	  pRG8ab	  reporter	  
Expression	  of	  both	  dsRED	  and	  EGFP	  was	  observed	  48	  hours	  after	  reporter	  
transfection	  into	  HEK293	  cells.	  Cells	  were	  fixed	  in	  4%	  PFA	  and	  nuclei	  stained	  with	  
Hoechst.	  
	  
The	  reporter	  plasmid	  contains	  a	  neo	  resistance	  gene.	  Therefore,	  transfected	  cells	  
were	   selected	   for	   using	   the	   aminoglycoside	   antibiotic,	   G418.	   Transiently	  
transfected	   cells	  were	   cultured	   in	  growth	  media	   containing	  500ug/ml	  G418	   for	  
14	   days.	   G418	   is	   toxic	   to	   eukaryotic	   cells,	   only	   cells	   expressing	   the	   resistance	  
gene	  survived	  the	  selection,	  to	  produce	  a	  HEK293	  cell	  line	  that	  stably	  expressed	  
pRG8ab.	   Following	   antibiotic	   selection,	   the	   cells	   were	   again	   imaged	   via	  
fluorescence	  microscopy.	   The	  majority	   of	   transfected	   cells	   now	  expressed	  only	  
dsRED,	   with	   little	   EGFP	   detectable	   (Figure	   3-­‐4).	   This	   corresponds	   with	   the	  
Hoechst  EGFP  dsRED 
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alternative	  splicing	  pattern	  of	  endogenous	  VEGF	  RNA	  in	  this	  cell	  type,	  as	  HEK293	  
cells	  predominantly	  express	  pro-­‐angiogenic	  VEGF	   isoforms,	  as	  demonstrated	  by	  
RT-­‐PCR	   (Figure	   3-­‐5).	   On	   the	   other	   hand,	   cells	   transiently	   transfected	   with	   the	  
reporter	  displayed	  both	  patterns	  of	  reporter	  alternative	  splicing.	  This	  is	  likely	  due	  
to	   each	   transfected	   cell	   having	   taken	   up	  many	   copies	   of	   the	   reporter	   plasmid.	  
This	  high	  copy	  number	  may	  overwhelm	  the	  splicing	  machinery	  configuration	  at	  




Figure	  3-­‐4	  Stable	  transfection	  of	  pRG8ab	  in	  HEK293	  cells	  
The	  reporter	  plasmid	  contains	  a	  neo	  gene	  which	  conveys	  resistance	  to	  G418	  
antibiotic.	  Transiently	  transfected	  cells	  underwent	  antibiotic	  selection	  (500ug/ml)	  
to	  produce	  a	  stable	  cell	  line	  expressing	  pRG8ab.	  No	  EGFP	  expression	  was	  
detected	  in	  the	  stable	  cells.	  
	  
	  
Hoechst  EGFP  dsRED 
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Figure	  3-­‐5	  VEGF	  mRNA	  isoform	  expression	  in	  HEK293	  cells	  
RNA	  was	  extracted	  from	  HEK293	  cells	  and	  reverse	  transcribed.	  Primers	  that	  
anneal	  with	  both	  VEGFxxx	  and	  VEGFxxxb	  were	  used	  to	  amplify	  the	  cDNA.	  Only	  pro-­‐
angiogenic	  VEGFxxx	  isoforms	  were	  detected	  (predicted	  size	  175bp).	  
	  
Reporter	   splicing	   can	   be	   easily	   visualised	   using	   fluorescent	   protein	   expression	  
but	   has	   also	   been	   confirmed	   using	   the	   traditional	   RT-­‐PCR	   method.	   Reporter	  
specific	  primers	  were	  used	   to	  amplify	   transcripts	  produced	   from	  both	  proximal	  
and	  distal	  splice	  site	  selection.	  The	  forward	  primer	  anneals	  to	  the	  artificial	  exon	  
and	  reverse	  primer	  to	  the	  dsRED	  sequence	  (Figure	  3-­‐6).	  Proximally	  spliced	  mRNA	  
would	  produce	  a	  PCR	  product	  of	  193bp	  whereas	  a	  product	  of	  128bp	  would	  be	  
produced	  from	  distal	  splice	  site	  selection.	  As	  expected	  from	  the	  splicing	  pattern	  
seen	   by	   fluorescence	   microscopy,	   only	   proximally	   spliced	   transcripts	   were	  
detected,	  confirming	  that	  the	  reporter	  follows	  accurately	  the	  splicing	  pattern	  of	  
the	  endogenous	  gene	  when	  stably-­‐transfected	  in	  HEK293	  cells.	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Figure	  3-­‐6	  Reporter	  proximal	  splice	  site	  is	  predominantly	  used	  in	  HEK293	  cells	  
RNA	  extracted	  from	  reporter	  expressing	  HEK293	  cells	  (pooled	  cells;	  stable	  
transfections)	  was	  reverse	  transcribed;	  the	  cDNA	  was	  amplified	  using	  reporter	  
specific	  primers.	  Only	  the	  PCR	  products	  corresponding	  to	  the	  proximally	  spliced	  
pattern,	  ie	  193bp	  in	  size,	  were	  detected.	  
	  
The	   reporter	   was	   also	   transfected	   into	   other	   mammalian	   cell	   lines.	   A	  
conditionally	   immortalized	  podocyte	  cell	   line	   (PCIP)	  has	  previously	  been	  shown	  
to	  express	  high	   levels	  of	  anti-­‐angiogenic	  VEGF165b	  (Amin	  et	  al.,	  2011;	  Cui	  et	  al.,	  
2004).	  Electroporation	  was	  used	  to	  transiently	  transfect	  podocytes	  with	  pRG8ab	  
and	   fluorescent	   micrographs	   taken	   of	   fixed	   cells.	   The	   podocytes	   expressed	  
predominantly	  EGFP	  indicating	  anti-­‐angiogenic	  style	  splicing	  via	  use	  of	  the	  distal	  
splice	  site	  (Figure	  3-­‐7)	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Figure	  3-­‐7	  pRG8ab	  distal	  splice	  site	  is	  used	  during	  alternative	  splicing	  in	  
proliferating	  conditionally	  immortalized	  podocytes	  
Selection	  of	  the	  VEGF	  reporter’s	  distal	  splice	  site	  leads	  to	  EGFP	  expression.	  No	  
dsRED,	  only	  EGFP	  expression	  was	  observed	  in	  transfected	  podocytes	  indicating	  
anti-­‐angiogenic	  splicing	  pattern.	  
	  
A	  third	  cell	  line	  transfected	  with	  the	  reporter	  was	  PC3.	  It	  is	  recognised	  that	  anti-­‐
angiogenic	  VEGF	   isoforms	  are	  down	  regulated	   in	  prostate	  cancers	  compared	  to	  
normal	  prostate	   tissue.	  Fluorescence	   from	  both	  EGFP	  and	  dsRED	  was	  observed	  
when	  PC3	  cells	  were	  transiently	  transfected	  with	  pRG8ab	  (Figure	  3-­‐8)	  indicating	  
use	  of	  the	  proximal	  and	  distal	  splice	  sites	  of	  the	  reporter.	  Cells	  were	  cultured	  in	  
750ug/ml	  G418	  to	  select	  for	  reporter	  expressing	  cells	  and	  create	  a	  stable	  cell	  line	  
expressing	   the	   reporter	  plasmid.	  Similar	   to	   the	  effect	   seen	   in	  HEK293	  cells,	   the	  
PC3	   stably	   transfected	   cells	   did	   not	   express	   EGFP,	   just	   dsRED.	   This	   suggests	  
predominant	   use	   of	   the	   proximal	   splice	   site,	   correlating	   with	   the	   alternative	  
splicing	  of	  the	  endogenous	  VEGF	  gene	  in	  these	  cells	  (Mavrou	  et	  al.,	  2014).	  These	  
experiments	  suggest	  that	  the	  reporter	  is	  following	  accurately	  the	  splicing	  pattern	  
of	  the	  endogenous	  gene	  in	  various	  cell	  lines.	  
Hoechst  EGFP  dsRED 
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Figure	  3-­‐8	  pRG8ab	  expression	  in	  the	  prostate	  cancer	  cell	  line,	  PC3	  
PC3	  cells	  were	  transfected	  the	  pRG8ab	  and	  imaged.	  Transiently	  transfections	  
expressed	  dsRED	  and	  EGFP.	  A	  PC3	  pRG8ab	  stable	  cell	  line	  was	  created	  using	  
antibiotic	  selection.	  Only	  dsRED	  expression	  could	  be	  detected	  in	  the	  stable	  
transfections.	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3.2.3 Fluorescence  activated  cell  sorting  of  reporter  cells  
	  A	   main	   advantage	   of	   splicing	   reporters	   is	   that	   fluorescence	   can	   be	   used	   to	  
quantify	  the	  splicing	  pattern	  within	  live	  cells.	  This	  can	  be	  achieved	  by	  using	  flow	  
cytometry	   to	   measure	   the	   fluorescent	   protein	   expression	   within	   a	   sample	   of	  
cells.	   Flow	   cytometry	   can	   quickly	   measure	   the	   fluorescence	   of	   a	   sample	   of	  
millions	  of	  cells.	  Cells	  were	  collected	  for	  flow	  cytometry	  using	  trypsin	  to	  detach	  
them	   from	   culture	   plates	   and	   resuspended	   in	   growth	   media	   containing	   1%	  
paraformaldehyde	  for	  fixation.	  For	  flow	  cytometric	  analysis,	  cells	  are	  transported	  
through	  a	  fluidics	  system	  within	  the	  flow	  cytometer	  in	  single	  file	  where	  they	  are	  
illuminated	  by	  a	  series	  of	  lasers.	  The	  size	  and	  granularity	  of	  cells	  is	  measured	  by	  
the	  forward	  and	  side	  scatter	  caused	  when	  laser	  light	  hits	  a	  cell.	  A	  laser	  is	  used	  to	  
excite	  fluorophores.	  In	  the	  HEK	  pRG8ab	  cells,	  both	  the	  fluorescent	  proteins	  were	  
excited	   using	   a	   laser	   at	   488nm	   wavelength.	   Different	   emission	   filters	   allowed	  
detection	  of	  dsRED	  and	  EGFP	  and	  to	  count	  the	  number	  of	  cells	  expressing	  either	  
or	   both	   proteins.	   The	   emission	   profile	   produced	   by	   HEK293	   pRG8ab	   cells	   was	  
compared	  to	  untransfected	  HEK293	  cells	  (Figure	  3-­‐9).	  The	  emission	  produced	  by	  
untransfected	  cells	  (background	  fluorescence)	  was	  used	  to	  create	  a	  gate	  (see	  left	  
panel),	   any	   cells	   that	   produce	   fluorescence	   within	   this	   gate	   were	   expressing	  
dsRED	  or	  EGFP.	  This	  was	  used	  to	  count	  the	  number	  of	  fluorescent	  cells	  within	  a	  
sample.	  
After	   selection	   with	   geneticin,	   ∼16%	   of	   the	   HEK293	   cells	   population	   were	  
expressing	   the	   reporter	   construct.	   Flow	   cytometry	   detected	   that	   the	   cells	  
positive	   for	   reporter	   expression	   predominantly	   produced	   dsRED	   (Figure	   3-­‐9),	  
right	  panel),	  indicating	  use	  of	  the	  proximal	  splice	  site.	  This	  corresponds	  with	  the	  
splicing	  pattern	  seen	  via	  fluorescence	  microscopy	  and	  RT-­‐PCR.	  For	  the	  purposes	  
of	  further	  validation	  and	  screening	  a	  higher	  percentage	  of	  fluorescent	  cells	  was	  
needed.	   The	   fluorescent	   population	   was	   increased	   by	   selecting	   cells	   using	  
fluorescence	  activated	  cell	  sorting	  (FACS).	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Figure	  3-­‐9	  Flow	  cytometric	  analysis	  of	  reporter	  expressing	  cells	  
The	  fluorescent	  protein	  expression	  in	  reporter	  expressing	  HEK293	  cells	  was	  
measured	  by	  flow	  cytometry.	  Untransfected	  HEK293	  cells	  were	  used	  as	  a	  
negative	  control	  and	  to	  create	  a	  gate.	  Any	  cells	  which	  fell	  within	  this	  gate	  were	  
regarded	  as	  transfected	  and	  therefore,	  expressing	  dsRED	  or	  EGFP.	  
	  
Cell	  sorting	  allows	  different	  populations	  of	  cells	  to	  be	  isolated	  from	  each	  other.	  
Different	  cell	  types	  can	  be	  separated	  by	  flow	  cytometry	  according	  to	  their	  size	  or	  
fluorescently	   labelled	   on	   cell	   type-­‐specific	   markers	   for	   separation	   via	   FACS.	   In	  
this	   case,	   reporter-­‐positive	   cells	   were	   able	   to	   be	   separated	   from	   the	  
untransfected	   population	   as	   transfected	   cells	   expressed	   dsRED	   or	   EGFP	  
producing	   a	   fluorescent	   signal.	   In	   the	   first	   instance,	   a	   sample	   of	   untransfected	  
HEK293	   cells	   were	   run	   through	   the	   cell	   sorter.	   Similarly	   as	   described	   for	  
analytical	   flow	   cytometry,	   the	   scatter	   pattern	   produced	   by	   untransfected	   cells	  
was	  used	  as	  a	  negative	  control.	  Using	  the	  sorter	  software,	  a	  gate	  was	  set	  around	  
the	  scatter	  created	  by	  untransfected	  cells.	  When	  the	  pRG8ab	  transfected	  sample	  
was	  analysed	  by	  the	  sorter,	  any	  cells	  that	  produced	  fluorescence	  (red	  or	  green)	  
outside	  of	  the	  gate	  were	  deemed	  to	  be	  reporter	  positive	  (Figure	  3-­‐10).	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Figure	  3-­‐10	  Fluorescent	  activated	  cell	  sorting	  of	  HEK293	  pRG8ab	  cells	  
FACS	  was	  used	  to	  gain	  a	  higher	  percentage	  of	  fluorescent	  protein	  expressing	  cells	  
within	  the	  HEK293	  pRG8ab	  stably	  transfected	  cell	  line.	  Untransfected	  HEK293	  
cells	  were	  used	  as	  a	  negative	  control	  and	  to	  create	  gates	  that	  will	  measure	  and	  
separate	  fluorescent	  cells	  from	  non-­‐fluorescent	  cells.	  
	  
Fluorescent,	   reporter-­‐expressing	   cells	   were	   electrostatically	   separated	   from	  
untransfected	  cells.	  Two	  rounds	  of	  FACS	  were	  performed	  to	  gain	  a	  stable	  HEK293	  
pRG8ab	  cell	  line	  in	  which	  88%	  of	  the	  population	  were	  expressing	  the	  fluorescent	  
reporter	  (Figure	  3-­‐11).	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Figure	  3-­‐11	  pRG8ab	  expression	  in	  HEK293	  cells	  after	  fluorescence	  activated	  cell	  
sorting	  
Cells	  were	  subjected	  to	  FACS	  to	  separate	  fluorescent,	  reporter	  expressing	  cells	  
from	  non-­‐fluorescent	  cells.	  After	  two	  rounds	  of	  FACS,	  88%	  of	  the	  HEK293	  pRG8ab	  
population	  were	  fluorescent	  (v03	  positive).	  dsRED	  was	  highly	  expressed	  (x	  axis)	  
with	  only	  a	  small	  population	  expressing	  EGFP.	  
	  
3.2.4 SRPK1  inhibition  increases  reporter  distal  splice  site  selection  
Before	  using	  the	  VEGF	  fluorescent	  splicing	  reporter	  cells	  in	  a	  screening	  capacity,	  
further	   validation	   was	   required	   to	   show	   that	   the	   reporter	   splicing	   accurately	  
mimics	   endogenous	  VEGF	   splicing.	   The	   association	   between	   SRPK1,	   SRSF1	   and	  
exon	  8	  splicing	  regulation	  is	  well	  established	  (Gammons	  et	  al.,	  2014;	  Mavrou	  et	  
al.,	   2014;	  Nowak	  et	  al.,	   2010;	  Oltean	  et	  al.,	   2012).	   Inhibition	  of	   SRPK1	   reduces	  
phosphorylation	   and	   activation	   of	   SRSF1.	   SRSF1	   binds	   to	   VEGF	   mRNA	   and	  
promotes	  selection	  of	  the	  proximal	  splice	  site	  of	  exon	  8:	  SRPK1	  inhibition	  reduces	  
this	  interaction	  and	  increases	  the	  expression	  of	  anti-­‐angiogenic	  VEGF	  proteins	  via	  
increased	   use	   of	   the	   distal	   splice	   site.	   Therefore	   validation	   was	   attempted	   by	  
inhibiting	   SRPK1	   in	   reporter	   expressing	   cells.	   HEK293	   pRG8ab	   cells	   were	  
incubated	  with	   SRPIN340	   and	   a	   series	   of	   newly	   developed	   SRPK1	   inhibitors	   at	  
10µM	   for	   48	   hours.	   Effect	   of	   SPRK1	   inhibition	   on	   reporter	   splicing	  within	   cells	  
was	   observed	   using	   flow	   cytometry	   to	   measure	   expression	   of	   dsRED	   (pro-­‐
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angiogenic	   splicing)	   and	   EGFP	   (anti-­‐angiogenic	   splicing)	   compared	   to	   control	  
treatment	  	  	  
As	  described	  previously,	  gates	  were	  created	  within	  the	  flow	  cytometry	  software	  
to	  measure	  the	  percentage	  of	  cells	  that	  express	  dsRED	  or	  EGFP,	  which	  was	  used	  
to	   indicate	   which	   splice	   site	   is	   being	   selected.	   The	   percentage	   of	   cells	   with	   a	  
sample	  that	  express	  dsRED	  or	  EGFP	  were	  used	  to	  calculate	  the	  ratio	  of	  splice	  site	  
selection.	  Changes	  in	  dsRED/EGFP	  ratio	  implied	  altered	  splice	  site	  selection.	  The	  
sum	  of	  the	  two	  population	  percentages	  (dsRED+EGFP)	  was	  calculated	  and	  used	  
as	  an	  indicator	  of	  increases	  or	  decreases	  in	  the	  overall	  expression	  of	  the	  reporter	  
construct;	   this	   may	   be	   caused	   by	   effects	   of	   transcription,	   translation	   or	  
fluorescent	  protein	  stability.	  Treatment	  with	  SRPIN340	  did	  not	  cause	  a	  change	  in	  
reporter	  splicing	  at	  10µM.	  Two	  of	  the	  other	  SRPK1	   inhibitors	  used,	  SPHINX	  and	  
SPHINX7,	  have	  greater	  potency	  than	  SRPIN340	  shown	  in	  an	  in	  vitro	  kinase	  assay	  
(Gammons	  et	   al.,	   2013a).	   SRPIN340	   and	   SPHINX	   produced	   a	   slight	   decrease	   in	  
the	  ratio	  but	  it	  was	  not	  statistically	  significant.	  Treatment	  with	  SPHINX7	  caused	  a	  
significant	  decrease	  in	  dsRED/EGFP	  i.e	  increased	  use	  of	  the	  reporter	  distal	  splice	  
site.	  Additionally,	  cells	  were	  treated	  with	  a	  negative	  control	  compound	  (AZ2.46)	  
that	   had	   a	   similar	   molecular	   structure	   to	   the	   inhibitor	   SPHINX7	   but	   does	   not	  
block	  SRPK1	  activity.	  AZ2.46	  treatment	  did	  not	  cause	  a	  change	  from	  the	  DMSO	  
control	  (Figure	  3-­‐12).	  This	  further	  demonstrated	  that	  the	  VEGF	  reporter	  splicing	  
responds	   to	   stimuli	   in	   a	   similar	  way	   to	  endogenous	  VEGF	  mRNA	  and	   therefore	  
would	  be	  a	  useful	  tool	  for	  investigating	  exon	  8	  alternative	  splicing.	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Figure	  3-­‐12	  SRPK1	  inhibition	  increases	  use	  of	  the	  pRG8ab	  reporter	  distal	  splice	  
site	  
HEK293	  pRG8ab	  cells	  were	  treated	  with	  SRPK1	  inhibitors	  at	  10µM	  for	  48	  hours.	  
After	  treatment,	  live	  cells	  were	  collected	  and	  flow	  cytometry	  used	  to	  measure	  the	  
percentage	  of	  cells	  expressing	  dsRED	  and	  EGFP.	  Percentages	  were	  used	  to	  
calculate	  the	  ratio	  of	  splice	  site	  selection	  (dsRED/EGFP).	  A	  decrease	  in	  the	  ratio	  
suggests	  increased	  selection	  of	  the	  distal	  splice	  site.	  Changes	  in	  overall	  reporter	  
expression	  are	  indicated	  by	  dsRED+EGFP.	  The	  effect	  of	  treatment	  on	  alternative	  
splicing	  are	  measured	  by	  dsRED/EGFP.	  n=3,	  *P<0.05.	  No	  significant	  difference	  in	  
RFP+GFP	  measurements.	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3.2.5 Preliminary  screens  using  pRG8ab  to  identify  novel  regulators  of  
VEGF  alternative  
As	  discussed,	  splicing	  reporters	  are	  a	  useful	  tool	  to	  identify	  novel	  regulators	  of	  an	  
individual	  alternative	  splicing	  event.	  This	  may	  be	  achieved	  via	  overexpression	  or	  
silencing	  of	  different	  genes,	  stimulation	  with	  signalling	  molecules	  or	  using	  small	  
molecules	  inhibitors/agonists.	  Such	  reporters	  can	  be	  used	  in	  large	  high-­‐
throughput	  scale	  screens,	  but	  should	  be	  first	  be	  trialled	  in	  preliminary	  
experiments.	  
It	   is	   recognised	   that	   growth	   factors	   can	  modify	   alternative	   splicing	   patterns	   by	  
activation	  of	  cell	  signalling	  pathways	  (Blaustein	  et	  al.,	  2005;	  Matter	  et	  al.,	  2002;	  
Pelisch	  et	  al.,	  2005;	  Zhou	  et	  al.,	  2012).	  IGF1,	  TNFα	  and	  TGFβ1	  have	  all	  previously	  
been	  shown	  to	  influence	  VEGF	  exon	  8	  alternative	  splicing	  (Nowak	  et	  al.,	  2008).	  A	  
small	  group	  of	  growth	  factors	  were	  tested	  for	  their	  effect	  on	  pRG8ab	  alternative	  
splicing	  (Figure	  3-­‐13).	  HEK293	  pRG8ab	  cells	  were	  treated	  with	  each	  growth	  factor	  
at	   100nM	   for	   48hours	   and	   flow	   cytometry	   used	   to	   quantify	   the	   alternative	  
splicing	   of	   pRG8ab.	   EGF	   and	   FGF2	   displayed	   the	   greatest	   effect	   on	   reporter	  
splicing.	  Both	   increased	  the	  use	  of	  the	  distal	  splice	  site	  seen	  by	   increased	  EGFP	  
expression.	  The	  other	  growth	  factors	  did	  not	  cause	  any	  considerable	  change	  to	  
reporter	  splicing.	  	  
Additionally,	  a	  small	  cohort	  of	  small	  molecule	  inhibitors	  were	  used	  treat	  HEK293	  
cells	  and	  activity	  on	  pRG8ab	  alternative	  splicing	  examined	  (Figure	  3-­‐14).	  5-­‐Aza-­‐2ʹ′-­‐
deoxycytidine	  (5’AZAdC),	  BIX02194	  trihydrochloride	  hydrate	  and	  3-­‐
deazaneplanocin	  A	  (DZnep)	  are	  all	  compounds	  known	  to	  cause	  changes	  to	  
epigenetic	  marks.	  5’AZAdc	  is	  an	  inhibitor	  of	  DNA	  methylation,	  BIX02194	  is	  an	  
inhibitor	  of	  histone-­‐lysine	  methyl	  transferases,	  and	  DZnep	  can	  block	  histone	  3	  
lysine	  27	  and	  histone	  4	  lysine	  20	  trimethylation.	  HEK293	  pRG8ab	  cells	  were	  
treated	  with	  10µM	  of	  each	  epigenetic	  modifier	  for	  48	  hours.	  Following	  
treatment,	  the	  cells	  were	  collected	  for	  analysis	  of	  reporter	  alternative	  splicing	  
patterns	  via	  flow	  cytometry.	  5’AZAdC	  did	  not	  have	  an	  effect	  on	  the	  dsRED/EGFP	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expression	  ratio	  of	  the	  cells,	  however,	  BIX02194	  significantly	  increased	  and	  
DZnep	  significantly	  decreased	  the	  ratio,	  without	  marked	  changes	  to	  sum	  of	  
dsRED	  and	  EGFP	  expression,	  indicating	  these	  drugs	  may	  change	  the	  pattern	  of	  
reporter	  alternative	  splicing.	  A	  previous	  study	  has	  demonstrated	  DZnep	  to	  
exhibit	  anti-­‐angiogenic	  activity	  (Smits	  et	  al.,	  2011;	  Smits	  et	  al.,	  2010).	  
	  
Figure	  3-­‐13	  The	  effect	  of	  a	  growth	  factor	  panel	  on	  reporter	  alternative	  splicing	  
HEK293	  pRG8ab	  cells	  were	  treated	  with	  100nM	  EGF,	  FGF2,	  IGF1,	  TNFα	  or	  PDGF	  
for	  48	  hours.	  The	  treated	  cells	  were	  collected	  and	  reporter	  alternative	  splicing	  
was	  quantified	  using	  flow	  cytometry	  to	  measure	  dsRED	  and	  EGFP	  expression.	  
n=3,	  **P<0.01.	  FGF2	  also	  significantly	  changed	  dsRED+EGFP.	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Figure	  3-­‐14	  The	  effect	  of	  epigenetic	  modifying	  compounds	  on	  VEGF	  SSFR	  
alternative	  splicing.	  	  
HEK293	  cells	  were	  treated	  with	  10µM	  5’AZAdC,	  BIX02194	  or	  DZnep	  for	  48	  hours.	  
Subsequently,	  dsRED	  and	  EGFP	  were	  measured	  by	  flow	  cytometry.	  dsRED/EGFP	  
changes	  indicated	  a	  change	  in	  the	  ratio	  of	  reporter	  splice	  site	  selection.	  Total	  
expression	  of	  the	  reporter	  was	  indicated	  by	  dsRED+EGFP.	  DZnep	  treatment	  is	  
compared	  to	  water	  control.	  DMSO	  was	  used	  a	  control	  treatment	  for	  BIX02194	  
and	  5’AZAdc.	  n=6,	  *P<0.05	  vs.	  DMSO	  dsRED/EGFP,	  **P<0.01	  vs.	  water	  
dsRED/EGFP.	  #P<0.01	  vs.	  DMSO	  dsRED+EGFP.	  
	  
Increasingly,	  naturally	  occuring	  compounds,	  such	  as	  resveratrol,	  are	  being	  
investigated	  to	  elucidate	  potential	  benefits	  and	  possible	  exploitation	  for	  medical	  
use.	  DIAVIT	  is	  a	  commercially	  available	  natural	  extract	  from	  bilberries	  and	  
buckthorn.	  It	  has	  been	  used	  to	  alleviate	  complications	  of	  diabetes,	  including	  
diabetic	  retinopathy,	  which	  is	  characterised	  by	  microvascular	  changes	  in	  the	  eye.	  
Reporter-­‐expressing	  HEK293	  cells	  were	  cultured	  in	  three	  dilutions	  of	  DIAVIT.	  One	  
tablet	  of	  DIAVIT	  was	  dissolved	  in	  100ml	  of	  distilled	  water	  and	  filtered	  using	  a	  
0.2µm	  filter.	  This	  dilution	  was	  termed	  ‘high	  dose’	  and	  100µl	  was	  added	  to	  cells	  in	  
6-­‐well	  plates.	  A	  further	  10x	  and	  100x	  dilutions	  were	  termed	  mid	  and	  low	  dose,	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respectively.	  Following	  48	  hours	  of	  DIAVIT	  treatment,	  cells	  were	  collected	  and	  
flow	  cytometry	  used	  to	  measure	  dsRED	  and	  EGFP-­‐positive	  cells.	  DIAVIT	  
treatment	  resulted	  in	  a	  dose-­‐dependent	  decrease	  in	  dsRED/EGFP,	  suggesting	  
increased	  use	  of	  SSFR	  distal	  splice	  site	  –	  this	  may	  provide	  a	  mechanistic	  
explanation	  for	  the	  anti-­‐angiogenic	  effect	  seen	  in	  patients	  with	  diabetic	  
retinopathy	  that	  take	  DIAVIT	  as	  a	  adjuvant	  therapy.	  DIAVIT	  is	  marketed	  as	  a	  
diabetic	  therapy,	  however,	  there	  are	  no	  published	  trials	  demonstrating	  these	  
effects.	  The	  total	  expression	  of	  the	  reporter	  was	  was	  increased,	  as	  measured	  by	  




Figure	  3-­‐15	  Natural	  extract	  DIAVIT	  reduces	  the	  ratio	  of	  VEGF	  SSFR	  splice	  site	  
selection	  
HEK293	  cells	  were	  cultured	  with	  three	  increasing	  doses	  of	  a	  DIAVIT	  solution	  for	  48	  
hours.	  n=3,	  **P<0.01	  vs.	  untreated	  dsRED/EGFP.	  #P<0.01	  vs.	  untreated	  
dsRED+EGFP.	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3.3  DISCUSSION  
3.3.1 VEGF  splicing-­‐sensitive  fluorescent  reporter  is  expressed  and  follows  
endogenous  VEGF  splicing  patterns  in  vitro  
Signalling	   stimulated	  by	  VEGF	   is	   crucial	   in	   the	  process	   of	   angiogenesis	   and	  has	  
been	  intensively	  studied	  in	  physiology	  and	  pathology	  (Carmeliet,	  2003;	  Carmeliet	  
and	  Jain,	  2000;	  Ferrara	  et	  al.,	  2003).	  Discovering	  a	  family	  of	  alternatively	  spliced	  
VEGF	   protein	   isoforms	   with	   anti-­‐angiogenic	   properties	   added	   a	   new	   layer	   of	  
complexity	  to	  the	  role	  of	  VEGF	  (Bates	  et	  al.,	  2002;	  Bates	  and	  Harper,	  2005).	  Pro-­‐
angiogenic	   VEGFxxx	   is	   upregulated	   in	   tumours	   whereas	   VEGFxxxb	   isoforms	   are	  
decreased	   (Amin	   et	   al.,	   2011;	   Pritchard-­‐Jones	   et	   al.,	   2007).	   It	   is	   therefore	  
important	   to	   understand	   what	   controls	   the	   balance	   between	   pro	   and	   anti-­‐
angiogenic	  VEGF.	  	  
The	   VEGF	   pro/anti-­‐angiogenic	   splicing	   reporter,	   pRG8ab,	   was	   designed	   to	  
investigate	  the	  mechanisms	  that	  regulate	  exon	  8	  3’	  splice	  site	  selection	  and	  find	  
novel	  compounds	  that	  can	  modify	  the	  splicing	  decision.	  The	  design	  was	  adapted	  
from	   the	  RG6	  bichromatic	   splicing	   reporter	   developed	  by	  Orengo	  et	   al.	   Before	  
use	  in	  a	  screening	  scenario,	  the	  reporter	  first	  had	  to	  be	  validated	  to	  confirm	  if	  it	  
would	  be	  useful	  to	  find	  new	  regulators	  of	  pro	  vs.	  anti-­‐angiogenic	  VEGF	  splicing.	  It	  
needed	   to	   be	   ascertained	   if	   the	   reporter	   construct	   accurately	   mimicked	   the	  
alternative	  splicing	  of	  VEGF	  mRNA.	  For	  validation,	  pRG8ab	  was	  transfected	  and	  
expressed	  in	  several	  cell	   lines	  and	  known	  regulators	  of	  VEGF	  exon	  8	  alternative	  
splicing	  used	  to	  alter	  pRG8ab	  splicing.	  
It	  was	   first	  determined	  whether	   the	  pRG8ab	  plasmid	  was	  well	  expressed	  when	  
transfected	  into	  mammalian	  cell	  lines.	  Transient	  transfection	  was	  first	  attempted	  
in	  HEK293	   cells	  using	   lipofection	   to	   introduce	   the	  plasmid	   into	   the	   cells.	   Forty-­‐
eight	   hours	   after	   transfection,	   expression	   of	   both	   dsRED	   and	   EGFP	   could	   be	  
detected	  in	  cells	  (Figure	  3-­‐3).	  This	  confirmed	  expression	  of	  the	  plasmid	  in	  culture	  
and	   that	   both	   reporter	   splice	   sites,	   proximal	   and	   distal,	   can	   be	   selected	   and	  
produce	   fluorescent	   protein.	   The	   gene	   expression	   produced	   by	   transient	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transfection	  is	  not	  permanent.	  As	  the	  cells	  replicate	  and	  divide	  the	  plasmid	  may	  
be	  lost,	  therefore	  stable	  transfections	  were	  made.	  In	  these	  cells,	  EGFP	  expression	  
could	   no	   longer	   be	   seen	   when	   imaging	   the	   cells,	   whereas	   dsRED	   was	   highly	  
expressed	  indicating	  proximal	  splice	  site	  selection	  (Figure	  3-­‐4).	  This	  corresponds	  
to	   the	   alternative	   splicing	   of	   VEGF	   in	   this	   cell	   line,	   the	   proximal	   splice	   site	   is	  
dominant	  causing	  pro-­‐angiogenic	  splice	  site	  selection.	  The	  change	  in	  the	  splicing	  
pattern	  between	   transient	   and	   stable	   transfections	  may	  be	   an	   issue	   caused	  by	  
copy	  number.	  After	  transient	  transfection,	  there	  are	  likely	  to	  be	  many	  copies	  of	  
the	   plasmid	   in	   each	   transfected	   cell	   and	   being	   highly	   expressed.	   Under	   these	  
circumstances,	   the	   splicing	  machinery	  may	  not	  act	   in	   its	  usual	  manner	  and	   the	  
splice	  factors	  needed	  at	  a	  certain	  splice	  site	  diluted	  out	  resulting	   in	  an	  artificial	  
splice	   pattern	   (Cooper,	   2005;	   Libri	   et	   al.,	   1989).	   In	   the	   HEK293	   pRG8ab	   stably	  
transfected	  cells,	   the	  plasmid	  has	  been	   integrated	   into	  the	  genome	  of	   the	  cells	  
and	  copy	  number	  should	  be	  lower.	  Here,	  the	  reporter	  splicing	  seems	  to	  be	  closer	  
to	  the	  endogenous	  pattern.	  A	  similar	  effect	  was	  observed	  when	  PC3	  cells	  were	  
transfected	  (Figure	  3-­‐8).	  The	  predominant	  use	  of	  the	  proximal	  5’	  splice	  site	  of	  the	  
reporter	   in	   stable	   HEK293	   pRG8ab	   cells	   was	   confirmed	   by	   RTPCR	   and	   flow	  
cytometry.	  	  
Another	   of	   the	   cell	   lines	   transfected	   with	   pRG8ab	   was	   PCIP	   (proliferating	  
conditionally	  immortalized	  podocytes).	  Anti-­‐angiogenic	  VEGF	  isoforms	  are	  highly	  
expressed	   in	   this	   cell	   line	   (Cui	   et	   al.,	   2004).	   Podocytes	   were	   transiently	  
transfected	   with	   pRG8ab	   using	   electroporation.	   Fluorescence	   microscopy	  
showed	  the	  transiently	  transfected	  PCIP	  cells	  expressed	  only	  EGFP	  and	  no	  dsRED,	  
indicating	   the	  distal	   splice	  site	  of	   the	   reporter	   is	  being	  predominantly	   selected.	  
This	  mimics	  with	  the	  splicing	  of	  VEGF	  mRNA	  in	  this	  cell	  type	  but	  contrast	  with	  the	  
situation	   seen	   when	   PC3	   and	   HEK293	   cells	   were	   transiently	   transfected;	   both	  
dsRED	  and	  EGFP	  were	  highly	  expressed	  in	  transients.	  This	  may	  be	  caused	  by	  the	  
use	   of	   two	   different	   methods	   to	   transfect	   with	   cells;	   lipofection	   was	   used	   to	  
express	   the	  pRG8ab	  plasmid	   in	  PC3	  and	  HEK293	  cells	  whereas	  podocytes	  were	  
transfected	  using	  electroporation.	  The	  transfection	  efficiency	  of	  the	  reporter	  into	  
podocytes	  was	   relatively	   low	   compared	   to	   the	   other	   cell	   lines,	   this	  may	  mean	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that	  less	  copies	  of	  the	  plasmid	  were	  integrated	  in	  each	  cell.	  Less	  integrants	  would	  
not	   have	   such	   a	   disruptive	   effect	   on	   the	   splicing	   machinery	   leading	   to	   the	  
reporter	   transcripts	   to	   be	   alternatively	   spliced	   in	   the	   same	   pattern	   as	   the	  
endogenous	  VEGF	  mRNA.	  
3.3.2 Inhibition  of  SRPK1  modifies  reporter  alternative  splicing  
In	  order	  to	  maximise	  the	  potential	  of	  reporter	  expressing	  cells	  for	  screening	  and	  
measuring	  changes	  in	  reporter	  splicing,	  it	  was	  necessary	  to	  have	  a	  high	  
percentage	  of	  the	  cells	  expressing	  the	  fluorescent	  proteins.	  Fluorescent	  cells	  
were	  isolated	  using	  FACS	  to	  obtain	  a	  population	  in	  which	  88%	  of	  the	  cells	  are	  
expressing	  dsRED	  or	  EGFP.	  SRPK1	  and	  the	  downstream	  splice	  factor	  SRSF1	  are	  
known	  to	  be	  important	  for	  promoting	  the	  selection	  of	  VEGF	  exon	  8	  proximal	  
splice	  site	  and	  therefore	  producing	  pro-­‐angiogenic	  VEGF	  isoforms.	  Knockdown	  or	  
chemical	  inhibition	  of	  SRPK1	  reduces	  the	  expression	  of	  VEGF165	  and	  increases	  
VEGF165b	  production.	  SRPIN340	  and	  other	  selective	  SRPK1	  inhibitors	  (SPHINXes)	  
have	  been	  shown	  to	  be	  anti-­‐angiogenic	  in	  vitro	  and	  in	  several	  in	  vivo	  models	  
(Gammons	  et	  al.,	  2013a;	  Gammons	  et	  al.,	  2013b).	  SRPIN	  340	  did	  not	  have	  an	  
effect	  on	  pRG8ab	  splicing	  but	  SPHINX	  caused	  a	  slight	  decrease	  in	  dsRED/EGFP	  
ratio.	  A	  reduction	  in	  dsRED/EGFP	  suggests	  SRPK1	  inhibition	  has	  increased	  distal	  
splice	  site	  selection	  and	  reduced	  use	  of	  the	  proximal	  splice	  site.	  SRPIN	  340	  and	  
SPHINX	  have	  similar	  IC50	  values	  for	  inhibiting	  SRPK1.	  SRPIN340	  has	  inhibitory	  
activity	  on	  SRPK1	  and	  SRPK2	  whereas	  SPHINX	  is	  more	  specific	  for	  SRPK1.	  The	  
inhibitor	  that	  causes	  the	  most	  potent	  SRPK1	  inhibition,	  SPHINX7,	  had	  the	  
greatest	  effect	  on	  reporter	  splicing.	  A	  negative	  control	  compound,	  AZ2.46,	  was	  
also	  used	  to	  treat	  reporter	  cells	  and	  caused	  no	  change	  to	  reporter	  alternative	  
splicing.	  AZ2.46	  has	  a	  similar	  molecular	  structure	  to	  the	  SRPK	  inhibitors	  but	  does	  
not	  actively	  inhibit	  SPRK	  activity.	  
	  
	   85	  
3.3.3 Pilot  screens  using  pRG8ab  to  measure  alternative  splicing  switches  
Upstream	   of	   splice	   factors	   and	   kinases,	   growth	   factors	   can	   influence	   cell	  
signalling	   to	   cause	   changes	   in	   alternative	   splicing.	   Some	   pathways	   have	  
previously	  described	  the	  effect	  of	  certain	  growth	  factors	  on	  VEGF	  terminal	  exon	  
alternative	   splicing	   (Nowak	  et	   al.,	   2008).	   IGF1	   and	   TNFα	  were	   shown	   to	   cause	  
preferential	   selection	   of	   the	   proximal	   splice	   site	   whereas	   distal	   splice	   site	  
selection	   was	   induced	   by	   TGFβ.	   EGF	   has	   also	   been	   implicated	   in	   alternative	  
splicing	   regulation	   via	   signalling	   to	   Akt,	   which	   causes	   SRPK1	   and	   2	   activation	  
(Zhou	  et	  al.,	  2012).	  Reporter	  expressing	  HEK293	  cells	  were	  treated	  with	  a	  series	  
of	   growth	   factor	   and	   their	   alternative	   splicing	   measured	   using	   fluorescent	  
protein	   expression.	   IGF1	   and	   TNFα	   did	   not	   alter	   reporter	   splicing.	   Under	   basal	  
conditions	  in	  this	  cell	  line,	  reporter	  proximal	  splice	  site	  selection	  is	  predominant	  
shown	   by	   high	   dsRED	   expression,	   therefore	   if	   PSS	   selection	   is	   already	   at	   a	  
maximum	  IGF	  and	  TNFα	  many	  not	  have	  a	  measurable	  effect	  on	  reporter	  splicing.	  
EGF	  and	  FGF2	  both	  induced	  a	  decrease	  in	  the	  RFP/GFP	  ratio	  indicating	  increased	  
use	  of	   the	  anti-­‐angiogenic	  distal	   splice	  site.	  This	   is	  despite	  EGF	  being	  known	  to	  
stimulate	  SRPKs	  which	   induce	  PSS	  use	  via	  SRSF1.	  This	  effect	  may	  be	  due	  to	  the	  
other	  splice	  factors	  that	  are	  influenced	  by	  EGF	  stimulation.	  The	  effect	  of	  EGF	  on	  
SRPKs	   is	   thought	   to	   be	   dependent	   on	  Akt,	   but	  Akt	   also	   activates	   several	   other	  
splice	  factors	  kinases	  including	  Clk	  (Jiang	  et	  al.,	  2009;	  Li	  et	  al.,	  2013).	  One	  of	  the	  
splice	   factors	   phosphorylated	   by	   Clk	   is	   SRp55	   (also	   known	   as	   SRSF6),	   which	  
increases	   VEGFxxxb	   expression	   through	   increased	   DSS	   selection	   (Nowak	   et	   al.,	  
2008).	   Therefore	   it	   may	   be	   activation	   of	   Clk	   caused	   by	   EGFR	   signalling	   that	  
creates	  increased	  EGFP	  expression	  from	  the	  reporter	  construct.	  
Another	  of	  the	  pilot	  screens	  conducted	  used	  a	  series	  of	  small	  molecules	  known	  
to	   interfere	  with	   epigenetic	  modifications.	   The	   association	   between	   epigenetic	  
marks	  and	  alternative	  splicing	   is	  a	  relatively	  new	  area	  of	  research	  but	   is	  rapidly	  
evolving.	   It	   is	   now	   understood	   that	   chromatin	   organisation,	   DNA	   methylation	  
and	  histone	  modifications	  may	  all	  impact	  alternative	  splicing	  regulation.	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Mapping	  of	  the	  position	  of	  nucleosomes	  within	  the	  whole	  genome	  has	  revealed	  
the	  boundaries	  where	  introns	  and	  exons	  meet	  to	  be	  enriched	  with	  nucleosomes,	  
potentially	   indicating	   nucleosomes	   to	   have	   a	   role	   in	   exon	   definition	   and	  
alternative	  splicing	  decisions	  (Andersson	  et	  al.,	  2009).	  Nucleosome	  mapping	  also	  
demonstrated	  that	  excluded	  exons	  are	  less	  enriched	  in	  nucleosomes	  than	  exons	  
included	  in	  spliced	  transcripts	  (Schwartz	  et	  al.,	  2009).	  
Chromatin	  conformation	  is	  a	  major	  mechanism	  used	  to	  control	  gene	  expression,	  
with	   transcription	   blocked	   when	   chromatin	   is	   in	   ‘closed’	   conformation.	  
Chromatin	   remodellers,	   including	  methyltransferases,	   change	   the	  conformation	  
to	  enable	  or	  inhibit	  transcription	  and	  to	  effect	  alternative	  splicing	  events.	  Certain	  
methyltransferases	  have	  been	  demonstrated	  to	   interact	  with	  snRNPs	  (Cheng	  et	  
al.,	  2007;	  Martinez	  et	  al.,	  2001).	  The	  SWI/SNF	  nucleosome-­‐remodelling	  complex	  
has	  also	  been	   shown	   to	  mediate	   changes	   to	  alternative	   splicing	   via	   association	  
with	  and	  recruitment	  of	  the	  U1	  and	  U5	  snRNPs	  (Batsche	  et	  al.,	  2006).	  
Histone	   modifications	   are	   known	   to	   mediate	   changes	   in	   gene	   expression	   by	  
changing	   chromatin	   structural	   conformation	   and	   recruitment	   of	   other	   factors.	  
Their	   role	   as	   regulators	   of	   alternative	   splicing	   is	   an	   emerging	   area	   of	  
investigation.	   Genome	  mapping	   of	   various	   common	   histone	   modifications	   has	  
demonstrated	   some	   histone	   marks	   to	   be	   enriched	   or	   depleted	   in	   exons	  
compared	   to	   the	   surrounding	   introns	   (Schwartz	   et	   al.,	   2009).	   Additionally,	   the	  
histone	  deacetylase	   inhibitor,	  trichostatin	  A,	  was	  shown	  to	  promote	  skipping	  of	  
specific	  exons	  in	  fibronectin	  and	  neural	  cell	  adhesion	  molecule	  mRNA	  (Nogues	  et	  
al.,	  2002;	  Schor	  et	  al.,	  2009).	  	  
The	  FGFRII	  mRNA	  contains	  two	  mutually	  exclusive	  exons,	  IIIb	  and	  IIIc.	  Inclusion	  of	  
either	  alternative	  exon	  in	  the	  final	  transcript	  is	  highly	  cell	  type-­‐specific,	  with	  IIIb	  
being	   maintained	   in	   epithelial	   cells	   and	   IIIc	   in	   mesenchymal	   cell	   types.	  
Investigation	   demonstrated	   the	   gene	   to	   be	   enriched	   in	   different	   histone	  
modifications	   depending	   on	   which	   exon	   is	   normally	   spliced.	   H3K27me3	   and	  
H3K4me3	   marks	   were	   enriched	   in	   IIIb	   expressing	   cells,	   and	   H3K27me3	   and	  
	   87	  
H3K4me1	   were	   present	   in	   cells	   that	   include	   IIIc.	   Overexpression	   or	   RNAi	  
knockdown	   of	   the	   required	   histone	   methyltransferases	   was	   able	   to	   modify	  
FGFRII	   alternative	   splicing	   to	  promote	  or	   inhibit	   IIIb	  or	   IIIc	   splicing	   (Luco	  et	   al.,	  
2010).	   Collectively,	   these	   observations	   indicate	   that	   modulation	   of	   epigenetic	  
marks	  and	  changes	  to	  chromatin	  organisation	  can	  alter	  splicing	  decisions.	  
Of	  the	  three	  epigenetic-­‐modifying	  small	  molecules	  tested,	  one	  increased	  and	  one	  
decreased	   dsRED/EGFP	   expression	   ratio	   of	   the	   VEGF	   SSFR.	   DZnep	   induced	   a	  
significant	  decrease	   in	  the	  dsRED/EGFP	   indicating	   increased	  use	  of	  the	  reporter	  
distal	   splice	   site,	   the	   splice	   site	   used	   to	   create	   anti-­‐angiogenic	   VEGF	   isoforms	  
from	   the	   endogenous	   VEGF	   mRNA.	   DZnep	   inhibits	   trimethylation	   of	   histone	  3	  
lysine	  27	   and	   histone	  4	   lysine	  20.	   The	   small	   molecule	   acts	   via	   an	   indirect	  
inhibitory	   mechanism.	   DZnep	   inhibits	   the	   enzyme	   S-­‐adenosylhomocysteine	  
hydrolase,	   which	   metabolises	   S-­‐adenosylhomocysteine	   to	   adenosine	   and	  
homocysteine.	   Increased	   concentration	   of	   S-­‐adenosylhomocysteine	   caused	   by	  
this	   results	   in	   inhibition	  of	   reactions	   that	   are	  S-­‐adenosylmethionine	  dependent	  
including	   histone	   methylation,	   in	   which	   methyltransferases	   use	   S-­‐
adenosylmethionine	   as	   a	   methyl	   donor.	   Trimethylation	   of	   H3K27	   by	   EZH2,	   a	  
methyltransferase	   component	   of	   the	   Polycomb	   repressor	   complex	   (PRC),	   is	  
inhibited	   by	   DZnep.	   H3K27me3	   is	   associated	   with	   repressive	   chromatin	  
conformation	   and	   EZH2	   overexpression	   has	   been	   observed	   in	   several	   types	   of	  
cancer.	   Through	   inhibition	   of	   these	  mechanisms,	   DZnep	   has	   demonstrated	   the	  
ability	   to	   re-­‐express	   genes	   switched	   off	   in	   cancer	   and	   stimulate	   apoptosis	   of	  
cancer	  cells	  (Sha	  et	  al.,	  2015).	  	  
When	  used	  to	   treat	  HEK293	  cells	  expressing	   the	  VEGF	  SSFR,	  DZnep	  produced	  a	  
marked	   decrease	   in	   the	   ratio	   of	   dsRED/EGFP	   expression.	   This	   indicated	   that	  
DZnep	  reduced	  use	  of	  the	  reporter’s	  proximal	  splice	  site,	  while	  increasing	  distal	  
splice	   site	   selection.	   DZnep,	   or	   other	   histone-­‐modifying	   compounds	   have	   not	  
been	   previously	   demonstrated	   to	   modify	   VEGF	   alternative	   splicing.	   However,	  
DZnep	  or	  knockdown	  of	  EZH2	  have	  been	  shown	  to	  effect	  angiogenesis	  and	  VEGF	  
expression.	  DZnep	   inhibition	  of	   the	  PRC	  was	   shown	   to	  decrease	  VEGF	   levels	   in	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endothelial	  cells.	  Smits	  et	  al	  used	  DZnep	  to	  reduce	  proliferation,	  migration	  and	  
invasion	   of	   glioblastoma	   cells	   in	   vitro.	   Gene	   ontology	   analysis	   found	   that	  
expression	   of	   33	   genes	   associated	   with	   angiogenesis	   were	   correlated	   with	  
expression	  of	  EZH2	   in	  glioblastoma	  samples.	  Additionally,	   the	  study	  co-­‐cultured	  
endothelial	  cells	  with	  glioblastoma	  cells	  that	  had	  been	  pre-­‐treated	  with	  DZnep	  or	  
EZH2	  siRNA.	  The	  cells	  were	  cultured	  on	  Matrigel	  and	  the	  effect	  on	  tubule	  length	  
and	   branching	   measured.	   Inhibition	   of	   EZH2	   by	   siRNA	   or	   DZnep	   reduced	  
endothelial	  tubule	  formation.	  Furthermore,	  the	  effect	  of	  EZH2	  on	  tumour	  growth	  
was	  investigated	  further	  in	  vivo.	  Glioblastoma	  cells	  were	  subcutaneously	  injected	  
into	  nude	  mice	  and	  tumour	  growth	  monitored.	  Tumour	  growth	  was	  reduced	  by	  
intravenous	  treatment	  with	  DZnep	  (Smits	  et	  al.,	  2010).	  DZnep	  treatment	  induced	  
a	  marked	  change	  to	  the	  ratio	  of	  VEGF	  SSFR	  splice	  site	  selection.	  Use	  of	  the	  distal	  
splice	   site,	   which	   is	   used	   to	   produce	   anti-­‐angiogenic	   VEGF	   isoforms	   from	   the	  
endogenous	  mRNA,	  was	  significantly	   increased.	  Another	  of	   the	  small	  molecules	  
used	  in	  the	  small	  pilot	  screens	  was	  BIX02194,	  a	  selective	  inhibitor	  of	  G9a	  histone	  
methyltransferase.	   BIX02194	   significantly	   increased	   the	   ratio	   of	   dsRED/EGFP	  
positive	   cells	   compared	   with	   DMSO	   control-­‐treated	   cells.	   The	   association	  
between	  histone	  modifications	  and	  VEGF	  alternative	  splicing,	  and	  how	  this	  may	  
be	   involved	   in	   the	   regulation	   of	   angiogenesis,	   is	   an	   area	   that	   requires	   further	  
investigation.	  
Using	   naturally	   occurring	   compounds	   as	   therapeutic	   agents	   is	   an	   attractive	  
prospect	   as	   they	   are	   often	   readily	   available	   and	   may	   not	   have	   extreme	   side	  
effects	  or	  toxicity.	  DIAVIT,	  a	  natural	  extract	  from	  bilberry	  and	  sea	  buckthorn,	  was	  
tested	  for	  its	  effect	  on	  the	  alternative	  splicing	  of	  the	  VEGF	  SSFR.	  In	  HEK293	  cells,	  
DIAVIT	  significantly	  increased	  the	  number	  of	  cells	  that	  expressed	  EGFP	  indicating	  
increased	   selection	   of	   the	   reporter	   distal	   splice	   site.	   As	   DIAVIT	   is	   a	   natural	  
extract,	   it	   is	   comprised	   of	   numerous	   different	   compounds.	   Any	   one,	   or	   a	  
combination	   of	   several,	   may	   cause	   the	   alternative	   splicing	   change.	   DIAVIT	  
contains	  many	   anthocyanins,	   a	   class	   of	   flavonoid	  molecules.	   Anthocyanins	   are	  
found	   in	   many	   fruits,	   vegetables	   and	   other	   natural	   products,	   and	   have	   been	  
observed	   to	  protect	  against	  various	  diseases.	  The	   reported	  biological	  effects	  of	  
	   89	  
anthocyanins	   include	   inhibition	   of	   certain	   enzymes,	   increased	   cytokine	  
expression,	   reduced	   permeability	   of	  microvessels	   and	   anti-­‐inflammatory	   action	  
(Lila,	  2004).	  Anthocyanins	  and	  other	  flavonoids	  are	  being	  studied	  to	  elucidate	  the	  
mechanisms	  by	  which	  they	  regulate	  physiological	   functions.	  DIAVIT	   is	  marketed	  
as	   a	   diabetic	   therapy,	   however,	   there	   are	   no	   published	   trials	   demonstrating	  
these	  effects.	  Further	  investigation	  has	  demonstrated	  DIAVIT	  to	  be	  protective	  in	  
a	  mouse	  model	  of	  diabetes	  (Stevens,	  unpublished)	  and	  more	  research	  is	  required	  
to	  isolate	  the	  active	  compounds	  within	  the	  extract	  that	  cause	  such	  effects.	  
	  In	   conclusion,	   a	   splicing-­‐sensitive	   fluorescent	   reporter	   was	   designed	   to	  
investigate	   the	   alternative	   splicing	   decision	   that	   creates	   two	   families	   of	   VEGF	  
isoforms	   with	   either	   pro-­‐	   or	   anti-­‐angiogenic	   properties.	   The	   reporter	   was	  
validated	  for	  use	  by	  transfection	  into	  different	  cell	  lines	  and	  treatment	  with	  small	  
molecule	   inhibitors	   targeting	   pathways	   known	   to	   influence	   VEGF	   splicing	  
decisions.	   This	   enabled	   the	   reporter	   to	  be	  approved	   for	  use	   in	   larger	  unbiased	  
screens	  attempting	  to	  find	  chemicals	  that	  can	  alter	  VEGF	  alternative	  splicing	  and	  
change	  the	  balance	  between	  pro-­‐	  and	  anti-­‐angiogenic	  isoforms.	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Chapter	  4   
Screening   for   small   molecules   that   can  
modulate  VEGF  alternative  splicing  
  
4.1  INTRODUCTION  
Angiogenesis	   is	  required	  for	  the	  growth	  of	  solid	  tumours.	  Nutrients	  and	  oxygen	  
are	  supplied	  to	  the	  tumour	  and	  waste	  products	  removed	  (Bergers	  and	  Benjamin,	  
2003).	   The	   development	   of	   new	   vessels	   through	   angiogenesis	   predominantly	  
depends	  on	  VEGF.	  Endothelial	  cells	  express	  VEGFR-­‐2,	  which	   initiates	  angiogenic	  
signalling	   pathways	   upon	   VEGF	   binding.	   VEGF	   expression	   is	   increased	   in	  many	  
tumours-­‐	  secreted	  from	  cancer	  cells	  and	  associated	  stromal	  cells	  (Dvorak	  et	  al.,	  
1995;	  Gerber	  et	  al.,	  1999).	  
There	  has	  been	  an	  abundance	  of	  investigations	  into	  finding	  anti-­‐angiogenic	  drugs	  
for	  use	  in	  the	  treatment	  of	  cancers,	  with	  the	  majority	  targeting	  VEGF	  or	  VEGFRs.	  
A	  humanized	  monoclonal	  anti-­‐VEGF	  antibody,	  bevacizumab,	  gave	  patients	  with	  
metastatic	   colorectal	   cancer	   improved	   survival	   when	   combined	   with	  
chemotherapy	  in	  a	  randomised	  phase	  three	  clinical	  trial	  (Hurwitz	  et	  al.,	  2004)and	  
has	  also	  shown	  use	   in	   treating	  advanced	  non-­‐small	  cell	   lung	  cancer	   (Hurwitz	  et	  
al.,	   2004;	   Sandler	   et	   al.,	   2006)	   .	   Other	   anti-­‐angiogenic	   agents	   that	   have	   been	  
trialled	   include	   the	   small	   molecule	   receptor	   tyrosine	   kinase	   inhibitors	   (RTKIs),	  
sorafenib	   and	   sunitinib,	   which	   inhibit	   several	   RTKs	   including	   VEGF	   receptor-­‐2	  
(Escudier	   et	   al.,	   2007;	   Motzer	   et	   al.,	   2007).	   But	   so	   far,	   most	   angiogenesis	  
targeting	   cancer	   treatments	   have	   only	   provided	   moderate	   benefits	   and	   are	  
associated	  with	  considerable	  side	  effects	  (Eskens	  and	  Verweij,	  2006).	  
The	   anti-­‐angiogenic	   VEGFxxxb	   isoforms	   are	   produced	   by	   alternative	   splicing	   of	  
VEGF	   mRNA.	   The	   proteins	   produced	   only	   differ	   in	   the	   six	   amino	   acids	   at	   the	  
carboxy	   terminal.(Bates	   et	   al.,	   2002)	  VEGFxxxb	  makes	   up	   a	  major	   proportion	  of	  
total	  VEGF	  expression	  in	  many	  normal	  tissues	  and	  is	  decreased	  in	  tumours.	  Use	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of	   a	   plasmid	   to	   overexpress	   VEGF165b	   slows	   the	   growth	   of	   tumours	   in	   kidney,	  
colon	  and	  prostate	  models	  (Rennel	  et	  al.,	  2008;	  Woolard	  et	  al.,	  2004).	  	  
Even	   since	   the	   discovery	   of	   anti-­‐angiogenic	   VEGF	   isoforms,	   most	   studies	  
investigating	   VEGF	   and	   anti-­‐VEGF	   agents	   have	   not	   distinguished	   between	   the	  
two	   isoform	   families.	   A	   study	  has	   shown	   that	   bevacizumab	   inhibited	   the	   quick	  
growth	   of	   tumours	   expressing	   VEGF165	   in	   mice,	   but	   was	   not	   as	   effective	   at	  
inhibiting	  the	  slower	  growth	  of	  tumours	  expressing	  VEGFxxxb.	  Considering	  this,	  it	  
is	  important	  to	  develop	  anti-­‐angiogenic	  agents	  that	  specifically	  target	  VEGFxxx	  or	  
to	   alter	   VEGF	   splicing,	   reducing	   the	   pro-­‐angiogenic	   and	   enhancing	   anti-­‐
angiogenic	  VEGF	  expression	  (Varey	  et	  al.,	  2008b).	  
Alternative	  splicing	   is	  a	   fundamentally	   important	  step	  of	  gene	  regulation.	  Thus,	  
much	  investigation	  has	  focused	  on	  how	  differential	  splicing	  is	  regulated	  and	  how	  
this	   goes	   awry	   during	   disease.	   One	   technique	   to	   study	   an	   individual	   splicing	  
event	   is	  high	   throughput	  screening,	   in	  which	  many	  siRNAs,	  cDNAs	  or	  chemicals	  
can	  be	  assayed	  for	  their	  effect	  on	  the	  alternative	  splicing	  of	  a	  gene	  or	  construct.	  
This	   can	   give	   insight	   into	   alternative	   splicing	   control	   and	   potentially	   find	  
chemicals	  that	  can	  be	  used	  as	  a	  therapeutic	  in	  diseases	  that	  have	  altered	  splicing	  
of	  the	  target	  transcript.	  
Splicing	   reporters	   have	   been	   successfully	   used	   in	   siRNA,	   cDNA	   and	   small	  
molecule	  screens	  to	   investigate	  particular	  alternative	  splicing	  events	   (Naryshkin	  
et	   al.,	   2014;	   Stoilov	   et	   al.,	   2008;	   Warzecha	   et	   al.,	   2009).	   Screening	   for	   small	  
molecules	   that	  modulate	  VEGF	   alternative	   splicing	   could	  give	  more	   insight	   into	  
which	   pathways	   are	   involved	   in	   regulating	   this	   splicing	   event	   and	   how	   it	   is	  
altered	  in	  cancer.	  This	  could	  provide	  potential	  new	  anti-­‐angiogenic	  therapeutics.	  
Using	   the	   VEGF	   reporter	   we	   aimed	   to	   screen	   for	   small	   molecules	   that	   could	  
increase	  use	  of	  VEGF’s	  distal	  exon	  8	  splice	  site	  and/or	  reduce	  proximal	  splice	  site	  
selection.	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4.2  RESULTS  
4.2.1 A   primary   screen   using   the   Library   of   Pharmacologically   Active  
Compounds  
In	   PC3	   cells	   transfected	   with	   the	   pRG8ab	   construct,	   reporter	   pre-­‐mRNA	   is	  
predominantly	   spliced	   at	   the	   proximal	   5’	   splice	   site,	   resulting	   in	   high	   levels	   of	  
dsRED	   expression.	   This	   correlates	   with	   the	   alternative	   splicing	   pattern	   of	   the	  
endogenous	   VEGF	   gene-­‐	   PC3	   cells	   highly	   express	   the	   pro-­‐angiogenic	   VEGF	  
isoforms.	   A	   small	  molecule	   screen	  was	   performed	   to	   identify	   compounds	   that	  
can	  alter	  VEGF	  reporter	  alternative	  splicing.	  
The	  screen	  was	  performed	  using	  the	  VICTOR	  X	  multi-­‐label	  plate	  reader.	  The	  plate	  
reader	   has	   a	   variety	   of	   parameters	   that	   can	   be	   altered	   to	   achieve	   the	   most	  
sensitive	   fluorescent	   detection.	   This	   includes	   different	   filters,	   excitation	   lamp	  
energy,	   size	   of	   the	   measurement	   aperture	   etc.	   Combinations	   of	   different	  
parameters	  were	  tested	  to	  optimise	  detection	  of	  increasing/decreasing	  levels	  of	  
dsRED	   and	   EGFP	   expression.	   The	   PC3	   pRG8ab	   cell	   line	   was	   used	   to	   optimise	  
dsRED	  measurement	  as	  the	  cells	  predominantly	  produce	  red	  fluorescence	  due	  to	  
selection	  of	  the	  reporter	  proximal	  splice	  site.	  A	  second	  cell	  line,	  with	  a	  different	  
reporter	  construct,	  was	  used	  for	  EGFP	  detection.	  HEK293	  cells	  were	  transfected	  
with	  a	  fluorescent	  reporter	  based	  on	  the	  alternative	  splicing	  of	  FGFRII,	   in	  these	  
cells	  EGFP	  is	  highly	  expressed	  (Oltean	  et	  al.,	  2006).	  Decreasing	  number	  (50,000	  to	  
5000)	  of	  each	  cell	  type	  were	  mixed	  with	  non-­‐fluorescent	  cells	  and	  seeded	  into	  96	  
well	   plates	   and	   different	   parameter	   combinations	   were	   used	   to	   measure	   the	  
levels	   of	   each	   fluorescent	   protein.	   Excitation	   and	   emission	   filters	   with	   narrow	  
bandwidth	   ranges	   were	   used	   to	   avoid	   bleed-­‐through	   between	   the	   two	  
fluorescent	  channels	  when	  detecting	  each	  protein.	  Measurements	  were	  plotted	  
and	   the	   R2	   value	   for	   each	   line	   calculated	   to	   determine	   which	   parameter	  
combination	   that	   most	   accurately	   reflected	   the	   linear	   decrease	   in	   cell	  
number/fluorescence	   (Figure	   4-­‐1).	   The	   chosen	   parameters	   for	   fluorescent	  
detection	  are	  summarised	  in	  Table	  3.	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Figure	  4-­‐1	  Optimised	  conditions	  for	  detecting	  fluorescent	  proteins	  using	  VICTOR	  
plate	  reader	  and	  pRG8ab	  VEGF	  reporter	  cells.	  
(A)	  dsRED	  was	  measured	  using	  excitation	  filter	  with	  excitation	  range	  at	  550	  +/-­‐	  
10nm	  and	  emission	  filter	  that	  detects	  at	  632	  +/-­‐	  10nm.	  (B)	  EGFP	  was	  measured	  
using	  excitation	  filter	  with	  excitation	  range	  at	  485	  +/-­‐	  10nm	  and	  emission	  filter	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 dsRED EGFP 
Excitation filter (nm) 550 485 
Emission filter (nm) 632 535 
Measurement height (mm) 3 (above) 
Measurement time (secs) 3  
Emission aperture Small 
Lamp energy 30000 
Table	  3	  Fluorescent	  protein	  measurement	  parameters	  used	  during	  chemical	  
screen.	  
Each	  of	  the	  excitation	  or	  emission	  filters	  used	  were	  of	  the	  narrow	  bandwidth	  
variety,	  only	  allowing	  passage	  of	  light	  within	  a	  +/-­‐	  10nm	  range	  of	  the	  stated	  
wavelength.	  
	  
The	   chemical	   library	   that	   was	   chosen	   to	   be	   used	   during	   the	   screen	   was	  
LOPAC®,1280	  produced	  by	  Sigma-­‐Aldrich.	  The	  acronym	  LOPAC	  stands	  for	  Library	  of	  
Pharmacologically	   Active	   Compounds.	   All	   the	   1280	   compounds	   of	   the	   LOPAC	  
have	  known	  pharmacological	  activity	  and	  had	  previously	  been	  approved	  for	  use	  
by	  the	  U.S.	  Food	  and	  Drug	  Administration.	  This	  is	  a	  broad-­‐spectrum	  library,	  which	  
contains	  molecules	  that	  would	  target	  many	  major	  receptor	  and	  enzyme	  classes	  
such	  as	  GPCRs,	  ion	  channels	  and	  kinases.	  	  
A	  primary	  screen	  was	  performed	  to	   identify	  compounds	  that	  can	  alter	  reporter	  
alternative	  splicing	  in	  PC3	  cells	  (Figure	  4-­‐2,	  step	  1).	  10,000	  PC3	  pRG8ab	  cells	  were	  
seeded	  into	  96-­‐well	  plates	  and	  treated	  with	  10µM	  of	  each	  LOPAC	  compound,	  this	  
was	  done	  in	  triplicate	  wells.	  The	  wells	  at	  the	  edge	  of	  the	  96-­‐well	  plate	  were	  left	  
untreated	  and	  not	  used	  as	  controls.	  All	  the	  molecules	  were	  dissolved	  in	  DMSO	  so	  
triplicate	  wells	  were	  also	  treated	  with	  the	  same	  volume	  DMSO	  as	  controls.	  Cells	  
were	   incubated	  under	   their	  normal	  growth	  conditions	   for	  48	  hours	  after	  which	  
reporter	  splicing	  was	  determined	  using	  a	  fluorescent	  plate	  reader	  to	  measure	  the	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levels	  of	  dsRED	  and	  EGFP	  expression	  in	  individual	  wells	  of	  the	  96	  well	  plate.	  The	  
triplicate	  measurement	   recorded	   for	   both	   dsRED	   and	   EGFP	  were	   compared	   to	  
control	  and	  statistically	  analysed	  using	  a	  one-­‐way	  ANOVA.	  Each	  treated	  condition	  
was	   compared	   to	   DMSO	   control	   using	   Dunnett’s	   post-­‐test.	   As	   it	  was	   aimed	   to	  
identify	  molecules	  that	  can	  reduce	  the	  pro-­‐angiogenic	  VEGF	  proteins	  or	  increase	  
the	  anti-­‐angiogenic	  isoforms,	  compounds	  that	  caused	  a	  dsRED	  reduction	  or	  GFP	  
increase	   compared	   to	   control	   with	   a	   P-­‐value<0.05	   were	   selected	   for	   further	  
investigation.	  	  
The	   primary	   screen	   yielded	   299	   small	   molecules	   that	   caused	   a	   significant	  
increase	   in	   EGFP	  measurement,	   34	   that	  had	   reduced	  dsRED	  and	  36	   that	  had	  a	  
significant	  effect	  on	  both	  fluorescent	  proteins.	   In	  theory,	  a	  switch	  in	  alternative	  
splicing	   of	   VEGF	   SSFR	   transcripts	   from	   predominant	   use	   of	   the	   proximal	   splice	  
site	   to	   the	   distal	   splice	   site	   should	   produce	   an	   increase	   in	   EGFP	   and	   reduce	  
dsRED.	  As	  the	  majority	  of	  changes	  in	  fluorescent	  protein	  levels	  were	  increases	  in	  
EGFP,	  it	  is	  possible	  there	  is	  some	  bias	  in	  the	  screen	  with	  small	  decreases	  in	  dsRED	  
more	   difficult	   to	   detect	   using	   this	   method.	   As	   such,	   chemicals	   that	   produced	  
EGFP-­‐only	   increases	   were	   also	   selected	   to	   be	   investigated	   further	   as	   part	   of	  
control	  and	  secondary	  screening.	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Figure	  4-­‐2	  Screening	  the	  LOPAC	  library	  for	  small	  molecules	  that	  effect	  the	  
alternative	  splicing	  of	  the	  VEGF	  reporter	  construct.	  
PC3	  cells	  transfected	  with	  the	  fluorescent	  VEGF	  splicing	  reporter	  were	  treated	  
with	  the	  LOPAC	  compound	  library	  and	  reporter	  AS	  measured	  using	  a	  fluorescent	  
plate	  reader	  (Primary	  screen,	  step	  1).	  Hit	  compounds	  were	  used	  to	  treat	  non-­‐
splicing	  control	  reporter	  constructs	  (Control	  screen,	  step	  2).	  Flow	  cytometry	  was	  
used	  to	  measure	  the	  effect	  of	  the	  hit	  compounds	  on	  reporter	  splicing	  (Secondary	  
screen,	  step	  3).	  	  
PC3 pRG8ab cells treated with 
10µM of LOPAC compounds  
48 hours 
Reporter splicing quantified by 
fluorescent plate reader 
Compounds creating a significant dsRED 
decrease, EGFP decrease or both selected 
PC3 cells expressing two control reporter 
constructs treated with selected compounds 
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   97	  
4.2.2 Using  control  reporter  constructs  to  eliminate  false  positive  hits  
The	   expression	   of	   fluorescent	   proteins	   within	   the	   reporter	   transfected	   cells	  
depend	  on	  several	  factors	  with	  alternative	  splicing	  being	  just	  one.	  Treatment	  of	  
the	   reporter	   cell	   line	   with	   a	   small	   molecule	   may	   have	   unknown	   effects	   on	  
fluorescent	  protein	  stability	  or	   the	  molecule	  may	  be	   fluorescent	   itself.	  This	  will	  
impact	   the	   measurements	   recorded	   by	   the	   fluorescent	   plate	   reader	   and	   may	  
have	   led	   to	   false	   positive	   hits	   during	   the	   primary	   screen.	   To	   rectify	   this,	   two	  
control	   reporters	   were	   designed	   and	   cloned	   (Figure	   4-­‐3).	   The	   control	   plasmid	  
DNA	  did	  not	  contain	  the	  intron	  of	  the	  original	  reporter,	  therefore,	  mimicked	  the	  
mRNA	   transcripts	   that	  are	  produced	  when	  either	  proximal	  or	  distal	   reporter	  3’	  
splice	  site	   is	  chosen.	  The	  plasmids	  were	  termed	  PSS	  and	  DSS	  control	   reporters.	  
PC3	   cells	   were	   transfected	   with	   either	   the	   PSS	   or	   DSS	   control	   reporter	   and	  
selected	   for	  plasmid	  uptake	  using	  G418	  antibiotic.	  Flow	  cytometry	  was	  used	  to	  
confirm	   expression	   of	   each	   control	   reporter	   and	   fluorescence	   activated	   cell	  
sorting	  was	  used	  isolate	  fluorescent	  cells	  (Figure	  4-­‐3).	  	  
Almost	  300	  LOPAC	  compounds	  induced	  an	  increase	  in	  EGFP	  output	  when	  used	  to	  
treat	   PC3	   cells.	   Due	   to	   this	   high	   number	   of	   molecules,	   they	   were	   ranked	  
according	  to	  their	  significance	  and	  the	  100	  compounds	  with	  the	  smallest	  p-­‐value	  
were	   used	   to	   treat	   PC3	   PSS	   and	   DSS	   control	   cells	   at	   10µM	   for	   48	   hours.	  
Compounds	  that	  significantly	  reduced	  dsRED	  and	  affected	  both	  dsRED	  and	  EGFP	  
were	   also	   used	   to	   treat	   control	   reporter	   cells	   (Figure	   4-­‐2,	   step	   2).	   The	   control	  
reporter	  mRNA	  cannot	  be	  spliced,	  as	  there	  is	  no	  intron	  present,	  thus	  any	  changes	  
in	  the	  fluorescence	  measured	  by	  the	  plate	  reader	  were	  not	  due	  to	  the	  treatment	  
having	   an	   effect	   on	   reporter	   alternative	   splicing.	   Again,	   dsRED	   and	   EGFP	  
measurements	  were	  statistically	  compared	  to	  control.	  Compounds	  that	  induced	  
a	  significant	  difference	  (p<0.05)	  in	  fluorescence	  output	  were	  deemed	  to	  be	  false	  
positives	  and	  eliminated	  from	  further	  investigation.	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Figure	  4-­‐3	  Design	  and	  expression	  of	  proximal	  splice	  site	  and	  distal	  splice	  site	  
control	  reporters	  
Two	  control	  reporters	  were	  designed	  and	  cloned	  to	  mimic	  the	  two	  mature	  mRNA	  
transcripts	  that	  can	  be	  produced	  from	  the	  alternative	  splicing	  of	  pRG8ab	  pre-­‐
mRNA-­‐proximal	  (PSS)	  and	  distal	  splice	  site	  (DSS)	  controls.	  Both	  constructs	  were	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4.2.3 A  secondary  screen  for  modifiers  of  reporter  alternative  splicing  
Following	   the	   elimination	   of	   false-­‐positives,	   26	   compounds	   that	   significantly	  
decreased	  dsRED	  signal,	  90	   that	   increased	  EGFP	  and	  19	   that	  caused	  both	  were	  
selected.	  Again,	  due	  to	  the	  high	  number	  of	  hits	  causing	  an	  EGFP	  increase,	  these	  
were	   ranked	   according	   to	   their	   difference	   from	   the	   control	   and	   the	   50	  
compounds	  with	  the	  greatest	  difference	  were	  used	  during	  the	  primary	  screen	  of	  
LOPAC	   molecules.	   The	   selected	   compounds	   were	   tested	   again	   in	   a	   secondary	  
screen	  to	  confirm	  any	  effects	  on	  reporter	  alternative	  splicing	  (Figure	  4-­‐2,	  step	  3).	  
The	   secondary	   screen	   was	   performed	   using	   flow	   cytometry	   to	   measure	   the	  
expression	   of	   fluorescent	   proteins	   in	   cells	   treated	   with	   the	   hit	   LOPAC	  
compounds.	   Cells	   were	   treated	   with	   each	   compound	   at	   10µM	   for	   48	   hours	  
before	   collection	   and	   flow	   cytometric	   analysis	   (Figure	   4-­‐4).	   Flow	   cytometry	  
measured	  the	  percentage	  of	   the	  cell	  population	  that	  were	  expressing	  dsRED	  or	  
EGFP.	   This	   was	   used	   to	   calculate	   the	   ratio	   of	   dsRED/EGFP.	   A	   decrease	   in	  
dsRED/EGFP	   indicated	   reduced	   use	   of	   the	   reporter	   proximal	   splice	   site	   and	  
increased	   distal	   splice	   site	   selection.	   Out	   of	   the	   135	   compounds	   tested	   in	   the	  
secondary	  screen	  (using	  control	  reporter	  cell	  lines),	  nine	  compounds	  produced	  a	  
decrease	  in	  the	  ratio	  of	  PSS	  to	  DSS	  selection	  (Figure	  4-­‐4).	  The	  compounds	  were	  
given	  the	  shortened	  name	  ESSO1-­‐9.	  The	  names	  of	  the	  chemicals	  and	  their	  effect	  
on	  dsRED	  and	  EGFP	  during	  the	  primary	  screen	  (pRG8ab	  cells)	  are	  listed	  in	  Table	  
4.	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Figure	  4-­‐4	  A	  secondary	  screen	  of	  small	  molecule	  hits	  of	  LOPAC	  using	  flow	  
cytometry	  
PC3	  pRG8ab	  cells	  were	  treated	  with	  135	  compounds	  of	  the	  LOPAC	  library	  for	  48	  
hours.	  Reporter	  splicing	  was	  measured	  using	  flow	  cytometry.	  The	  ratio	  between	  
the	  two	  fluorescent	  proteins	  (dsRED/EGFP)	  measured	  changes	  in	  reporter	  splice	  
site	  selection.	  The	  sum	  of	  the	  populations	  expressing	  dsRED	  or	  EGFP	  was	  used	  to	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Table	  4	  Screening	  compounds	  shown	  to	  reduce	  the	  dsRED/EGFP	  ratio.	  
Compound Shortened name EGFP dsRED 
Trovafloxacin mesylate ESSO01 ! " 
















Flupirtine maleate ESSO06 ! 
RepSox ESSO07 ! 
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4.2.4 The   effect   of   hit   compounds   on   endogenous   VEGF   alternative  
splicing  
Nine	  compounds	  of	  the	  LOPAC	  library	  were	  shown	  to	  alter	  the	  ratio	  of	  pRG8ab	  
fluorescent	  reporter	  splice	  site	  selection.	  As	  the	  reporter	  is	  an	  artificial	  construct	  
under	  the	  transcriptional	  control	  of	  the	  highly	  active	  CMV	  promoter,	  it	  needed	  to	  
be	  determined	  if	  the	  small	  molecules	  have	  the	  same	  effect	  on	  endogenous	  VEGF	  
mRNA	  alternative	  splicing	  and	  if	  this	  then	  produces	  increased	  expression	  of	  anti-­‐
angiogenic	  protein	  isoforms.	  RNA	  was	  isolated	  from	  PC3	  cells	  treated	  with	  each	  
of	  the	  compounds	  for	  48	  hours,	  cDNA	  was	  reverse	  transcribed	  and	  amplified	  by	  
PCR.	  The	  primers	  used	  for	  amplification	  were	  designed	  to	  be	  able	  to	  detect	  both	  
pro-­‐	  and	  anti-­‐angiogenic	   isoform	  transcripts	  with	  the	  distally	  spliced	  transcripts	  
66bp	   small	   than	   transcripts	   that	   had	   proximal	   splice	   site	   use	   (Figure	   4-­‐5).	   The	  
compounds	   ESSO01	   and	   ESSO07	   demonstrated	   the	   clearest	   switch	   in	   VEGF	  
alternative	   splicing	   with	   increased	   VEGFxxxb	   and	   reduced	   VEGFxxx	   transcripts	  
detected.	  
VEGF	   anti-­‐angiogenic	   isoform	   expression	   was	   also	   gauged	   at	   the	   protein	   level	  
(Figure	  4-­‐6).	  PC3	  cells	  were	  treated	  with	  four	  of	  the	  lead	  compounds	  that	  were	  
being	   investigated	   in	   greater	   detail;	   ESSO01,	   07,	   08	   and	   09.	   Treatment	   with	  
SPHINX	  was	  used	  as	  a	  positive	  control	  as	  the	  SRPK1	  inhibitor	  is	  known	  to	  affect	  
VEGF	  alternative	  splicing,	  inducing	  exon	  8	  DSS	  selection	  and	  therefore,	  increasing	  
the	  expression	  of	  anti-­‐angiogenic	  VEGF	  isoforms	  (Amin	  et	  al.,	  2011;	  Gammons	  et	  
al.,	   2013b;	   Nowak	   et	   al.,	   2010).	   Following	   48	   hours	   of	   treatment,	   protein	  was	  
extracted	   from	   cells	   and	  western	   blotting	   used	   to	   detect	   anti-­‐angiogenic	   VEGF	  
isoforms	  and	  total	  VEGF	  levels.	  Membranes	  were	  probed	  with	  an	  antibody	  that	  
specifically	  detects	  VEGFxxxb	   isoforms	  before	   reprobing	  with	  another	   that	  binds	  
all	  VEGF	   isoforms,	  both	  pro-­‐	  and	  anti-­‐angiogenic.	  This	  provides	  an	   indication	  of	  
changes	   in	  VEGF	   alternative	   splicing.	   ESSO01	   appeared	   to	   greatly	   reduce	   total	  
protein	   levels.	   The	   other	   lead	   compounds	   reduced	   total	   VEGF	   expression	   but	  
increased	  VEGFxxxb	  isoforms.	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Figure	  4-­‐5	  The	  effect	  of	  ESSO	  compounds	  on	  the	  alternative	  splicing	  of	  
endogenous	  VEGF	  mRNA	  transcripts	  	  
RNA	  was	  extracted	  from	  PC3	  cells,	  reverse	  transcribed	  and	  amplified	  by	  PCR.	  
Anti-­‐angiogenic	  isoform	  transcripts	  were	  expected	  to	  be	  66bp	  smaller	  than	  pro-­‐
angiogenic	  transcripts.	  	  
	  
	  
Figure	  4-­‐6	  Changes	  in	  expression	  of	  anti-­‐angiogenic	  VEGF	  protein	  isoforms	  
following	  treatment	  with	  ESSO	  compounds	  
Following	  treatment	  with	  each	  small	  molecule	  (10uM,	  48	  hours),	  protein	  was	  
extracted	  and	  used	  for	  Western	  blotting.	  The	  bands	  observed	  correspond	  to	  VEGF	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4.3  DISCUSSION  
4.3.1 Success  and  limitations  of  current  anti-­‐angiogenic  therapies  
When	   first	   proposed,	   anti-­‐angiogenic	   therapy	   for	   cancer	   treatment	   was	   a	  
particularly	   attractive	   prospect	   as	   all	   solid	   tumours	   require	   angiogenic	   vessel	  
sprouting	  to	  grow	  beyond	  1-­‐2mm	  in	  diameter.	  VEGF	  is	  the	  key	  angiogenic	  driver	  
and	   overexpressed	   by	   most	   tumour	   types.	   Preliminary	   animal	   models	  
demonstrated	  that	  VEGF	  inhibition	  could	  reduce	  tumour	  growth.	  This	  resulted	  in	  
various	   anti-­‐cancer	   agents	   being	   developed	   to	   target	   VEGF	   and	   the	   VEGF	  
signalling	   pathways.	   Several	   classes	   of	   anti-­‐angiogenic	   drugs	   have	   been	  
produced.	  Agents	   that	  directly	   bind	   and	   inhibit	  VEGF	   include	  bevacizumab	  and	  
aflibercept.	   Other	   drugs	   target	   the	   VEGF	   receptors,	   such	   as	   the	   antibody	  
ramucirumab	   that	   binds	   VEGFR2.	   Small	   molecule	   receptor	   tyrosine	   kinase	  
inhibitors	   (TKIs)	  have	  also	  been	  used	   to	  block	   the	   signalling	  activity	  of	  VEGFRs.	  
The	  TKIs	  developed	  to	  inhibit	  VEGFRs	  do	  also	  have	  off	  target	  effects	  on	  PDGFRs	  
and	   FGFRs.	   Anti-­‐VEGF	   therapy	   has	   so	   far	   had	   relatively	   limited	   success	   in	  
combating	   cancer.	   Some	   of	   the	   treatments	   have	   shown	   efficacy	   in	   certain	  
cancers.	  As	  angiogenesis	  does	  not	  commonly	  occur	   in	   the	  healthy	  adult,	   it	  was	  
presumed	   that	   drugs	   targeting	   VEGF	   would	   avoid	   major	   issues	   of	   toxicity.	  
However,	   reported	   adverse	   effects	   during	   anti-­‐angiogenic	   therapy	   include	  
hypertension,	   proteinuria,	   haemorrhaging,	   endocrine	   defects	   and	  
gastrointestinal	  perforations	  (Vasudev	  and	  Reynolds,	  2014).	  
Despite	  angiogenesis	  being	  essential	  for	  the	  continued	  growth	  of	  solid	  tumours,	  
only	   a	   small	   number	   of	   cancers	   have	   been	   approved	   for	   treatment	   with	   anti-­‐
angiogenic	  therapeutics.	  Some	  patients	  develop	  resistance	  to	  anti-­‐VEGF	  agents.	  
Certain	   tumours	   respond	  well,	  with	   reduced	  perfusion	  of	   tumour	  blood	  vessels	  
and	  reduction	  of	  tumour	  volume.	  In	  others,	  the	  number	  of	  vessels	  is	  reduced	  but	  
the	   tumour	   is	   stabilised	   and	   does	   not	   regress.	   Many	   tumours	   have	   intrinsic	  
resistance	   to	   anti-­‐angiogenics	   and	   continue	   to	   grow	   during	   treatment,	   with	  
insensitive	  vasculature.	  Some	  tumours	  demonstrate	  acquired	  resistance	  whereby	  
the	   tumour	   initially	   respond	   but	   is	   followed	   by	   further	   growth	   either	   with	   or	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without	   angiogenic	   sprouting.	   Continued	   angiogenesis	   during	   treatment	   with	  
anti-­‐VEGF	   drugs	   may	   be	   due	   to	   adaption	   and	   activation	   of	   alternative	   pro-­‐
angiogenic	  pathways.	  The	  vasculature	  of	  a	  tumour	  is	  heterogeneous	  and	  vessels	  
vary	  in	  their	  response	  to	  VEGF	  inhibitors.	  Pre-­‐clinical	  data	  suggests	  newly	  formed	  
vessels	  within	  a	  tumour	  are	  sensitive	  to	  anti-­‐VEGF	  agents	  but	  as	  vessels	  mature	  
some	   lose	   dependency	   on	   VEGF	   and	   are	   therefore	   less	   responsive.	   Tumour	  
vessels	  are	  abnormal,	  tortuous	  and	  grow	  aberrantly.	  It	  has	  been	  suggested	  that	  
therapies	  should	  attempt	  to	  normalise	  tumour	  vessels	  to	  improve	  their	  perfusion	  
and	  optimise	  exposure	  of	  the	  tumour	  to	  chemotherapeutics	  (Jain,	  2005).	  
Many	   cancer	   cells	   secrete	   high	   levels	   of	   pro-­‐angiogenic	   VEGF,	   stimulating	   the	  
growth	   of	   new	   vessels	   to	   nourish	   the	   tumour.	   The	   VEGFxxxb	   family	   of	   sister	  
isoforms	  are	  anti-­‐angiogenic,	  have	  reduced	  expression	  in	  tumour	  tissues	  and	  can	  
reduce	   tumour	  growth.	  VEGF165b	  possesses	  binding	  domains	   that	  will	  associate	  
with	   most	   anti-­‐VEGF	   targeted	   antibodies,	   including	   therapeutic	   bevacizumab.	  
VEGF165	  and	  VEGF165b	  bind	  bevacizumab	  with	  the	  same	  affinity,	  but	  the	  ability	  of	  
bevacizumab	   to	   reduce	   tumour	   growth	   is	   affected	   by	   VEGF165b.	   In	   mice,	  
bevacizumab	   did	   not	   have	   the	   same	   inhibitory	   effect	   on	   tumour	   growth	  when	  
cancer	   cells	   were	   expressing	   VEGF165	   b.	   This	   has	   implications	   for	   anti-­‐VEGF	  
therapy	  (Varey	  et	  al.,	  2008a).	  New	  ways	  of	  targeting	  tumour	  angiogenesis	  must	  
be	   found	  and	  exploited.	  One	  potential	  method	  would	  be	   to	  not	  directly	   target	  
VEGF	  protein	  or	  VEGF	  expression	  but	  to	  control	  its	  alternative	  splicing	  to	  produce	  
VEGF165b	  as	  an	  endogenous	  anti-­‐angiogenic	  agent.	  
4.3.2 Screening  for  novel  regulators  of  VEGF  alternative  splicing  
This	   screen	   searched	   for	   small	   molecules	   that	   could	   alter	   VEGF	   alternative	  
splicing-­‐	  reducing	  the	  splicing	  pattern	  that	  creates	  pro-­‐angiogenic	  VEGF	  isoforms	  
and	   increasing	   the	   anti-­‐angiogenic	   isoforms.	   The	   library	   used	   for	   this	   screen,	  
LOPAC,	   was	   a	   collection	   of	   FDA-­‐approved	   compounds	   with	   known	  
pharmacological	   activities.	   This	   is	   an	   example	   of	   drug	   repositioning.	   Drug	  
repositioning	   allows	   established	   drugs	   to	   be	   investigated	   and	   find	   new	  uses	   in	  
alternative	   diseases.	   It	   can	   also	   deepen	   our	   insight	   into	   the	   mechanisms	   that	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cause	  pathogenesis	  and	  could	  facilitate	  more	  rapid	  transfer	  of	  drugs	  into	  clinical	  
trials.	   Repositioned	  drugs	  will	   have	  already	  endured	   toxicity	   and	  patient	   safety	  
assessment	   whereas	   this	   will	   still	   need	   to	   be	   completed	   for	   potential	  
therapeutics	   that	   are	   identified	   using	   traditional	   high-­‐throughput	   screening	  
libraries	  (Wilkinson	  and	  Pritchard,	  2015).	  
There	   have	   been	   a	   handful	   of	   instances	   in	   which	   drugs	   previously	   used	   for	   a	  
different	  disease	  have	  been	  found	  to	  be	  useful	  in	  treating	  certain	  cancers.	  A	  well-­‐
known	   example	   is	   thalidomide.	   Patients	   with	   leprosy	   that	   developed	   painful	  
lesions	   on	   their	   skin	   were	   given	   thalidomide	   for	   its	   sedative	   properties.	   The	  
quantity	   of	   lesions	  was	   decreased	  by	   thalidomide.	   Thalidomide	  has	   since	   been	  
used	   as	   a	   therapeutic	   for	   multiple	   myeloma	   and	   been	   shown	   to	   be	   anti-­‐
angiogenic	  (D'Amato	  et	  al.,	  1994;	  Singhal	  et	  al.,	  1999).	  	  
There	  are	  also	  various	  examples	  of	  drug	  repositioning	  candidates	  being	  identified	  
using	  in	  vitro	  screens	  in	  a	  range	  of	  diseases	  including	  cancers.	  It	  has	  been	  shown	  
that	   cell	   death	   can	   be	   stimulated	   in	   small	   cell	   lung	   cancer	   cells	   by	   tricyclic	  
antidepressants	  (Jahchan	  et	  al.,	  2013).	  Another	  example	  is	  the	  drug	  mebenozole,	  
which	   was	   identified	   as	   causing	   toxicity	   in	   cell	   lines	   from	   colon	   cancer.	  
Mebenozole	  is	  normally	  used	  as	  a	  treatment	  for	  infection	  with	  gut	  worms	  but	  is	  
now	  known	  to	  also	  inhibit	  kinases	  including	  B-­‐Raf	  (Nygren	  et	  al.,	  2013).	  Prostate	  
cancer	   cells,	  PC3	  and	  LnCap,	  were	   treated	  with	  a	  drug	   library	  and	  analysed	   for	  
proliferation	  and	  DNA	  synthesis.	  Digoxin,	  an	  anti-­‐arrhythmic	  agent,	  was	  found	  to	  
inhibit	  proliferation	   in	   these	  cells.	  An	  epidemiological	  analysis	   found	  the	  risk	  of	  
developing	  prostate	  cancer	  was	  lower	  in	  men	  who	  had	  used	  digoxin	  (Platz	  et	  al.,	  
2011)	  
4.3.3 Statistical  analysis  of  screen  data  
In	   large-­‐scale	   high	   throughput	   screens,	   there	   are	   several	   statistical	   methods	  
commonly	  employed	  to	  identify	  hits	  from	  the	  noise.	  Routinely	  during	  a	  primary	  
screen	  that	  tests	  millions	  of	  compounds,	  the	  activity	  of	  each	  compound	  will	  only	  
be	  measured	  once,	  without	  replicates.	  This	   limits	  the	  statistical	  testing	  that	  can	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be	  applied	  to	  the	  data.	  The	  ‘Z-­‐score’	  method	  is	  often	  used	  to	  select	  positive	  hits	  
from	  large	  data	  sets.	  Z-­‐scoring	  does	  not	  use	  control	  measurements	  but	  assumes	  
that	   most	   compounds	   within	   a	   screening	   library	   will	   not	   be	   active	   within	   the	  
assay	   so	   can	  be	  used	   as	   controls.	   In	   this	   case,	   the	   average	  measurement	   from	  
within	   a	   plate	   is	   subtracted	   from	   the	   compound	  measurement	   and	   divided	   by	  
the	   standard	   deviation	   from	   the	   entire	   plate.	   Alternatively,	   the	   ‘percentage	   of	  
control’	   method	   normalises	   compound	   activity	   relative	   to	   controls	   by	   dividing	  
raw	   compound	   measurements	   by	   the	   average	   of	   controls	   within	   each	   plate.	  
Measurements	  can	  then	  be	  compared	  across	  many	  different	  plates.	  Both	  these	  
methods	   assume	   randomly	   distributed	   error	   but	   this	   cannot	   be	   confirmed	  
without	   replicate	   measurements	   of	   compound	   activity.	   Statistical	   outliers	   will	  
also	  affect	  the	  mean	  and	  standard	  deviation	  across	  a	  plate.	  
As	  the	  compound	  library	  used	  in	  the	  screen	  for	  pRG8ab	  splicing	  modulators	  was	  
relatively	   small,	   it	  was	   feasible	   to	   include	   replicates	  within	   the	   screen	  allowing	  
the	   calculation	   of	   error	   and	   analysis	   of	   variance.	   The	   use	   of	   replicates	   was	  
decided	  on	  at	  cell-­‐based	  assays	  can	  encounter	  clumping	  and	  uneven	  distribution	  
of	  cells	  between	  wells.	  Evaporation	  of	  growth	  media	  may	  also	  occur	  across	  areas	  
of	  the	  96-­‐well	  plate	  altering	  growth	  conditions	  and	  leading	  to	  bias	  depending	  on	  
the	  well	  position.	  Some	  false	  positives	  within	  screens	  are	  known	  to	  be	  caused	  by	  
positional	  bias.	  To	  reduce	  this,	  each	  compound	  was	  used	  to	  treat	  three	  wells	  of	  a	  
96-­‐well	   plate.	   A	   one-­‐way	   AVOVA	   was	   performed	   on	   the	   dsRED	   and	   EGFP	  
measurements	  using	  DMSO	  reading	  from	  the	  same	  plate	  as	  the	  internal	  control	  
measurement.	   Fluorescence	   readings	   were	   normalized	   to	   the	   DMSO	   control	  
measurement	  from	  the	  same	  plate.	  As	  the	  screen	  was	  performed	  manually,	  with	  
readings	   taken	   over	   many	   different	   days,	   it	   was	   more	   appropriate	   to	   use	   the	  
DMSO	  of	  each	  plate	  as	  the	  control	  measurement	  rather	  than	  an	  average	  of	  the	  
DMSO	  readings	  over	  all	  plates	  used.	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4.3.4 Limitations  and  false  positive  elimination  within  fluorescent  reporter  
assays  
As	  with	  all	  drug	  discovery	  techniques,	  screening	  has	  limitations	  and	  down	  sides.	  
Cell-­‐based	   assays	   are	   a	   useful	   tool	   in	   the	   process	   of	   HTS	   but	   the	   potential	   for	  
variation	  and	  noise	  is	  increased	  by	  the	  use	  of	  live	  cells.	  This	  includes	  variation	  in	  
cell	   growth	   and	   response	   between	   different	   plates	   and	   uneven	  measurements	  
within	   the	   same	  plates.	  One	   such	   technical	   issue	   is	   the	   ‘edge	   effect’.	   It	   is	  well	  
established	  that	  luminescence	  or	  fluorescent	  measurements	  detected	  from	  wells	  
at	  the	  edge	  of	  96-­‐well	  plates	  are	  often	  considerably	  lower	  or	  higher	  than	  the	  rest	  
of	  the	  plate.	  This	  is	  possibly	  cause	  by	  a	  thermal	  gradient	  between	  the	  outer-­‐most	  
wells	   and	   those	   in	   the	  middle	   of	   the	   plate	   (Lundholt	   et	   al.,	   2003;	  Malo	   et	   al.,	  
2006).	   This	   may	   result	   in	   uneven	   distribution	   cells	   or	   altered	   adhesion	   and	  
morphological	   changes.	   During	   the	   LOPAC	   screen,	   cells	   were	   seeded	   into	   the	  
outer	  wells	  put	  were	  not	  treated	  or	  used	  as	  control	  measurements	  to	  avoid	  the	  
edge	  effect.	  
The	   primary	   screen	   produced	   369	   ‘hit’	   compounds	   that	   caused	   a	   significant	  
increase	   in	   EGFP,	   decrease	   in	   dsRED	   or	   both.	   Out	   of	   these	   369	   chemicals	   the	  
majority,	   299,	   had	   induced	   a	   significant	   increase	   in	   EGFP	   measurement.	   This	  
suggests	  there	  may	  be	  bias	  within	  the	  plate	  reader	  screen,	  with	  changes	  in	  EGFP	  
more	   readily	   detectable.	   During	   the	   secondary	   screen,	   fluorescent	   protein	  
expression	   was	   detected	   by	   flow	   cytometry.	   Nine	   compounds	   induced	   a	  
decrease	   in	   the	   fluorescent	   protein	   ratio,	   dsRED/EGFP.	   Out	   of	   these	   nine	  
compounds,	  four	  had	  been	  selected	  from	  the	  plate	  reader	  screen	  because	  of	  an	  
increase	   in	   EGFP	   and	   dsRED	   decrease.	   One	   small	   molecule	   had	   induced	   a	  
reduced	  dsRED	  measurement	  only	  and	  the	  other	   four	  had	   increased	  EGFP	  with	  
no	   effect	   on	  dsRED.	  Overall,	   eight	   out	   of	   nine	  of	   the	   compounds	   that	   reduced	  
dsRED/EGFP	  during	  the	  secondary	  screen	  had	  increased	  EGFP	  during	  the	  primary	  
screen.	   Again,	   this	   indicates	   there	   is	   some	   inherent	   bias	   either	   from	   the	  
fluorescent	   plate	   reader	   or	   the	   reporter	   construct	   itself	   whereby	   changes	   in	  
dsRED	  are	  more	  difficult	   to	  detect,	  harder	  to	   induce	  or	  there	  are	  differences	   in	  
the	  half-­‐lives	  of	  the	  fluorescent	  proteins.	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Small	  molecule	  screens	  have	  been	  used	  previously	  to	  elucidate	  compounds	  that	  
can	  change	   the	   inclusion	  of	  an	  exon	  or	   the	  use	  of	  an	  alternative	  5’	  or	  3’	   splice	  
site.	  Several	   screens	  have	  used	  splicing	  reporters	  with	   luciferase	  or	  GFP	  output	  
(Warzecha	   et	   al.,	   2009).	   Reporters	   such	   as	   these	   can	   be	   useful	   but	   do	   contain	  
limitations,	   for	   example,	   the	  effect	  of	   a	   small	  molecule	  on	   reporter	   alternative	  
splicing	   cannot	   always	   be	   differentiated	   from	   effects	   via	   transcriptional	   and	  
translational	  mechanisms.	   Dual	   colour	   fluorescent	   splicing	   reporters	   should	   be	  
less	   likely	   to	   suffer	   from	   false	   positives	   caused	   by	   transcription/translational	  
modifiers	  as	   true	   splicing	   switches	   should	   cause	  an	   increase	   in	  one	   fluorescent	  
protein	  and	  a	  decrease	  in	  the	  other.	  	  
Stoilov	  et	  al.,	  2008	  used	  a	  dual	  colour	  splicing	  reporter	  system	  to	  screen	  for	  small	  
molecules	   that	   can	   modify	   the	   alternative	   splicing	   of	   MAPT.	   They	   found	   that	  
some	   compounds	   that	   altered	   overall	   gene	   expression	   caused	   changes	   in	   the	  
ratio	   between	   the	   two	   fluorescent	   proteins	   of	   their	   reporter.	   They	   concluded	  
that	   this	   was	   caused	   by	   the	   fact	   that	   half-­‐lives	   of	   their	   RFP	   and	   GFP	   were	  
different.	   Transcription	   and	   splicing	   inhibitors	   also	   were	   a	   source	   of	   false	  
positives	   likely	   caused	   by	   the	   differing	   stabilities	   of	   the	   two	  mRNA	   transcripts	  
produced	  from	  alternative	  splicing	  of	  the	  reporter.	  Additionally,	  if	  the	  compound	  
is	   a	   strong	   fluorophore,	   which	   fluoresces	   in	   the	   same	   range	   as	   the	   measured	  
fluorescent	  protein,	  it	  will	  also	  produce	  a	  false	  positive.	  
In	   the	   VEGF	   SSFR	   screen,	   the	   issues	   regarding	   false	   positives	   were	   overcome	  
through	  the	  use	  of	  the	  two	  control	  reporters	  (Figure	  4-­‐3).	  The	  control	  reporters	  
could	  not	  be	  spliced	  as	   they	   lacked	  an	   intron	  but	  exactly	  mimicked	  the	  mature	  
mRNA	   transcripts	   produced	   after	   alternative	   splicing	   of	   RG8ab	   pre-­‐mRNA.	   Any	  
compounds	  that	  alter	   fluorescent	  protein	  expression	  during	  the	  primary	  screen	  
via	  transcriptional	  or	  translational	  mechanisms	  or	  by	  changing	  transcript/protein	  
stability	  will	   have	   the	   same	  effect	  on	   the	   control	   reporter	   constructs.	  Whereas	  
small	  molecules	  that	  caused	  a	  true	  splicing	  switch	  will	  not	  have	  had	  any	  effect	  on	  
the	  control	  reporters-­‐	  there	  is	  no	  intron	  therefore,	  no	  splicing.	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There	   are	   also	   other	   important	   forms	   of	   gene	   expression	   regulation	   beyond	  
transcriptional	   control	   and	   alternative	   splicing,	   which	   could	   affect	   reporter	  
transcripts	   and	   ultimately	   fluorescent	   protein	   measurements.	   One	   such	  
mechanism	   is	   unproductive	   splicing,	   a	   process	   used	   to	   down	   regulate	   the	  
expression	   of	   certain	   alternatively	   spliced	   transcripts	   post-­‐transcriptionally	   by	  
inducing	  nonsense-­‐mediated	  decay	  (NMD).	  NMD	  involves	  recognition	  of	  mRNAs	  
that	   contain	   premature	   termination	   codons	   (PTCs)	   and	   induces	   degradation	   of	  
the	   transcript	   for	   translation	   into	  what	  would	   be	   a	   truncated	   protein	   product.	  
Some	   details	   of	   how	   NMD	  machinery	   detects	   PTCs	   and	   targets	   the	  mRNA	   for	  
degradation	   remain	   unclear.	  Nonsense	  mutations	   and	   frameshifts	   can	   produce	  
mRNAs	   containing	   PTCs,	   as	   can	   use	   of	   alternative	   splice	   sites	   (Lareau	   et	   al.,	  
2004).	   Computational	   analysis	   of	   alternatively	   spliced	  mRNAs	   indicates	   that	   of	  
human	  genes	  known	  to	  undergo	  alternative	  splicing,	  around	  45%	  produce	  one	  or	  
more	  mRNAs	  containing	  a	  PTC	  making	  it	  a	  target	  for	  NMD.	  This	  gave	  rise	  to	  the	  
notion	   that	   unproductive	   splicing	   is	   not	   simply	   an	   irregularity,	   but	   a	   regulated	  
mechanism	   of	   post-­‐transcriptional	   gene	   regulation	   (Lewis	   et	   al.,	   2003).	   Aside	  
from	   inducing	   mechanisms	   that	   favour	   selection	   of	   either	   the	   VEGF	   SSFR	  
proximal	   or	   distal	   splice	   site,	   some	   compounds	   from	   the	   chemical	   library	  may	  
induce	   use	   of	   another	   sequence	  within	   the	   reporter	   construct	   as	   a	   splice	   site.	  
These	   transcripts	   could	   contain	  PTCs	   resulting	   in	  degraded	  by	  NMD.	  This	   could	  
act	  to	  decrease	  dsRED	  expression	  from	  the	  reporter	  without	  a	  splicing	  switch	  to	  
the	  distal	  splice	  site.	  The	  control	  reporters	  used	  as	  part	  of	  the	  VEGF	  SSFR	  screen	  
cannot	  be	  spliced	  at	  the	  VEGF	  proximal	  and	  distal	  splice	  sites	  as	  the	  VEGF	  exon	  7	  
intronic	   sequence	   has	   been	   removed.	   Processing	   of	   the	   control	   reporter	  
transcripts	   could	   still	   potentially	   produce	   products	   that	   are	   targeted	   for	  
degradation	  and	  these	  would	  not	  be	  eliminated	  during	  the	  control	  screen.	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Chapter	  5       
Anti-­‐angiogenic   effect   of   compounds  
identified   using   VEGF   splicing   sensitive  
reporter  
  
5.1  INTRODUCTION  
Angiogenesis	   is	   the	   physiological	   process	   of	   blood	   vessel	   growth	   from	   pre-­‐
existing	   vasculature.	   Angiogenesis	   is	   essential	   during	   embryogenesis	   and	  
development	  for	  the	  growth	  of	  organs	  and	  tissues	  but	  does	  not	  commonly	  occur	  
in	  adult	  life,	  apart	  from	  a	  few	  notable	  exceptions	  such	  as	  during	  wound	  healing	  
processes.	   The	   female	   reproductive	   system	   also	   undergoes	   periods	   of	  
physiological	   angiogenesis	   during	   follicle	   development	   in	   the	   ovary	   and	  within	  
the	  placenta	  during	  pregnancy	  (Carmeliet,	  2005).	  
Endothelial	   cells	   form	   the	   lining	   of	   all	   blood	   vessels.	   Under	   basal	   conditions,	  
endothelial	   cells	   are	   quiescent	   and	   their	   survival	   is	   maintained	   by	   many	  
autocrine	  factors	  including	  angiopoietins,	  FGFs	  and	  VEGFs.	  These	  signals	  provide	  
the	   quiescent	   endothelial	   cells	   with	   long	   half-­‐lives.	   Endothelial	   cells	   of	   the	  
microvasculature	   are	   arranged	   in	  monolayers	   covered	   by	   pericytes,	  which	   also	  
secrete	  survival	  signals	  and	  repress	  the	  proliferation	  of	  endothelial	  cells.	  When	  a	  
vessel	   is	  exposed	   to	  an	  angiogenic	   signal,	  pericytes	  become	  detached	   from	  the	  
basement	  membrane	  and	  the	  junctions	  between	  endothelial	  cells	  are	  weakened.	  
This	  makes	   the	  vessel	  more	  permeable	  and	  proteins	  move	   from	   the	  plasma	   to	  
create	  additional	  extracellular	  matrix	   for	  endothelial	  cells	   to	   form	  new	  vascular	  
structures	   on.	   ECM	   proteins	   are	   cleaved	   by	   proteases	   to	   release	   angiogenic	  
factors	  and	  to	  allow	  remodelling	  (Carmeliet	  and	  Jain,	  2011).	  
During	  angiogenesis,	  one	  endothelial	  cell	  from	  the	  stimulated	  vessel	  is	  chosen	  as	  
the	   tip	   cell,	  which	   leads	   sprouting	   vessels	   towards	   an	  angiogenic	   stimulus.	   The	  
adjacent	  cells	  become	  stalk	  cells,	  which	  proliferate	   to	  elongate	   the	  new	  vessel.	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After	   angiogenesis,	   endothelial	   cells	   return	   to	   quiescence	   with	   the	   cell-­‐to-­‐cell	  
junctions	  reforming	  and	  pericytes	  stimulated	  to	  sheath	  the	  new	  vascular	  tubules.	  
For	  such	  a	  complex	  process,	   it	   is	  surprising	  that	  one	  family	  of	  proteins,	  VEGF-­‐A,	  
regulates	  angiogenesis	  so	  prevalently	  (Carmeliet,	  2005).	  	  
Angiogenesis	  is	  highly	  regulated	  at	  each	  step.	  To	  investigate	  angiogenesis,	  assays	  
need	  to	  simulate	  each	   important	  stage	  of	   the	  process	   to	  be	  used	  to	  effectively	  
evaluate	  potential	  therapeutics.	  In	  vitro	  assays	  designed	  to	  explore	  vessel	  growth	  
often	   focus	   on	   one	   phase	   of	   angiogenesis	   i.e.	   endothelial	   cell	   proliferation,	  
migration	   etc.	   Endothelial	   proliferation	   can	   be	   assessed	   by	   measuring	   the	  
incorporation	  of	  radiolabelled	  nucleotides	  or	  expression	  of	  proliferative	  markers,	  
such	  as	  Ki-­‐67.	  Boyden	  chamber	  assays	  can	  be	  used	   to	  measure	  endothelial	   cell	  
migration	  in	  response	  to	  a	  stimulus.	  In	  such	  assays,	  cells	  are	  cultured	  on	  a	  porous	  
filter	   with	   their	  movement	   through	   the	   filter	   used	   as	   a	   quantification	   of	   their	  
migratory	  phenotype	  (Auerbach	  et	  al.,	  2003;	  Ferrara,	  2002).	  	  
Another	  common	  way	  to	  evaluate	  the	  effect	  of	  a	  treatment	  on	  endothelial	  cells	  
and	  angiogenesis	   in	  vitro	   is	  using	  tube	   formation	  assays.	  This	   involves	  culturing	  
ECs	   on	   a	  matrix	   of	   extracellular	   proteins.	   All	   cultured	   endothelial	   cell	   lines	   are	  
able	  to	  adhere	  to	  the	  gelatinous	  matrices	  and	  form	  tube-­‐like	  networks	  mimicking	  
capillaries	   of	   the	   microvasculature.	   A	   commonly	   used	   matrix	   is	   Matrigel,	  
produced	   from	   mouse	   sarcoma	   Engelbreth-­‐Holm-­‐Swarm	   cells.	   Similarly,	   tube	  
formation	   assays	   of	   endothelial	   cells	   can	   also	   be	   performed	   in	   co-­‐culture	  with	  
other	   cells	   such	   as	   fibroblasts.	   During	   the	   co-­‐culture,	   fibroblasts	   secrete	   ECM	  
proteins,	  which	  endothelial	  cells	  then	  use	  to	  form	  tubes	  in	  vitro.	  
In	   vitro	   angiogenesis	   assays	   are	   an	   important	   step	   in	   validating	   drugs	   or	  
determining	  which	  genes	   can	  alter	  angiogenesis.	  But,	  due	   to	   the	   complexity	  of	  
vessel	  growth,	  there	  is	  no	  way	  to	  fully	  simulate	  angiogenesis	   in	  vitro,	  therefore,	  
in	   vivo	  models	   must	   also	   be	   employed.	   An	   example	   of	   one	   such	   assay	   is	   the	  
corneal	   pocket	   angiogenesis	   assay.	   The	   cornea	   is	   a	   transparent	   tissue	   and	  
normally	  has	  no	  vasculature	  making	  it	  easy	  to	  observe	  neovascularation	  caused	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by	   an	   injury	   or	   injection	   of	   tumour	   cells	   into	   the	   corneal	   pocket.	   Another	  
common	   method	   used	   to	   investigate	   angiogenesis	   in	   vivo	   involves	  
subcutaneously	   injecting	   an	   animal	   with	   a	  Matrigel	   plug.	   The	  Matrigel	   can	   be	  
mixed	   with	   a	   potential	   pro/anti-­‐angiogenic	   molecule	   or	   cells	   expressing	  
angiogenic	  factors,	  which	  may	  stimulate	  or	  inhibit	  vessel	  growth	  and	  infiltration	  
into	   the	   plug.	   	   After	   several	   days	   the	   plug	   can	   be	   removed	   and	   vessel	   growth	  
within	  the	  plug	  quantified	  using	  endothelial	  markers	  (Staton	  et	  al.,	  2009).	  
In	   the	   previous	   chapter	   I	   described	   a	   chemical	   screen,	   which	   used	   a	   reporter	  
construct	   to	   identify	   molecules	   that	   may	   influence	   VEGF	   alternative	   splicing.	  
Some	   of	   the	   chemicals	   were	   shown	   to	   increase	   expression	   of	   anti-­‐angiogenic	  
VEGF	  protein	  isoforms.	  Here,	  I	  investigate	  whether	  these	  compounds	  produce	  an	  
anti-­‐angiogenic	  effect	  and	  if	  this	  effect	  is	  mediated	  by	  VEGF	  isoforms.	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5.2  RESULTS  
5.2.1 The  effect  of  ESSO  compounds  on  endothelial  cell  tube  formation  on  
Matrigel    
A	  library	  of	  compounds	  was	  used	  in	  a	  screen	  to	  identify	  molecules	  that	  can	  alter	  
VEGF	   alternative	   splicing	   using	   a	   splicing-­‐sensitive	   fluorescent	   reporter	   that	  
mimics	  VEGF	  terminal	  exon	  splicing.	  This	  splicing	  decision	  creates	  either	  pro-­‐	  or	  
anti-­‐angiogenic	  VEGF	  protein	  isoforms.	  Nine	  compounds	  were	  shown	  to	  increase	  
distal	   splice	   site	   selection/	   reduce	   proximal	   splice	   site	   selection	   following	   a	  
primary	  and	  secondary	  screen	  of	  a	  1280	  compound	  library.	  Hits	  had	  been	  shown	  
to	  change	  the	  alternative	  splicing	  of	  a	  reporter	  based	  on	  VEGF	  exon	  8,	  increasing	  
use	  of	  the	  distal	  splice	  site	  involved	  in	  producing	  anti-­‐angiogenic	  VEGF.	  Some	  of	  
the	  lead	  compounds	  affected	  the	  alternative	  splicing	  of	  endogenous	  VEGF	  mRNA	  
transcripts	   in	   PC3	   cells	   and	   increased	   expression	   of	   anti-­‐angiogenic	   VEGF	  
isoforms	   at	   the	   protein	   level.	   Continuing,	   I	   wanted	   to	   establish	   if	   any	   of	   the	  
compounds	  produced	  an	  anti-­‐angiogenic	  response.	  I	  chose	  to	  investigate	  this	  by	  
performing	   several	   anti-­‐angiogenesis	   assays	   in	   vitro	   and	   in	   vivo	   including	  
Matrigel	   tube	   formation	   assays,	   endothelial-­‐fibroblast	   co-­‐culture	   and	   in	   vivo	  
Matrigel	  assays.	  	  
Human	  umbilical	  vein	  endothelial	  cells	  (HUVECs)	  were	  cultured	  in	  for	  48	  hours	  in	  
EBM-­‐2	  media	   containing	   either	   control	   (DMSO)	  or	   one	  of	   the	  nine	  drugs.	   Cells	  
were	   then	   detached	   from	   culture	   plates	   and	   10,000	  HUVECs	   seeded	   into	   each	  
well	  of	  a	  96-­‐well	  plate	  coated	  with	  Matrigel	  and	  incubated	  at	  37°C.	  Micrographs	  
were	   taken	   of	   cells	   in	   each	   treatment	   condition	   after	   five	   hours	   of	   incubation	  
(Figure	  5-­‐1A).	  Five	  images	  were	  captured	  of	  each	  well.	  The	  total	  length	  of	  tubules	  
formed	  in	  each	  field	  was	  measured	  using	  ImageJ	  (Figure	  5-­‐1B)	  and	  the	  number	  of	  
branch	  points	  between	  tubules	  counted	  (Figure	  5-­‐1C).	  ESSO08	  (GW2974)	  and	  09	  
(AEBSF)	   significantly	   reduced	   the	   tube	   length	   and	   branch	   points	   compared	   to	  
control.	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Figure	  5-­‐1	  	  The	  effect	  of	  screened	  lead	  compounds	  on	  endothelial	  cells	  in	  an	  in	  
vitro	  angiogenesis	  assay	  
HUVECs	  were	  treated	  with	  each	  of	  the	  lead	  compounds	  for	  48	  hours	  at	  10μM	  
before	  being	  seeded	  onto	  Matrigel	  basement	  membrane	  matrix.	  Cells	  were	  
imaged	  after	  5	  hours	  (A),	  5	  microscopic	  fields	  were	  captured	  of	  each	  condition	  at	  
10x	  magnification.	  Total	  tubule	  length	  (B)	  and	  the	  number	  of	  branch	  points	  (C)	  in	  
each	  image.	  Statistical	  test	  performed	  one-­‐way	  ANOVA,	  with	  Dunnett’s	  post-­‐test	  
comparing	  each	  treatment	  to	  DMSO	  control.*p<0.05,	  **p<0.01	  n=3.	  
	  
HUVECs	   were	   used	   in	   the	   described	   in	   vitro	   angiogenesis	   assay.	   During	   the	  
Matrigel	   tube	   formation	   assay,	   two	   compounds	  were	   observed	   to	   significantly	  
reduce	   the	   ability	   of	   endothelial	   cells	   to	   form	   tubular	   networks.	   Trypan	   blue	  
staining	  was	  used	  confirm	  that	  the	  reduction	  in	  endothelial	  tube	  formation	  was	  
not	   merely	   due	   to	   treatment	   with	   the	   four	   compounds	   having	   a	   detrimental	  
effect	  on	  cell	  viability.	  HUVECs	  were	  treated	  with	  each	  lead	  compound	  at	  10μM	  
for	  48	  hours.	  Cells	  were	  then	  detached	  from	  the	  culture	  flasks	  and	  stained	  with	  
trypan	  blue	  and	   loaded	  into	  a	  haemocytometer.	  Viable	  cells	  exclude	  the	  trypan	  
blue	  chromophore,	  therefore	  remain	  unstained.	  Cells	  were	  counted	  to	  measure	  
cell	   viability	   following	   each	   compound	   treatment	   (Figure	   5-­‐2).	   There	   was	   no	  
significant	   difference	   in	   the	   percentage	   of	   viable	   cells	   between	   DMSO	   control	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Figure	  5-­‐2	  Endothelial	  cell	  viability	  is	  not	  altered	  by	  treatment	  with	  lead	  
compounds	  
HUVECs	  were	  cultured	  in	  growth	  media	  containing	  either	  DMSO	  or	  one	  of	  the	  
nine	  lead	  compounds	  at	  10μM.	  Cells	  were	  suspended	  in	  a	  trypan	  blue	  solution.	  
Total	  cell	  number	  and	  viable	  cells	  were	  counted	  to	  calculate	  the	  percentage	  of	  
viable	  cells	  after	  treatment.	  Statistical	  test	  performed	  one-­‐way	  ANOVA,	  with	  
Dunnett’s	  post-­‐test	  comparing	  each	  treatment	  to	  DMSO	  control.	  ns=	  not	  
significant.	  n=3.	  
	  
In	   the	   previous	   tubule	   formation	   experiment,	   endothelial	   cells	   were	   directly	  
treated	   with	   the	   small	   molecules	   over	   48	   hours	   before	   the	   functional	   assays	  
were	  performed.	  During	  cancer	  progression,	  the	  angiogenic	  switch,	  is	  induced	  by	  
the	  secretion	  of	   factors	   from	  tumour	  cells	   that	   stimulate	  endothelial	   cells.	  Pro-­‐
angiogenic	  VEGF	  isoforms	  are	  highly	  expressed	  by	  tumours	  and	  cancer	  cell	  lines.	  
Therefore,	   the	  small	  molecule	  screen,	  which	   identified	  compounds	   that	  altered	  
VEGF	   reporter	   alternative	   splicing,	   was	   performed	   using	   PC3	   cells,	   which	  
normally	   express	   pro-­‐angiogenic	   isoforms.	   In	   order	   to	  mimic	   the	   conditions	   of	  
the	   small	   molecule	   screen	   and	   mimic	   the	   in	   vivo	   situation,	   PC3	   cells	   were	  
cultured	  in	  EBM-­‐2	  growth	  medium	  and	  treated	  with	  each	  of	  the	  small	  molecules	  
at	  10μM.	  The	  conditioned	  media	  was	  removed	  from	  PC3	  cells	  after	  48	  hours	  of	  
treatment	  and	  used	  in	  a	  Matrigel	  angiogenesis	  assay.	  HUVECs	  were	  suspended	  in	  
the	   conditioned	  media	  and	   seeded	  onto	  Matrigel	  basement	  membrane	  matrix.	  
Tubule	   length	   in	   each	   condition	   was	   quantified	   as	   a	   measurement	   of	   the	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Conditioned	  media	   of	   8	   compounds	   significantly	   reduced	   tubule	   formation	   by	  
endothelial	  cells.	  
	  
Figure	  5-­‐3	  Endothelial	  cell	  function	  is	  altered	  by	  the	  conditioned	  media	  of	  PC3	  
cells	  exposed	  to	  lead	  compounds	  
PC3	  cells	  were	  cultured	  in	  EBM-­‐2	  containing	  10μM	  ESSOs	  with	  media	  collected	  
after	  48	  hours.	  1x104	  HUVECs	  were	  suspended	  in	  each	  conditioned	  medium	  and	  
seeded	  onto	  Matrigel.	  Cells	  were	  imaged	  after	  5	  hours	  with	  5	  microscopic	  fields	  w	  
captured	  of	  each	  condition.	  Total	  tubule	  length	  (B)	  in	  each	  image	  was	  quantified.	  
Statistically	  tested	  using	  a	  one-­‐way	  ANOVA,	  with	  Dunnett’s	  post-­‐test	  comparing	  
each	  treatment	  to	  DMSO	  control.*p<0.05,	  **p<0.01,	  n=5.	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5.2.2 Endothelial   tube   formation   was   reduced   by   trovafloxacin  mesylate  
and  RepSox  in  an  endothelial-­‐fibroblast  co-­‐culture  
The	  potential	  anti-­‐angiogenic	  effects	  of	  the	  lead	  compounds	  identified	  during	  the	  
VEGF	   splicing	   screen	   was	   investigated	   further	   using	   a	   second	   in	   vitro	  
angiogenesis	  assay.	  The	  effect	  of	   lead	  compounds	  on	  prostate	  cancer	  cells	  and	  
how	   secreted	   factors	   alter	   angiogenesis	  was	   investigated	   using	   a	   co-­‐culture	   of	  
endothelial	   cells	   and	   fibroblasts.	   In	   this	   assay,	   endothelial	   cells	   use	   the	  
extracellular	   matrix	   proteins	   secreted	   by	   fibroblasts	   as	   a	   scaffold	   on	   which	   to	  
form	  vessel-­‐like	  tubules	  (Figure	  5-­‐A).	  	  
As	  previously	  described,	  PC3	  cells	  were	  cultured	   in	  EBM-­‐2	  growth	  medium	  and	  
treated	   with	   each	   of	   the	   lead	   compounds	   at	   10μM.	   The	   media	   was	   collected	  
after	  48	  hours	  of	  treatment.	  Fibroblasts	  were	  cultured	  on	  coverslips	  with	  HUVECs	  
seeded	  when	  fibroblasts	  reached	  confluency.	  Conditioned	  media	  was	  applied	  to	  
the	   co-­‐culture	   48	   hours	   after	   the	   addition	   of	   the	   HUVECs	   and	   cells	   were	  
incubated	   for	   a	   further	   48	   hours	   (Figure	   5-­‐4A).	   Triplicate	   wells	   were	   used	   for	  
DMSO	   control	   and	   each	   treated	   condition.	   Treatment	   with	   1nM	   VEGF165	  
recombinant	   protein	   was	   used	   as	   a	   positive	   control	   for	   endothelial	   tube	  
formation	   (data	   not	   shown).	   	   The	   coverslips	   were	   fixed	   and	   stained	   with	   a	  
fluorescent	  antibody	  against	  CD31,	  an	  endothelial	  cell	  marker	  (Figure	  5-­‐4B).	  Five	  
fluorescent	  micrographs	  were	  taken	  of	  each	  control	  and	  treated	  conditions.	  The	  
total	   length	  of	  endothelial	   cell	   tubes	   formed	   in	  each	   image	  was	  quantified	  and	  
normalised	   to	   the	   total	   number	   of	   cells	   using	   nuclear	   staining	  with	   DAPI.	   Two	  
drugs	   out	   of	   the	   nine	   lead	   compounds	   (trovafloxacin	   mesylate	   and	   RepSox)	  
produced	  a	  decrease	  in	  the	  length	  of	  tubes	  formed	  compared	  to	  DMSO	  control	  
(Figure	  5-­‐4C).	  Under	  these	  two	  treatments,	  endothelial	  cells	  mostly	  grew	  in	  small	  
islands	   of	   cells	   without	   branching	   or	   any	   tubular	   structures	   created	   on	   the	  
extracellular	  protein	  scaffolds.	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Figure	  5-­‐4	  Endothelial	  cell	  tubule	  formation	  was	  reduced	  by	  trovafloxacin	  
mesylate	  and	  RepSox	  during	  endothelial	  fibroblast	  co-­‐culture.	  	  
(A)	  Endothelial	  cells	  were	  co-­‐cultured	  with	  confluent	  fibroblasts	  (NHDF)	  in	  
conditioned	  media	  taken	  from	  PC3	  cells	  treated	  with	  each	  of	  the	  lead	  compounds	  
(10μM).	  (B)	  Cells	  were	  fixed	  and	  stained	  with	  DAPI	  and	  a	  fluorescent	  antibody	  
against	  the	  endothelial	  cell	  marker	  CD31	  (C).	  10	  microscopic	  fields	  of	  each	  co-­‐
culture	  were	  quantified	  for	  the	  total	  length	  of	  endothelial	  tubules	  formed	  
normalised	  to	  the	  total	  cell	  area.	  Statistical	  test	  performed	  one-­‐way	  ANOVA,	  with	  
Dunnett’s	  post-­‐test	  comparing	  each	  treatment	  to	  DMSO	  control.	  **p<0.01,	  n=3.	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5.2.3 Is  the  ESSO  in  vitro  anti-­‐angiogenic  activity  sole  mediated  by  changes  
to  VEGF  alternative  splicing?  
I	  have	  shown	  that	  several	  of	  the	  compounds	  affect	  VEGF	  alternative	  splicing	  in	  
cultured	  PC3	  cells	  leading	  to	  increased	  expression	  of	  anti-­‐angiogenic	  VEGF	  
isoforms	  (Chapter	  4).	  Culture	  media	  removed	  from	  PC3	  cells	  exposed	  to	  the	  lead	  
compounds	  reduced	  tubule	  formation	  by	  endothelial	  cells	  following	  treatment	  
with	  8	  out	  of	  the	  9	  compounds	  being	  investigated.	  The	  chemicals	  all	  target	  
different	  molecules	  so	  will	  likely	  activate	  different	  pathways	  in	  the	  cells.	  The	  
inhibitory	  effect	  on	  the	  tube	  forming	  ability	  of	  endothelial	  cells	  may	  be	  caused	  by	  
increased	  VEGFxxxb,	  changes	  in	  expression	  of	  other	  secreted	  factors	  or	  from	  the	  
compounds	  directly.	  To	  assess	  if	  VEGFxxxb	  is	  the	  main	  effector,	  the	  Matrigel	  
angiogenesis	  assays	  were	  repeated	  using	  a	  neutralising	  antibody	  (56/1)	  that	  
specifically	  targets	  anti-­‐angiogenic	  VEGF	  isoforms.	  The	  same	  protocol	  as	  
previously	  described	  was	  followed	  but	  with	  either	  10μg/ml	  56/1	  or	  water	  control	  
added	  to	  each	  conditioned	  media	  sample.	  Consistently	  with	  previous	  
experiments,	  conditioned	  media	  from	  PC3	  cells	  treated	  with	  ESSO07	  and	  08	  
(RepSox	  and	  GW2974)	  significantly	  reduced	  tubule	  formation	  by	  HUVECs,	  
however	  the	  effect	  of	  ESSO08	  was	  partially	  rescued	  by	  the	  VEGFxxxb	  neutralising	  
antibody	  (Figure	  5-­‐5).	  This	  indicates	  that	  anti-­‐angiogenic	  VEGF	  isoforms	  
contributed	  to	  the	  reduced	  formation	  of	  endothelial	  tubes	  following	  treatment	  
with	  PC3	  conditioned	  media.	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Figure	  5-­‐5	  Anti-­‐angiogenic	  VEGF	  isoforms	  mediate	  in	  vitro	  inhibition	  of	  
endothelial	  tube	  formation	  
PC3	  cells	  were	  cultured	  for	  48	  hours	  in	  10μM	  of	  each	  compound.	  An	  endothelial	  
cell	  tube	  formation	  assay	  was	  performed	  with	  HUVECs	  seeded	  on	  to	  Matrigel	  in	  
PC3	  	  conditioned	  media	  either	  containing	  56-­‐1	  10μg/ml.	  5	  images	  of	  each	  well	  
were	  captured	  and	  quantified	  for	  tubule	  length.	  n=4,	  **P<0.01	  vs.	  DMSO	  control.	  
#	  P<0.01	  vs.	  ESSO08	  control.	  	  
	  
SR	  proteins	  are	  an	  important	  family	  of	  splicing	  regulatory	  proteins.	  The	  
phosphorylation	  and	  expression	  of	  SR	  proteins	  following	  treatment	  with	  
trovafloxacin	  mesylate,	  RepSox	  and	  GW2974	  (ESSO	  1,	  7	  and	  8)	  was	  assessed.	  
Cells	  were	  pre-­‐treated	  with	  the	  compounds	  and	  then	  stimulated	  with	  EGF	  as	  EGF	  
has	  been	  demonstrated	  to	  increase	  the	  phosphorylation	  of	  SR	  proteins	  (Zhou	  et	  
al.,	  2012).	  Proteins	  were	  extracted	  and	  analysed	  by	  western	  blot.	  Total	  SR	  
protein	  levels	  were	  measured	  and	  phosphor-­‐SR	  proteins	  detected	  using	  the	  
mab104	  antibody	  (Figure	  5-­‐6).	  	  RepSox	  and	  GW2974	  appeared	  to	  reduce	  the	  
detection	  of	  certain	  phospho-­‐SR	  bands.	  Phosphorylation	  of	  an	  approximately	  
30kDa	  protein	  was	  reduced.	  This	  band	  may	  represent	  SRSF1	  or	  2,	  which	  have	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Figure	  5-­‐6	  The	  effect	  of	  ESSO	  compounds	  on	  SR	  phosphorylation	  
PC3	  cells	  were	  pre-­‐treated	  with	  each	  ESSO	  compound	  for	  1	  hour	  prior	  to	  
stimulation	  with	  100ng/ml	  EGF.	  After	  2	  hour,	  proteins	  were	  extracted	  and	  SR	  
protein	  expression	  and	  phosphorylation	  analysed	  by	  western	  blot.	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5.2.4 Tumour   growth   is   reduced   by   the   anti-­‐angiogenic   compound,  
RepSox  
Angiogenesis	  is	  induced	  by	  cancers	  in	  order	  to	  create	  their	  own	  blood	  supply	  and	  
to	   allow	   further	   growth	   and	   metastasis.	   I	   have	   shown	   that	   ESSO07	   (RepSox)	  
increases	  anti-­‐angiogenic	  VEGF	  isoforms	  through	  increased	  use	  of	  a	  distal	  splice	  
site	   in	   VEGF	   exon	   8	   and	   demonstrated	   anti-­‐angiogenic	   activity	   in	   two	   in	   vitro	  
angiogenesis	   assays.	   It	   was	   next	   explored	   as	   to	   whether	   the	   anti-­‐angiogenic	  
activity	   of	   RepSox	   can	   be	   used	   to	   inhibit	   tumour	   growth.	   PC3	   cells	   were	   pre-­‐
treated	  with	  RepSox	  at	  10μM	  in	  culture	  for	  48	  hours	  before	  they	  were	  harvested	  
and	  injected	  subcutaneously	  into	  nude	  mice.	  The	  PC3s	  were	  mixed	  with	  Matrigel	  
prior	   to	   injection	   to	   aide	   their	   formation	   into	   tumours.	   2	   million	   cells	   were	  
injected	   into	  each	  mouse.	  Two	  weeks	  post-­‐injection,	   the	  tumours	  were	  excised	  
and	   weighed	   (Figure	   5-­‐7).	   The	   tumours	   formed	   from	   PC3	   cells	   that	   had	   been	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Figure	  5-­‐7	  Pre-­‐treatment	  of	  PC3	  cells	  with	  RepSox	  leads	  to	  reduced	  tumour	  
growth	  
PC3	  cells	  were	  cultured	  in	  medium	  containing	  10μM	  RepSox	  (ESSO07)	  or	  DMSO	  
for	  48	  hours.	  2x106	  PC3	  cells	  were	  mixed	  with	  400μl	  Matrigel	  and	  10	  μM	  RepSox.	  
PC3	  cells	  were	  injected	  subcutaneously	  into	  nude	  mice.	  After	  14	  days,	  the	  
tumours	  were	  harvested	  and	  weighed.	  Control	  and	  treatment	  tumour	  weights	  
were	  statistically	  compared	  using	  an	  unpaired	  t-­‐test,	  p=0.0002***.	  Control	  n=6,	  
ESSO07	  n=11.	  
	  
5.2.5 In  vivo  neovascularization  of  Matrigel  plugs  is  reduced  by  AEBSF    
ESSO09	   (AEBSF)	   is	   a	   sylfonyl	   fluoride	   serine	   protease	   inhibitor.	   Examples	   of	  
serine	   proteases	   that	   are	   inhibited	   by	   this	   small	   molecule	   are	   chymotrypsin,	  
thrombin	  and	  plasmin.	  There	  are	   reports	   that	  AEBSF	  also	  acts	  on	   targets	  other	  
than	   serine	   proteases	   including	   NADPH	   oxidase	   (Abid	   et	   al.,	   2000).	   AEBSF	  
significantly	   inhibited	   endothelial	   tube	   formation	   in	   an	   in	   vitro	   Matrigel	  
angiogenesis	  assay	  so	  was	  consequently	  used	  to	  test	  for	  anti-­‐angiogenic	  activity	  
in	  vivo.	  For	  this	  purpose	  I	  used	  a	  Matrigel	  plug	  assay.	  PC3	  cells	  were	  cultured	  in	  
10μM	  AEBSF	  for	  48	  hours.	  2	  million	  control	  or	  treated	  cells	  were	  then	  mixed	  with	  
Matrigel	  and	  10	  μM	  AEBSF.	  Cells	  and	  Matrigel	  were	  kept	  on	  ice	  at	  all	  times	  prior	  
to	  subcutaneous	  injection	  into	  nude	  mice.	  At	  37	  °C,	  Matrigel	  polymerizes	  to	  form	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the	   plug	   produce	   angiogenic	   signals	   stimulating	   sprouting	   angiogenesis	   and	  
infiltration	   of	   blood	   vessels	   into	   the	   Matrigel	   (Figure	   5-­‐8A).	   Four	   days	   after	  
injection,	   the	   plugs	   were	   removed	   to	   assess	   neovascularization.	   Images	   were	  
captured	   of	   the	   extracted	   plugs	   and	   Photoshop	   used	   to	   quantify	   the	   colour	  
intensity	  of	  the	  plugs	  (Figure	  5-­‐8B).	  Matrigel	  plugs	  with	  no	  infiltrating	  vessels	  are	  
colourless	   whereas	   neovascularization	   causes	   the	   plugs	   to	   become	   dark	   and	  
bloody.	   Plugs	   that	   had	   been	   injected	   along	   with	   PC3	   cells	   that	   had	   been	   pre-­‐
treated	   with	   AEBSF	   had	   significantly	   reduced	   colour	   intensity	   compared	   to	  
control	  plugs	  (Figure	  5-­‐8C).	  RNA	  was	  extracted	  from	  each	  plug	  and	  qRT-­‐PCR	  used	  
to	  measure	  mouse	  Vegfr-­‐2	  expression.	  VEGFR2	  is	  highly	  expressed	  on	  endothelial	  
cells,	  therefore,	  mouse-­‐specific	  Vegfr-­‐2	  primers	  were	  used	  to	  detect	  vasculature	  
in	   the	   plugs.	   The	   comparative	   Ct	  method	  was	   used	   to	   quantify	  mouse	  Vegfr-­‐2	  
transcript	   levels	  with	  human	  GAPDH	  used	   as	   the	   reference	   gene.	  Angiogenesis	  
was	   inhibited	   in	   plugs	   containing	   PC3	   cells	   that	   had	   bee	   treated	   with	   AEBSF	  
(Figure	  5-­‐8D).	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  Figure	  5-­‐8	  AEBSF	  reduces	  neovascularisation	  of	  Matrigel	  plugs	  in	  vivo	  
(A)	  PC3	  cells	  were	  cultured	  for	  48	  hours	  in	  either	  10μM	  AEBSF	  (ESSO09)	  or	  DMSO	  
only.	  2x106	  PC3	  cells	  were	  mixed	  with	  Matrigel	  and	  10	  μM	  AEBSF.	  The	  Matrigel	  
and	  cells	  were	  injected	  subcutaneously	  into	  nude	  mice.	  Four	  days	  post-­‐injection	  
the	  plugs	  were	  removed	  and	  RNA	  was	  extracted.	  (B)	  Photographs	  were	  taken	  of	  
each	  plug	  and	  (C)	  colour	  intensity	  quantified	  using	  ImageJ	  software.	  Control	  and	  
treatment	  plugs	  were	  compared	  using	  an	  unpaired	  t-­‐test,	  p=0.0002,	  control	  n=13,	  
ESSO09	  n=11.	  (D)	  RNA	  was	  extracted	  from	  the	  plugs	  to	  quantify	  VEGFR2	  
expression.	  Mouse	  VEGFR2	  expression	  was	  normalised	  to	  human	  GAPDH.	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A	   second,	   similar	  experiment	  was	  performed	  using	  another	  of	   the	   compounds,	  
which	   was	   shown	   to	   reduce	   angiogenesis	   during	   endothelial-­‐fibroblast	   co-­‐
culture.	  ESSO01	  (trovafloxacin	  mesylate)	  did	  not	  reduce	  tubule	  formation	  during	  
Matrigel	   angiogenesis	   assays	   but	   did	   show	   an	   inhibitory	   effect	   on	   endothelial	  
cells	   in	   co-­‐culture	   with	   fibroblasts	   and	   induced	   a	   shift	   from	  VEGF	   proximal	   to	  
distal	  splice	  site	  selection	  in	  PC3	  cells.	  Changes	  in	  VEGF	  isoform	  expression	  at	  the	  
protein	   level	  following	  treatment	  with	  trovafloxacin	  mesylate	  was	  undetectable	  
due	  to	  low	  total	  protein	  levels	  possibly	  because	  of	  a	  negative	  effect	  on	  PC3	  cell	  
growth.	   During	   endothelial-­‐fibroblast	   co-­‐culture,	   the	   cells	   were	   incubated	   in	  
conditioned	  media	  taken	  from	  PC3	  cells	  that	  had	  been	  treated	  with	  trovafloxacin	  
mesylate.	  This	  suggests	  that	  trovafloxacin	  may	  not	  alter	  VEGF	  alternative	  splicing	  
in	   endothelial	   cells	   or	   the	   secreted	   VEGF	   levels	   are	   too	   low	   for	   a	   change	   in	  
splicing	   to	   have	   an	   anti-­‐angiogenic	   effect.	   However,	   conditioned	   media	   taken	  
from	  PC3	  cells	  treated	  with	  trovafloxacin	  mesylate	  did	  reduce	  tubule	  formation	  
during	   endothelial-­‐fibroblast	   co-­‐culture	   so	   may	   have	   activity	   in	   PC3	   but	   not	  
endothelial	  cell.	  Therefore,	  the	  compound	  did	  not	  affect	  endothelial	  cells	  when	  
treated	   directly	   but	   reduced	   tube	   length	   after	   PC3	   conditioned	   media	   was	  
applied.	  To	  establish	  if	  a	  similar	  result	  is	  produced	  in	  vivo,	  PC3	  cells	  were	  cultured	  
in	   three	   varying	   concentrations	   of	   trovafloxacin	  mesylate.	  Matrigel	   was	  mixed	  
with	   the	   treated	   or	   control	   PC3	   cells	   before	   subcutaneous	   injection	   into	   nude	  
mice.	   When	   the	   plugs	   were	   removed,	   after	   four	   days,	   colour	   intensity	   was	  
quantified	   as	   previously	   described	   (Figure	   5-­‐9).	   Statistically,	   there	   was	   no	  
difference	  between	  the	  control	  plugs	  and	  any	  of	  the	  treatment	  concentrations.	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Figure	  5-­‐9	  Trovafloxacin	  mesylate	  does	  not	  reduce	  neovascularisation	  in	  vivo	  
PC3	  cells	  were	  cultured	  for	  48	  hours	  in	  5μM,	  10μM,	  15μM	  trovafloxacin	  mesylate	  
(ESSO07)	  or	  DMSO	  only.	  2x106	  PC3	  cells	  were	  mixed	  with	  Matrigel	  and	  10μM	  
trovafloxacin	  mesylate.	  The	  Matrigel	  and	  cells	  were	  injected	  subcutaneously	  into	  
nude	  mice.	  Four	  days	  post-­‐injection	  the	  plugs	  were	  extracted.	  Photographs	  were	  
taken	  of	  each	  plug	  and	  colour	  intensity	  quantified	  using	  ImageJ	  software.	  One-­‐
way	  ANOVA	  was	  used	  to	  compared	  the	  treated	  plug	  to	  DMSO	  control	  with	  n=4	  in	  
each	  group.	  ns=	  no	  significant	  difference.	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5.3  DISCUSSION  
Tumours	  exploit	  angiogenesis	   in	  order	  to	  create	  their	  own	  blood	  supply	  for	  the	  
delivery	   of	   oxygen	   and	   nutrients.	   The	   angiogenic	   switch	   is	   a	   rate-­‐limiting	   step	  
within	   tumourigenesis.	   Solid	   tumours	   only	   reach	   a	   volume	   of	   around	   1mm3	  
without	  stimulating	  angiogenesis	  or	  co-­‐opting	  pre-­‐existing	  blood	  vessels	  (Bergers	  
and	   Benjamin,	   2003).	   VEGF	   is	   established	   at	   the	   most	   important	   regulator	   of	  
angiogenesis	   in	   both	   normal	   physiology	   and	   during	   tumour	   growth.	   The	  
alternative	  splicing	  of	  VEGF	  pre-­‐mRNA	  creates	  many	  protein	  isoforms	  including	  a	  
sub-­‐family	  with	  anti-­‐angiogenic	  properties,	  VEGFxxxb	  proteins.	  A	  splicing-­‐sensitive	  
fluorescent	   reporter	  was	   designed	   to	  mimic	   the	   alternative	   splicing	   event	   that	  
creates	   the	   pro-­‐/anti-­‐angiogenic	   VEGF	   isoforms.	   The	   reporter	   was	   used	   in	   a	  
screen	  to	  identify	  small	  molecules	  that	  can	  alter	  splice	  site	  selection	  resulting	  in	  
less	  VEGFxxx	  protein	  and	  more	  VEGFxxxb.	  Nine	  compounds	  were	  identified	  as	  able	  
to	   change	   the	   ratio	   of	   reporter	   splice	   site	   selection.	   I	   aimed	   to	   assess	   if	   these	  
small	  molecules	  could	  reduce	  angiogenesis	  by	  increasing	  the	  expression	  of	  anti-­‐
angiogenic	  VEGF	  isoforms.	  This	  was	  achieved	  using	  a	  series	  of	  assays	  to	  measure	  
anti-­‐angiogenic	  activity	  of	  the	  molecules,	  both	  in	  vitro	  and	  in	  vivo.	  
5.3.1 The  use  and  limitations  of  angiogenesis  assays  
In	  a	  healthy	  individual,	  endothelial	  cells	  are	  not	  proliferative	  but	  remain	  
quiescent	  awaiting	  angiogenic	  stimulation.	  In	  culture,	  endothelial	  cells	  adapt	  and	  
become	  proliferative	  allowing	  them	  to	  be	  utilised	  for	  in	  vitro	  migration,	  
proliferation	  and	  differentiation	  assays.	  Endothelial	  cells	  acquire	  proliferative,	  
angiogenic	  character	  in	  culture,	  which	  can	  potentially	  cause	  difficulty	  when	  
assessing	  if	  a	  factor	  or	  molecule	  is	  pro-­‐angiogenic.	  Care	  must	  be	  taken	  when	  
using	  primary	  endothelial	  cells	  as	  they	  begin	  to	  lose	  their	  endothelial	  phenotype	  
and	  expression	  of	  markers	  after	  multiple	  passages.	  HUVECs	  are	  very	  commonly	  
used	  for	  such	  assays	  however	  they	  are	  derived	  from	  umbilical	  vein	  when	  
angiogenesis	  is	  predominantly	  a	  process	  of	  the	  microvasculature.	  HMVECs	  may	  
be	  a	  more	  suitable	  cell	  type	  for	  use	  in	  vitro.	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In	  vitro	  angiogenesis	  assays	  that	  use	  only	  endothelial	  cells	  are	  quick,	  easily	  
quantified	  and	  usually	  reproducible.	  But,	  they	  are	  not	  able	  to	  reflect	  the	  complex	  
interactions	  that	  occur	  physiologically	  i.e	  the	  effect	  of	  flow	  and	  shear	  stress	  on	  
microvessels	  or	  indirect	  effects	  on	  endothelium	  via	  factors	  produced	  by	  other	  
cell	  types,	  which	  then	  modulate	  endothelial	  cells.	  To	  assess	  pro-­‐	  or	  anti-­‐
angiogenic	  activity	  of	  a	  molecule,	  it	  is	  common	  practice	  to	  use	  multiple	  in	  vitro	  
assays	  and	  then	  in	  vivo	  models.	  
Tubule	  formation	  assays	  are	  widely	  used	  for	  measuring	  the	  effect	  of	  molecules	  
and	  drugs	  on	  angiogenesis.	  These	  assays	  are	  thought	  to	  simulate	  the	  later	  phases	  
of	  angiogenesis,	  as	  tubules	  develop	  and	  lumen	  forms.	  Tubules	  form	  when	  
endothelial	  cells	  are	  seeded	  on	  a	  gel	  matrix	  of	  basement	  membrane	  and	  
extracellular	  proteins.	  Which	  matrix	  is	  used	  in	  tubule	  formation	  assays	  is	  an	  
important	  consideration.	  Endothelial	  cells	  proliferate	  on	  matrices	  of	  collagen	  I	  
and	  III	  but	  do	  not	  form	  tubules	  well,	  whereas,	  on	  collagens	  IV	  and	  V	  the	  cells	  do	  
not	  proliferate	  much	  but	  do	  develop	  into	  tubes.	  I	  used	  Matrigel	  during	  
angiogenesis	  assays,	  this	  is	  the	  most	  commonly	  used	  and	  potent	  gel	  matrix	  for	  
use	  in	  such	  assays.	  There	  is	  dispute	  whether	  the	  endothelial	  tubules	  formed	  
accurately	  simulate	  microvessels.	  The	  cells	  do	  associate	  with	  each	  other	  using	  
tight	  junctions	  but	  whether	  they	  form	  lumen	  is	  debated	  (Bikfalvi	  et	  al.,	  1991;	  
Connolly	  et	  al.,	  2002;	  Grant	  et	  al.,	  1991).	  It	  has	  also	  been	  observed	  that	  other	  cell	  
types,	  besides	  endothelial	  cells,	  can	  form	  tubule-­‐like	  structures	  on	  Matrigel,	  
including	  fibroblasts	  and	  some	  cancer	  cell	  lines	  (Donovan	  et	  al.,	  2001).	  	  
The	  in	  vitro	  Matrigel	  assays	  described	  were	  performed	  in	  2D	  with	  endothelial	  
cells	  plated	  on	  a	  thin	  layer	  of	  the	  gel	  matrix.	  Similar	  assays	  can	  also	  be	  performed	  
in	  3D	  to	  more	  accurately	  simulate	  angiogenesis	  in	  vivo.	  Such	  3D	  assays	  often	  
involve	  endothelial	  cells	  placed	  between	  two	  layers	  of	  matrix.	  Within	  around	  two	  
weeks	  in	  culture,	  endothelial	  cells	  will	  form	  a	  3D	  tubule	  complex	  (Gagnon	  et	  al.,	  
2002).	  However,	  3D	  angiogenesis	  assays	  are	  more	  challenging	  to	  perform	  and	  
quantify,	  the	  matrix	  must	  be	  optimised	  for	  appropriate	  thickness	  to	  allow	  oxygen	  
to	  reach	  the	  cells.	  The	  enhancement	  or	  inhibition	  of	  angiogenesis	  can	  be	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measured	  by	  fixing,	  sectioning	  and	  staining	  the	  gels	  for	  microvessels.	  3D	  tubule	  
formation	  assays	  are	  more	  time	  consuming	  in	  regards	  to	  experimental	  
procedures	  and	  quantification.	  
One	  method	  to	  mimic	  angiogenesis	  in	  vitro	  is	  co-­‐culturing	  stromal	  cells	  along	  
with	  endothelial	  cells.	  Cells	  commonly	  used	  include	  fibroblasts	  or	  smooth	  muscle	  
cells.	  An	  extracellular	  matrix	  can	  be	  externally	  provided	  in	  co-­‐cultures,	  but	  when	  
fibroblasts	  are	  used	  this	  is	  not	  required	  as	  the	  fibroblasts	  naturally	  produce	  the	  
necessary	  extracellular	  proteins.	  The	  tubules	  formed	  in	  this	  assay	  do	  possess	  
lumen	  and	  the	  tubule	  networks	  more	  comparable	  to	  in	  vivo	  capillaries	  than	  
endothelial	  tubes	  formed	  on	  Matrigel	  alone.	  However,	  the	  assay	  has	  a	  much	  
longer	  time	  course	  (14	  days)	  compared	  to	  simple	  endothelial-­‐only	  Matrigel	  
assays	  and	  the	  matrix	  proteins	  produced	  by	  fibroblasts	  may	  alter	  making	  the	  
assay	  more	  variable	  (Donovan	  et	  al.,	  2001).	  The	  major	  advantage	  of	  co-­‐culture	  is	  
that	  an	  exogenous	  matrix	  in	  not	  required	  due	  to	  natural	  secretion	  from	  
fibroblasts,	  but	  due	  to	  the	  total	  length	  of	  the	  assay	  effects	  to	  tubule	  formation	  
may	  be	  caused	  by	  changes	  in	  endothelial	  cell	  proliferation.	  
Compounds	  that	  demonstrate	  potent	  activity	  in	  vitro	  will	  not	  necessarily	  have	  
the	  same	  effect	  in	  vivo.	  Therefore,	  potential	  anti-­‐angiogenic	  molecules	  must	  also	  
be	  evaluated	  using	  animal	  models	  of	  angiogenesis.	  Matrigel	  plugs	  are	  a	  
commonly	  used	  and	  simple	  method	  for	  measuring	  the	  effect	  of	  a	  test	  substance	  
on	  the	  angiogenic	  response	  in	  vivo.	  Matrigel	  is	  useful	  for	  in	  vivo	  applications.	  The	  
matrix	  is	  in	  liquid	  form	  below	  4°C	  but	  solidifies	  following	  injection.	  Following,	  
removal	  of	  the	  plug	  from	  a	  mouse	  after	  several	  days,	  neovascularisation	  can	  be	  
quantified	  in	  various	  ways.	  I	  used	  colour	  intensity	  as	  a	  measurement	  of	  
haemoglobin	  presence	  and	  extracted	  RNA	  to	  quantify	  an	  endothelial	  cell	  marker.	  
Plugs	  can	  also	  be	  sectioned	  and	  stained	  to	  visualise	  vessel	  formation	  within	  the	  
plug.	  	  
Angiogenesis	  is	  a	  one	  of	  the	  hallmarks	  of	  cancer	  and	  the	  angiogenic	  switch	  a	  
rate-­‐limiting	  step.	  This	  leads	  to	  many	  potential	  anti-­‐angiogenic	  molecules	  to	  be	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tested	  for	  anti-­‐tumour	  activity.	  In	  my	  investigations,	  I	  used	  a	  common	  approach	  
of	  subcutaneous	  injection	  of	  cancer	  cells	  and	  measuring	  the	  subsequent	  tumour	  
formation.	  This	  method	  allows	  measurement	  of	  tumour	  size	  throughout	  the	  
experiment	  time	  course	  with	  tumours	  easily	  excised	  and	  weighed.	  Angiogenesis	  
itself	  cannot	  be	  measured	  or	  visualised	  during	  the	  experiment,	  however,	  if	  the	  
study	  was	  large	  enough,	  tumours	  may	  be	  excised	  from	  sub	  groups	  of	  mice	  at	  
various	  time	  points	  to	  determined	  how	  a	  drug	  affects	  angiogenesis	  progression	  
and	  at	  what	  stage	  the	  anti-­‐angiogenic	  drug	  predominantly	  takes	  effect.	  If	  
promising	  anti-­‐tumour	  activity	  is	  shown	  in	  subcutaneous	  cancer	  models,	  drugs	  
should	  be	  investigated	  further	  in	  orthotopic	  models,	  as	  the	  microenvironment	  of	  
a	  tumour	  is	  a	  very	  important	  factor	  during	  tumour	  angiogenesis	  (Watnick,	  2012).	  
A	  significant	  drawback	  to	  many	  in	  vivo	  cancer	  models	  is	  that	  tumours	  form	  and	  
can	  grow	  very	  quickly	  over	  a	  short	  period	  of	  time.	  In	  reality	  cancer	  development	  
takes	  place	  over	  many	  months	  or	  even	  years.	  Further	  pre-­‐clinical	  investigation	  of	  
anti-­‐angiogenic	  compounds	  is	  needed,	  possibly	  using	  transgenic	  spontaneous	  
tumour	  models,	  which	  overexpress	  specific	  oncogenes	  to	  promote	  tumour	  
development	  over	  time	  (Di	  Carlo	  et	  al.,	  1999;	  Hanahan,	  1985).	  
Several	  angiogenesis	  inhibitors	  have	  shown	  promising	  anti-­‐angiogenic	  effects	  
during	  pre-­‐clinical	  investigation	  in	  vitro	  and	  in	  vivo,	  with	  some	  causing	  reduced	  
tumour	  growth	  and	  development	  in	  mouse	  models.	  Despite	  this,	  many	  have	  
gone	  on	  to	  produce	  disappointing	  results	  during	  clinical	  trials.	  Angiogenesis	  
assays	  using	  isolated	  endothelial	  cells	  in	  vitro	  are	  a	  useful	  tool	  for	  early	  
investigation	  and	  screening	  of	  potential	  angiogenesis	  inhibitors	  due	  to	  their	  
speed	  and	  reproducibility,	  but	  must	  be	  followed	  with	  several	  in	  vivo	  angiogenesis	  
models.	  The	  in	  vivo	  angiogenesis	  experiments	  I	  used	  involved	  pre-­‐treating	  
cultured	  cells	  before	  injection.	  If	  the	  compounds	  discussed	  here	  were	  to	  be	  
tested	  further	  for	  use	  as	  anti-­‐angiogenic	  drugs	  they	  would	  ideally	  be	  
administered	  to	  the	  animal	  systemically	  and	  to	  measure	  their	  effect	  on	  
established	  tumours.	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5.3.2 In   vitro   assays   identified   compounds  with   potential   anti-­‐angiogenic  
activity  
VEGF	  is	  highly	  expressed	  by	  various	  cell	  lines	  including	  cancer	  cells.	  Angiogenesis	  
is	  stimulated	  by	  secreted	  VEGF	  binding	  to	  VEGFRs	  on	  the	  endothelium	  inducing	  
branching	  and	  vessel	  growth.	  The	  lead	  compounds	  identified	  were	  initially	  tested	  
for	  anti-­‐angiogenic	  activity	  by	  treating	  HUVECs	  for	  48	  hours	  with	  10μM	  of	  each	  
small	  molecule	  before	  harvesting	  the	  cells	  and	  allowing	  them	  to	  form	  tubules	  on	  
Matrigel	  matrix	   of	   basement	  membrane	   proteins.	   Two	  of	   the	   small	  molecules,	  
GW2974	   and	   AEBSF,	   significantly	   reduced	   the	   length	   of	   endothelial	   tubules	  
formed	   and	   the	   number	   of	   branch	   points	   of	   the	   tubes	   5	   hours	   after	   seeding	  
(Figure	   5-­‐1).	   This	   indicates	   these	   compounds	   can	   produce	   a	   direct	   effect	   on	  
endothelial	   cells	   diminishing	   their	   tube	   forming	   ability,	   whereas	   in	   vivo,	  
angiogenesis	   is	  usually	   stimulated	  by	  VEGF	   in	  a	  paracrine	  manner	  via	   secretion	  
from	  surrounding	  cells	  or	  tumour.	  	  
The	   lead	   compounds	  were	   identified	   for	   their	   ability	   to	   alter	  VEGF	   alternative	  
splicing	   using	   a	   reporter	   construct	   overexpressed	   in	   PC3	   cells.	   There	   has	   been	  
limited	  investigation	  into	  endothelial	  VEGF	  expression	  and	  the	  role	  of	  autocrine	  
VEGF	   signalling	   on	   endothelial	   cells.	   It	   has	   been	   established	   that	   expression	   of	  
VEGF	   from	   endothelium	   is	   low	   but	   involved	   in	   maintaining	   vessel	   survival.	  
Vascular	  development	  is	  normal	  in	  transgenic	  mice	  with	  Vegf	  knocked	  out	  in	  only	  
endothelial	   cells.	   However,	   some	   vascular	   beds	   progressively	   degenerate	   with	  
around	  half	  of	  knock-­‐out	  mice	  experiencing	  sudden	  death	  within	  25	  weeks	  after	  
birth	   (Lee	   et	   al.,	   2007).	   In	   vitro,	   knock-­‐down	   of	  VEGF	   using	   siRNA	   induces	   cell	  
death	   in	  HUVECs.	  HUVECs	  express	   low	   levels	  of	  VEGF	  compared	  to	  many	  other	  
cell	  types	  and	  a	  significant	  proportion	  of	  the	  protein	  is	  not	  secreted	  from	  the	  cell.	  
Endothelial	  derived	  VEGF	  is	  thought	  to	  be	  involved	  in	  upregulating	  survival	  genes	  
including	   cell	   cycle	   and	   mitochondrial	   genes	   and	   required	   for	   homeostasis	   in	  
developed	  vessels	   (Domigan	  et	  al.,	  2015).	  Alternative	  splicing	  of	  VEGF	   isoforms	  
within	   the	   endothelium	   itself	   is	   poorly	   understood.	   The	   two	   lead	   compounds	  
that	   reduced	   tube	   formation	  on	  Matrigel	  were	  GW2974,	  an	   inhibitor	  of	  Erb1/2	  
receptor	   tyrosine	   kinases	   and	   AEBSF,	   a	   non-­‐specific	   serine	   protease	   inhibitor.	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Neither	   of	   the	   compounds	   has	   been	   previously	   linked	  with	   alternative	   splicing	  
events	   in	   endothelial	   cells	   or	   other	   cell	   types.	   The	   screen	   in	  which	   the	   splicing	  
modifiers	  were	  identified	  was	  performed	  using	  PC3	  cells,	  not	  endothelial	  cells.	  It	  
is	  possible	  that	  the	  effect	  on	  tube	  formation	  seen	  by	  directly	  treating	  endothelial	  
cells	  is	  also	  mediated	  my	  mechanisms	  independent	  of	  VEGF	  alternative	  splicing.	  	  
Pro-­‐angiogenic	  VEGF	  is	  known	  to	  be	  upregulated	  in	  prostate	  cancers	  tissues	  and	  
in	   prostate	   cancer	   cell	   lines.	   VEGF	   expression	   is	   higher	   in	  more	   aggressive	   cell	  
lines	  from	  prostate	  cancer	  (Harper	  et	  al.,	  1996).	  Inhibiting	  angiogenesis	  through	  
manipulation	  of	  VEGFxxx/VEGFxxxb	  alternative	  splicing	  can	  reduce	  tumour	  growth	  
in	   models	   of	   prostate	   cancer	   and	   others	   (Amin	   et	   al.,	   2011;	   Gammons	   et	   al.,	  
2014;	  Mavrou	  et	  al.,	  2014).	  As	  the	  chemical	  library	  screen	  that	  isolated	  the	  list	  of	  
lead	   compounds	   was	   performed	   using	   PC3	   cells	   and	   tumour	   angiogenesis	   is	  
induced	   through	   pro-­‐angiogenic	   VEGF	   secretion	   from	   tumour	   cells,	   PC3s	   were	  
used	  again	  as	  part	  of	  additional	  angiogenesis	  assays.	  HUVECs	  were	  cultured	  on	  
Matrigel	  with	  conditioned	  media	  taken	  from	  PC3	  cells	  that	  had	  been	  treated	  with	  
each	  of	   the	   lead	  compounds	   (Figure	  5-­‐).	   If	   the	   compounds	  were	  altering	   splice	  
site	  selection	  of	  VEGF	  pre-­‐mRNA	  and	  increasing	  VEGFxxxb	  isoform	  expression,	  this	  
will	   be	   present	   in	   the	   media	   and	   influence	   HUVEC	   tube	   forming	   ability.	   Tube	  
formation	  was	  significantly	  reduced	  by	  conditioned	  media	  from	  eight	  out	  of	  nine	  
compound	  treatments.	  The	  media	  was	  taken	  directly	  from	  cultured	  PC3	  cells	  and	  
not	   concentrated.	   Therefore	   the	   media	   will	   contain	   secreted	   proteins	   such	   as	  
VEGFxxxb	  but	  also	  remaining	  concentrations	  of	  the	  small	  molecule	  inhibitors.	  The	  
effect	  seen	  on	  HUVECs	  may	  be	  a	  combined	  effect	  of	  the	  compound	  directly	  and	  
changes	  in	  VEGF	  isoform	  expression	  and	  any	  other	  secreted	  proteins	  induced	  or	  
inhibited	  by	  the	  compound	  treatment	  in	  PC3	  cells.	  
In	   addition	   to	   using	   Matrigel	   angiogenesis	   assays,	   the	   effect	   of	   the	   lead	  
compounds	  in	  vitro	  was	  further	  investigated	  using	  a	  second	  angiogenesis	  assay,	  
endothelial-­‐fibroblast	   co-­‐culture	   (Figure	   5-­‐).	   During	   the	   co-­‐culture,	   endothelial	  
cells	  are	  given	  a	  longer	  time	  in	  which	  to	  associate	  and	  form	  vessel-­‐like	  structures	  
compared	   to	   the	   short	  Matrigel	   angiogenesis	   assay.	  HUVECs	  were	   seeded	   into	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wells	   with	   confluent	   fibroblasts	   and	   cultured	  without	   stimulation	   for	   48	   hours	  
before	  adding	  compound	  treated	  PC3	  conditioned	  media	  for	  a	  further	  48	  hours.	  
In	  this	  case	  two	  out	  of	  the	  nine	  conditioned	  media	  samples	  caused	  a	  significant	  
reduction	   in	   endothelial	   vessel	   growth,	   trovafloxacin	   mesylate	   (ESSO01)	   and	  
RepSox	   (ESSO07).	   Again,	   this	   effect	   may	   be	   produced	   by	   VEGFxxxb	   expression,	  
remaining	  compound	  and/or	  other	  secreted	  proteins.	  	  
In	   an	   additional	   experiment,	   GW2974-­‐treated	   PC3	   conditioned	  media	   reduced	  
endothelial	   tube	   formation	   but	   the	   effect	   was	   rescued	   by	   the	   addition	   of	   a	  
VEGFxxxb-­‐specific	   neutralising	   antibody	   (Figure	   5-­‐).	   This	   indicates	   that	   anti-­‐
angiogenic	  VEGF	  isoforms	  are	  indeed	  involved	  in	  the	  inhibitory	  effect	  of	  GW2974	  
on	  endothelial	   tube	  formation.	  To	   further	   investigate	  how	  the	   lead	  compounds	  
mediate	   their	   anti-­‐angiogenic	   activity	   and	   their	   influence	   on	   VEGF	   alternative	  
splicing,	  the	  effect	  on	  SR	  protein	  phosphorylation	  was	  analysed.	  SR	  proteins	  have	  
been	   demonstrated	   to	   be	   important	   in	   determining	   VEGF	   proximal	   and	   distal	  
splice	   site	   selection	   and	   it	   is	   established	   that	   their	   activity	   is	   modulated	   via	  
phosphorylation.	   RepSox	   and	  GW2974	   treatment	   reduced	   the	   phosphorylation	  
of	  some	  SR	  protein	  band	  on	  western	  blot	  analysis.	  The	  antibody	  used	  to	  measure	  
phosphorylation	  detects	  all	  members	  of	  the	  SR	  protein	  family,	  therefore,	  which	  
SR	  proteins	  are	  effected	  by	  the	  compounds	  cannot	  be	  fully	  determined.	  Specific	  
antibodies	   or	   immunoprecipitation	   should	   be	   used	   in	   the	   future	   for	   further	  
investigation	  into	  the	  mechanism	  of	  action	  of	  both	  molecules.	  
Novel  inhibitors  of  angiogenesis  and  tumour  growth  
I	   wanted	   to	   further	   investigate	   the	   several	   lead	   compounds	   that	   showed	  
functional	  activity	  during	   in	  vitro	   assays	  and	   increased	  VEGFxxxb	  mRNA/protein.	  
This	   included	   trovafloxacin	   mesylate	   (ESSO01),	   RepSox	   (ESSO07)	   and	   AEBSF	  
(ESSO09).	   A	   simple	  Matrigel	   plug	   assay	  was	   used	   to	   demonstrate	   inhibition	   of	  
neovascularisation	  by	  the	  anti-­‐angiogenic	  compounds	  in	  vivo.	  The	  composition	  of	  
Matrigel	   is	   similar	   to	   basement	   membrane	   proteins	   that	   associate	   with	  
microvessels.	  Matrigel	  also	  contains	  various	  growth	   factors	  associated	  with	   the	  
matrix	  that	  stimulate	  vessel	  sprouting.	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PC3	   cells	   that	   had	   been	   pre-­‐treated	   for	   48	   hours	   with	   the	   lead	   compounds,	  
trovafloxacin	  mesylate	  (Figure	  5-­‐)	  or	  AEBSF	  Figure	  5-­‐),	  were	  mixed	  with	  Matrigel	  
to	   examine	   inhibitory	   action	   of	   the	   molecules.	   Four	   days	   after	   subcutaneous	  
injection	   of	   nude	   mice,	   the	   plugs	   were	   harvested	   and	   imaged.	   Matrigel	   is	  
colourless	   making	   larger	   infiltrating	   vessels	   clear	   to	   see	   by	   eye.	   More	   vessel	  
growth	  made	  the	  plugs	  darker	  and	  bloody.	  Quantification	  of	  the	  plug	  colour	  was	  
used	  as	  a	   simple	  method	  of	  measuring	  neovascularisation.	  AEBSF	   treatment	  of	  
PC3	   cells	   caused	   a	   reduction	   in	   the	   colour	   intensity	   of	   the	   harvested	   plugs	  
indicating	  the	  treatment	  reduced	  the	  ability	  of	  PC3s	  to	  induce	  angiogenesis.	  RNA	  
was	  extracted	  from	  each	  plug	  and	  qRT-­‐PCR	  performed	  to	  measure	  expression	  of	  
mouse	  Vegfr-­‐2	  mRNA	  as	  a	  marker	  for	  the	  presence	  of	  endothelial	  cells.	  Human	  
GAPDH	  expression	  was	  used	  as	  a	  reference	  gene	  for	  normalisation	  as	  it	   is	   likely	  
that	   the	   majority	   of	   the	   extracted	   RNA	   is	   from	   PC3	   cells.	   AEBSF	   treatment	  
reduced	  the	  induction	  of	  neovascularisation	  by	  PC3	  cells.	  AEBSF	  is	  a	  non-­‐specific	  
serine	   protease	   inhibitor.	   The	   compound	   has	   not	   previously	   been	   linked	   with	  
angiogenesis	  or	  alternative	  splicing.	  AEBSF	  inhibits	  various	  serine	  proteases	  such	  
as	   kallikrein	   and	   urinary	   plasminogen	   activator	   (uPA).	   The	   drug	   has	   previously	  
been	  tested	  in	  models	  of	  embryo	  implantation	  in	  rats	  and	  to	  have	  an	  inhibitory	  
effect	   on	   cell	   adhesion	   and	   protein	   secretion	   in	   vitro	   (Jiang	   et	   al.,	   2011).	   The	  
inhibitor	   also	   has	   other	   activities	   of	   which	   the	   exact	   mechanism	   of	   action	   is	  
unclear.	   For	   example,	   expression	   of	   the	   transcription	   factor,	   CHOP	   (C/EBP	  
homologous	  protein),	  is	  induced	  by	  PI3K	  activation	  but	  this	  induction	  is	  blocked	  
by	  AEBSF.	  Additionally,	  AEBSF	  inhibits	  NADPH	  oxidase.	  NADPH	  oxidase	  produces	  
reactive	  oxygen	   species	  and	   is	   important	   for	   the	  proliferation	  and	  migration	  of	  
endothelial	  cells	  (Abid	  et	  al.,	  2000).	  
Trovafloxacin	   mesylate	   reduced	   tube	   formation	   in	   endothelial-­‐fibroblast	   co-­‐
culture	   in	  vitro	  and	   increased	  VEGF	  distal	   splice	  site	  selection,	  as	  shown	  by	  RT-­‐
PCR,	  but	  did	  not	  cause	  a	  change	  to	  Matrigel	  plug	  neovascularisation	  at	  any	  of	  the	  
concentrations	  tested	  (Figure	  5-­‐).	  The	  drug	  is	  a	  broad	  spectrum	  fluoroquinolone	  
antibiotic	  agent	  which	  acts	  by	  inhibiting	  bacterial	  DNA	  gyrase	  and	  topoisomerase	  
IV.	  Trovafloxacin	  was	  previously	  used	  as	  an	  antibiotic	  but	   removed	   from	  use	   in	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patients	  due	  to	  an	  association	  with	   liver	  damage	  (Lazarczyk	  et	  al.,	  2001).	  Other	  
fluoroquinolones	  within	  the	  same	  class	  have	  demonstrated	  some	  anti-­‐angiogenic	  
and	  anti-­‐tumour	  activity	  alone	  and	  when	  combined	  with	  chemotherapy	  (Kamat	  
et	  al.,	  1999).	  
The	  compound	  RepSox	  reduced	  the	  formation	  of	  endothelial	  tubules	  during	  co-­‐
culture	   of	   fibroblasts	   and	   HUVECs	   (Figure	   5-­‐).	   Tumour	   formation	   from	  
subcutaneous	  PC3	  xenografts	  was	  significantly	  reduced	  by	  treatment	  of	  the	  PC3	  
cells	  with	  RepSox.	  RepSox	  is	  a	  specific	  inhibitor	  of	  ALK5,	  a	  type-­‐I	  TGF-­‐β1	  receptor.	  
There	   has	   been	   some	   investigation	   into	   TGF-­‐β1	   regulation	   of	   VEGF	   expression	  
including	  alternative	  splicing	  of	  the	  pro	  and	  anti-­‐angiogenic	  isoforms.	  Podocytes	  
treated	  with	  TGF-­‐β1	  displayed	  increased	  anti-­‐angiogenic	  VEGFxxxb	  transcripts	  and	  
reduced	   pro-­‐angiogenic	   VEGFxxx	   (Nowak	   et	   al.,	   2008),	   whereas	   I	   have	   shown	  
inhibiting	  the	  TGF-­‐β1	  receptor,	  ALK5,	  with	  RepSox	  is	  anti-­‐angiogenic.	  (Gammons	  
et	  al.,	  2013a;	  Gammons	  et	  al.,	  2014;	  Gammons	  et	  al.,	  2013b)	  
The	   role	   of	   TGF-­‐β1	   signalling	   in	   angiogenesis	   and	   cancer	   is	   extremely	   complex	  
and	   context	   dependent.	   TGF-­‐β1	   is	   implicated	   as	   a	   tumour	   suppressor	   but	   also	  
pro-­‐metastatic	  (Papageorgis	  and	  Stylianopoulos,	  2015).	  Additionally,	  the	  growth	  
factor	   is	  reported	  by	  some	  to	  promote	  angiogenesis	   in	  tumours	  but	  also	   inhibit	  
angiogenesis	   in	   other	   studies	   (Pardali	   and	   Moustakas,	   2007).	   Mice	   with	   gene	  
deletion	   of	   TGF-­‐β1,	   TβRII	   and	   ALK5	   have	   vasculogenic	   and	   angiogenic	  
abnormalities.	   The	   chick	   chorioallantoic	  membrane	   angiogenesis	   assay	   showed	  
TGF-­‐β1	   to	   be	   capable	   of	   strongly	   inducing	   an	   angiogenic	   response	   (Yang	   and	  
Moses,	  1990).	  Whereas	   in	   vitro,	   TGF-­‐β1	   reduced	  proliferation	  and	  migration	  of	  
endothelial	  cells	  and	  stimulates	  apoptosis	  (Pollman	  et	  al.,	  1999).	  It	  has	  therefore	  
been	   proposed	   that	   TGF-­‐β1	   stimulates	   angiogenesis	   in	   vivo	   via	   an	   indirect	  
mechanism	   causing	   induction	   of	   VEGF	   or	   other	   pro-­‐angiogenic	   stimuli	   (Pardali	  
and	   Moustakas,	   2007).	   TGF-­‐β1	   and	   VEGF	   are	   often	   both	   expressed	   in	  
vascularising	  tissues	  and	  many	  tumour	  types.	  CHO	  cells	  expressing	  TGF-­‐β1	  form	  
large,	  highly	  vascular	   tumours	  when	  subcutaneously	   injected	   into	  mice.	  TGF-­‐β1	  
neutralising	   antibodies	   can	   reduce	   the	   growth	   of	   these	   tumours	   (Ueki	   et	   al.,	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1992).	   In	   prostate	   cancers,	   increased	   TGF-­‐β1	   expression	   is	   associated	   with	  
greater	  angiogenesis.	  Use	  of	  TGF-­‐β1	  antibodies	  reduced	  blood	  vessel	  density	  and	  
tumour	   growth	   in	  mouse	  models	   (Tuxhorn	   et	   al.,	   2002).	   In	   contrast,	   TGF-­‐β1	   is	  
highly	   expressed	   by	   tumours	   of	   the	   gallbladder,	   inhibiting	   their	   growth	   and	  
angiogenesis.	   Other	   models	   suggest,	   TGF-­‐β1	   can	   reduce	   VEGF	   expression	   in	  
pancreatic	  cancer	  cells	  (Pardali	  and	  Moustakas,	  2007).	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Chapter	  6   
Discussion  and  future  direction  
  
6.1  Alternative  spl ic ing  dysregulation   in  disease  and  the  
potential    for  therapeutic   intervention  
mRNA	   splicing	   is	   a	   crucial	   process	   for	   functional	   cell	   physiology.	   Alternative	  
splicing	   is	   an	   important	   mechanism	   of	   post-­‐transcriptional	   gene	   regulation.	  	  
Aberrant	  splicing	  and	  inappropriate	  expression	  of	  certain	  splice	  isoforms	  can	  lead	  
to	  various	  diseases,	   including	  cancers.	  Attempts	  have	  been	  made	   in	  pre-­‐clinical	  
studies	   to	   target	   drugs	   to	  modify	   dysregulated	   splicing	   patterns	   as	   a	   potential	  
method	  to	  treat	  disease.	  Various	  methods	  have	  been	  employed	   including	  using	  
oligo	   nucleotide	   to	   base	   pair	  with	   pre	  mRNA	   to	   promote	   or	   inhibit	   the	   use	   of	  
specific	  splice	  sites	  (Crooke,	  2004).	  Similarly,	  exon	  specific	  RNA	  interference	  has	  
been	  used	  to	  downregulate	  specific	  splice	  isoforms	  (Celotto	  and	  Graveley,	  2002).	  
Additionally,	   chemicals	   can	   be	   used	   to	   change	   splicing	   patterns	   by	   directly	  
associating	  with	   transcripts	  or	  modulating	   the	  action	  of	   splice	   factors	  and	   their	  
upstream	   regulators.	   Examples	   include	   amiloride,	   a	   diuretic	   that	   was	  
demonstrated	   to	   increase	   the	   expression	   of	   pro-­‐apoptotic	   splice	   isoforms	   of	  
certain	  genes	  in	  leukaemia	  cells	  (Chang	  et	  al.,	  2011).	  Drugs	  have	  also	  been	  used	  
to	  target	  the	  alternative	  splicing	  of	  SMN2	  transcripts	  to	  increase	  the	  expression	  
of	   functional	   protein	   isoforms	   and	   potentially	   treat	   spinal	   muscular	   atrophy	  
(Naryshkin	  et	  al.,	  2014;	  Palacino	  et	  al.,	  2015).	  
It	   also	   clearly	   established	   that	   the	   regulation	   of	   alternative	   splicing	   is	   highly	  
distorted	   during	   cancer	   and	   several	   splicing	   factors	   are	   confirmed	   oncogenes	  
that	   contribute	   to	   cancer	   development	   and	   progression.	   One	   of	   the	   genes	  
heavily	   investigated	   regarding	   association	   with	   cancer,	   and	   the	   effect	   of	  
alternative	   splicing,	   is	   VEGF.	   Traditionally	   thought	   of	   as	   a	   potent	   angiogenic	  
growth	  factor,	  in	  2002,	  Bates	  et	  al	  detected	  a	  family	  of	  alternatively	  spliced	  VEGF	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isoforms	   with	   very	   different	   properties	   to	   the	   canonical	   proteins.	   VEGFxxxb	  
isoforms	  differed	  from	  the	  pro-­‐angiogenic	  family	  by	  only	  six	  amino	  acids	  at	  the	  C	  
terminal	  of	  the	  protein	  isoforms.	  The	  VEGFxxxb	  isoforms	  have	  been	  demonstrated	  
to	   be	   anti-­‐angiogenic,	   reduced	   vessel	   permeability	   and	   reduce	   tumour	   growth	  
compared	   with	   the	   VEGFxxx	   isoforms.	   The	   anti-­‐angiogenic	   isoforms	   are	   highly	  
expressed	  in	  many	  normal	  tissues	  but	  their	  expression	  is	  reduced	  in	  tumours	  and	  
highly	   angiogenic	   tissues	   (Bates	   and	  Harper,	   2005).	   As	   such,	   numerous	   studies	  
have	   focused	  on	  understanding	  the	  mechanisms	  that	   regulate	  VEGF	  alternative	  
splicing	  and	  if	  these	  mechanisms	  are	  disrupted	  during	  disease.	  	  
SR	   proteins	   are	   trans-­‐acting	   regulators	   of	   alternative	   splicing.	   Binding	   of	   SR	  
proteins	  to	  specific	  sequences	  within	  an	  mRNA	  transcript	  can	  promote	  the	  use	  of	  
a	   splice	   site.	   SR	   proteins	   are	   often	   activated	   via	   phosphorylation	   by	   kinases,	  
which	   in	   turn	   are	  often	   regulated	  by	  other	   kinases	  upstream	   (Giannakouros	   et	  
al.,	  2011).	  SR	  proteins	  have	  been	  demonstrated	  to	  be	  important	  in	  the	  selection	  
of	   the	   splice	   sites	   that	   produce	   pro-­‐	   or	   anti-­‐angiogenic	   VEGF.	   SRSF1	   binding	  
promotes	   the	   use	   of	   a	   proximal	   splice	   site	   in	  VEGF	   exon	   8	   leading	   to	   VEGFxxx	  
expression.	   Inhibition	  of	  the	  SRSF1-­‐activating	  kinase,	  SRPK1,	  reduces	  expression	  
of	   VEGFxxx	   and	   increases	   used	   of	   a	   distal	   splice	   site	   creating	   anti-­‐angiogenic	  
VEGFxxxb.	   As	   a	   kinase	   enzyme,	   SRPK1	   can	   be	   targeted	   with	   small	   molecule	  
inhibitors.	  Via	  changes	  in	  VEGF	  splice	  isoform	  expression,	  SRPK1	  inhibitors,	  such	  
as	  SRPIN340,	  can	  reduce	  tumour	  growth	  (Amin	  et	  al.,	  2011;	  Oltean	  et	  al.,	  2012).	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6.2  Using  spl ic ing-­‐sensit ive  f luorescent  reporters  as  a  
screening  tool  
As	   changing	   the	   expression	   of	   VEGF	   alternatively	   spliced	   isoforms	   with	   SRPK1	  
inhibitors	  was	  able	  to	  reduce	  tumour	  growth	   in	  vivo	  (Amin	  et	  al.,	  2011;	  Mavrou	  
et	   al.,	   2014),	   further	   investigation	   was	   required	   to	   find	   additional	   small	  
molecules	  that	  may	  target	  VEGF	  alternative	  splicing.	  Elucidated	  compounds	  have	  
the	   potential	   to	   be	   used	   for	   disease	   treatment	   and	   further	   our	   understanding	  
how	  VEGF	  exon	  8	  splicing	  is	  regulated.	  The	  method	  used	  for	  this	  purpose	  was	  a	  
splicing-­‐sensitive	  fluorescent	  reporter	  designed	  to	  mimic	  the	  alternative	  splicing	  
pattern	   which	   creates	   either	   pro-­‐	   or	   anti-­‐angiogenic	   VEGF	   isoforms.	   Initial	  
validation	   of	   the	   VEGF	   SSFR	   construct	   required	   transfection	   of	   the	   reporter	  
plasmid	  into	  several	  cell	  types	  and	  monitoring	  the	  pattern	  of	  reporter	  alternative	  
splicing	   when	   cells	   were	   treated	   with	   SRPK1	   inhibitors.	   This	   validation	   and	  
preliminary	   screens	   suggested	   the	   VEGF	   SSFR	  may	   be	   a	   useful	   tool	   for	   finding	  
molecules	  that	  can	  influence	  VEGF	  splicing.	  Previous	  studies	  have	  used	  SSFRs	  to	  
screen	   small	   molecule	   or	   siRNA	   libraries	   (Newman	   et	   al.,	   2006;	   Stoilov	   et	   al.,	  
2008).	  
High-­‐throughput	   and	   smaller	   screens	   usually	   involve	   primary	   and	   secondary	  
stages	  followed	  by	  further	  validation	  in	  functional	  assays	  (Macarron	  et	  al.,	  2011;	  
Pereira	   and	  Williams,	   2007).	   The	  primary	   screen	  was	   performed	  using	   the	   PC3	  
prostate	   cancer	   cell	   line.	   A	   fluorescent	   plate	   reader	   was	   used	   to	  measure	   the	  
levels	  of	  EGFP	  and	  dsRED	  in	  cells	  treated	  with	  a	  library	  of	  1,280	  small	  molecules.	  
The	   compounds	  were	   part	   of	   a	   repurposing	   library	   i.e.	   all	   the	   compounds	   had	  
been	  previously	  FDA-­‐approved	  for	  a	  different	  use.	  As	  VEGF	  is	  a	  key	  growth	  factor	  
during	   tumourigenesis	   and	   anti-­‐angiogenic	   therapy	   has	   the	   potential	   to	   inhibit	  
the	  growth	  of	  many	  cancers,	   I	  aimed	  to	  find	  molecules	  that	  could	  change	  VEGF	  
splicing	   to	   increase	   the	   expression	   of	   anti-­‐angiogenic	   VEGF	   and	   reduce	   pro-­‐
angiogenic	   isoforms.	   Molecules	   that	   increased	   reporter	   distal	   splice	   site	   or	  
reduced	   proximal	   splice	   site	   selection,	   measured	   by	   fluorescent	   protein	  
expression,	  were	  used	   in	   the	  secondary	  screen	  that	  measured	  EGFP	  and	  dsRED	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using	   flow	  cytometry.	  Nine	  compounds	  were	  validated	   in	   the	  secondary	  screen	  
and	  used	  in	  functional	  assays.	  	  
The	   screen	  performed	  was	   relatively	   small	   scale	  compared	  with	  drug	  discovery	  
undertaken	  by	  pharmaceutical	  companies.	  There	  are	  advantages	  and	  drawbacks	  
to	  every	  screening	  method.	  Large	  compounds	  libraries	  often	  contain	  many	  drug	  
candidates	  which	  may	  not	  be	  active,	  not	  be	  able	  to	  permeate	  the	  cell	  membrane	  
or	   may	   be	   toxic	   when	   used	   in	   vitro	   or	   in	   vivo.	   Advantages	   of	   the	   VEGF	   SSFR	  
screen	   include	   that	   the	   compounds	   of	   the	   repurposing	   library	   have	   known	  
cellular	  targets	  and	  the	  screen	  was	  performed	  in	  live	  cells	  rather	  than	  using	  cell	  
extracts	  or	  isolated	  proteins.	  	  
A	   fluorescent	   plate	   reader	   was	   utilised	   during	   the	   primary	   screen	   to	   quantify	  
dsRED	  and	  EGFP	  levels	  in	  cells	  treated	  with	  the	  compound	  library,	  as	  a	  measure	  
of	  reporter	  proximal	  or	  distal	  splicing.	  In	  analysis	  of	  the	  primary	  screen,	  over	  300	  
compounds	  were	  significantly	  increased	  EGFP	  or	  decreased	  dsRED.	  This	  number	  
was	  reduced	  to	  9	  following	  the	  secondary,	  flow	  cytometric	  screen.	  This	  indicated	  
that	  the	  fluorescent	  plate	  reader	  produced	  many	  ‘hits’	  that	  were	  not	  validated.	  
Other	  methods	  of	  fluorescent	  measurement	  may	  improve	  the	  screening	  accuracy	  
such	  as	  high-­‐content	  cell	  analysis	  (e.g	  using	  IN	  Cell	  analyser)	  or	  high-­‐throughput	  
flow	  cytometry.	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6.3  Investigating  the  anti-­‐angiogenic  activity  of  small   
molecules   in  vitro   and   in  vivo   
The	  aim	  of	  screen	  for	  molecules	  that	  can	  modify	  VEGF	  splicing	  was	  to	  ultimately	  
use	   such	   molecules	   to	   inhibit	   angiogenesis	   in	   vivo.	   Before	   animal	   studies	   are	  
performed,	   there	   are	   many	   in	   vitro	   angiogenesis	   assays	   that	   can	   be	   used	  
(Auerbach	   et	   al.,	   2003;	   Donovan	   et	   al.,	   2001).	   Each	   angiogenesis	   assay	   has	  
advantages	   and	   limitations.	   Endothelial	   tube	   formation	   assays	   are	   simple	   to	  
perform	  and	  reproduce	  but	  do	  not	  represent	  angiogenesis	  as	  accurately	  as	  some	  
other	   assays.	   Co-­‐culture	   of	   endothelial	   cells	   with	   stromal	   cells	   is	   more	  
physiological	   in	  vitro	  angiogenesis	  assay	  but	  still	  does	  not	  mimic	  the	  complexity	  
of	  angiogenesis	  in	  the	  tumour	  microenvironment.	  Similarly,	  there	  are	  numerous	  
animal	  models	  of	  angiogenesis	  that	  are	  commonly	  used	  to	  test	  potential	  anti-­‐	  or	  
pro-­‐angiogenic	   molecules,	   including	   the	   chick	   chorioallantoic	   membrane	  
angiogenesis	   assay,	   the	   corneal	   pocket	   assay	   and	   a	   Matrigel	   plug	   assay.	  
Additional	   tumour	  models	  are	   required	   to	   investigate	   if	  anti-­‐angiogenic	  activity	  
of	  a	  novel	  compound	  inhibits	  tumour	  growth	  (Staton	  et	  al.,	  2009).	  	  
Several	  of	  the	  lead	  compounds	  identified	  during	  the	  VEGF	  SSFR	  screen	  exhibited	  
anti-­‐angiogenic	  activity	  in	  vitro	  or	  in	  vivo.	  	  Some	  also	  increased	  VEGF	  distal	  splice	  
site	   selection	   and	   increased	   VEGFxxxb	   the	   protein	   level.	   It	   is	   not	   clearly	  
established	   if	   the	  anti-­‐angiogenic	  effects	  observed	  are	  predominantly	  mediated	  
by	  changes	  in	  the	  ratio	  of	  VEGF	  splice	  isoforms.	  While	  I	  have	  strong	  evidence	  that	  
165b	   is	   involved,	   I	   cannot	   rule	   out	   completely	   other	   additional	   anti-­‐angiogenic	  
mechanisms.	   A	   rescue	   experiment	   was	   performed	   using	   a	   VEGFxxxb-­‐specific	  
neutralising	   antibody	   during	   a	   Matrigel	   angiogenesis	   assay.	   Addition	   of	   the	  
neutralising	   antibody	   partially	   rescued	   the	   anti-­‐angiogenic	   effect	   promoted	   by	  
GW2974	   EGFR	   inhibitor.	   Whether	   VEGF	   alternative	   splicing	   is	   the	   major	  
mechanism	  that	  mediates	  the	  respective	  in	  vivo	  anti-­‐angiogenic	  and	  anti-­‐tumour	  
activity	  of	  AEBSF	  and	  RepSox	  requires	  further	  investigation.	  	  
Anti-­‐angiogenesis	  as	  a	  cancer	  treatment	  has	  had	  relatively	   limited	  success.	  This	  
has	  been	  attributed	  to	  several	  mechanisms,	   including	  resistance	  to	  therapy	  and	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reduced	  delivery	  of	  chemotherapeutics	  to	  the	  tumour	  (Carmeliet	  and	  Jain,	  2011;	  
Kerbel	   and	   Folkman,	   2002).	   Small	   molecules	   that	   reduce	   the	   expression	   of	  
VEGFxxx	  while	  promoting	  the	  endogenous	  anti-­‐angiogenic	   factor,	  VEGFxxxb,	   is	  an	  
intriguing	  strategy	  for	  cancer	  therapy.	  
In	  conclusion,	  the	  molecules	  identified	  to	  modulate	  VEGF	  splicing	  and	  inhibit	  
angiogenesis	  require	  further	  investigation	  to	  clearly	  define	  their	  mechanism	  of	  
action	  and	  explore	  their	  potential	  as	  anti-­‐angiogenic/anti-­‐tumour	  therapeutics.	  
This	  will	  require	  detailed	  molecular	  analysis	  to	  elucidate	  the	  pathways	  that	  
mediate	  the	  effects	  on	  VEGF	  alternative	  splicing	  and	  to	  establish	  which	  other	  
factors	  are	  involved	  in	  the	  anti-­‐angiogenic	  activity.	  Several	  additional	  in	  vivo	  
models	  should	  be	  used	  to	  further	  demonstrate	  the	  angiogenic	  activity	  of	  the	  hit	  
compounds,	  to	  determine	  optimal	  dosing	  of	  the	  compounds	  and	  to	  establish	  if	  
they	  provide	  functional	  effects	  on	  angiogenesis	  when	  administered	  systemically.	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